bargain kinerase

Transcription

bargain kinerase

H.H. Sheikh Khalifa Bin Zayed Al Nahyan
President of the United Arab Emirates
H.H. Sheikh Mohammed Bin Rashid Al Maktoum
Vice-President, Prime Minister of the United Arab Emirates, Ruler of Dubai
H.H. Sheikh Hamdan Bin Rashid Al Maktoum
Deputy Ruler of Dubai, Minister of Finance
President of the Dubai Health Authority
T ABLE OF C ONTENTS
About Dubai
Welcome Message from the Director
General of Dubai Health Authority
Message from the Chairman of DUPHAT
Message from the President of INDEX HOLDING
Message from ASHP
Message from EUFEPS
Message from ESCP
Message from SHPA
Message from IATDMCT
Message from Monash University
Message from Utrecht University
Message from ESOP
Message from CPhA
Message from ISPE
General Information
Organizing Committee
Scientific Committee & Social Committee
Volunteers
Chairpersons
8- 9
28
29 - 31
32 - 33
Accreditations
Scientific Program
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
Pharmacy Workshop Schedule
Exclusive Session on
Pharmacovigilance and Pharmacoepidemiology
Parallel Session Schedule
Exclusive Parallel Session
Professional Poster Presentations
Student Oral Presentations
DUPHAT Managerial Skills Workshop
Acknowledgment
Day 1
Day 2
Day 3
Professional Posters
Student Posters
Floor Plan
Exhibitors List
Exhibitors Profile
34 - 35
36 - 37
38
39
40 - 45
46 - 47
48 - 49
51 - 64
67 - 91
93 - 108
109 - 126
127 - 151
152
153
154 - 192
7
About
DUBAI a city with fabulous infrastructure,
has changed dramatically over the last
three decades, becoming a major business
centre with a more dynamic and diversified
economy. Dubai enjoys a strategic location
and serves as the biggest re-exporting
centre in the Middle East. Amidst its
relentless development is an influx of
significant International, Regional and
National Conferences, Conventions
and Exhibitions. Its low logistical and
operational costs, international outlook
and liberal government policies are
attracting investors in a big way.
It offers a kaleidoscope of attractions for
visitors, from the timeless tranquility
of the desert to the lively bustle of the
souk. In a single day, the tourist can
experience everything from rugged
mountains and awe-inspiring sand dunes
to sandy beaches and lush green parks,
from ancient houses with wind towers
to ultra-modern shopping malls. These
contrasts give Dubai its unique flavor
and personality; a cosmopolitan society
with an international lifestyle, yet with
Dubai
a culture deeply rooted in the Islamic
traditions of Arabia.
Dubai which is a melting pot of the races
serves as a second home to an amalgam
of nationalities. A city boasting a critical
mass of world-class companies, health
care institutions, professional service
firms and financial institutions with
first-rate housing, medical, education
and transport facilities available. It has
the factors which contribute to an overall
quality of life making it one of the most
sought-after places to live and work. A
virtually crime-free, tolerant society with
world class hotels and entertainment
facilities, excellent value shopping,
enviable sports and leisure amenities all
combine to make living and working in
Dubai a pleasure.
Area: 3,885 sq. kms.
Population: 971,000 (2001 estimate)
Majority live in Dubai City and its suburbs
which has a cosmopolitan population.
A small percentage lives in village and
agrarian communities.
Local Time: GMT plus four hours.
Religion: Islam is the official religion of
the UAE and there are a large number of
mosques throughout the city.
Language: Arabic is the official language.
English is widely spoken and understood.
Hindi, Urdu, Farsi, and other languages
are widely used by the large expatriate
population.
Visas: All visitors except GCC countries
(Bahrain, Kuwait, Oman, Qatar &
Saudi Arabia) Western Europe countries
(France, Italy, Germany, Holland,
Belgium, Luxembourg, Switzerland,
Austria, Sweden, Norway, Denmark,
Portugal, Ireland, Greece, Finland, Spain,
Monaco, Vatican City, Iceland, Andorra,
San Marino and Liechtenstein) Other
countries (USA, Canada, Australia,
New Zealand, Japan, Brunei, Singapore,
Malaysia, Hong Kong and South Korea)
require a Visa sponsored by a local entity
such as a hotel or company. There are two
types of visas; transit visa for 14 days and
visit visa for 60 days (Renewable).
Climate: Temperature ranges from
10°C/50°F to 40°C/118°F. During March
the average temperature is expected to be
25°C/87°F.
Currency: The local currency is UAE
Dirham and is tied to the US dollar
at an exchange rate $1 = Dhs 3.68
(fluctuating).
Banks: Bank opening hours are 8:00 am
to 1:00 pm, from Saturday to Wednesday,
although some also open from 4:30 pm to
6:30 pm. On Thursdays, banks operate
only from 8:00 am to noon. However,
ATM services are available around the
clock.
Credit Cards: American Express, Diner,
Visa, Access, MasterCard and all other
major credit cards are accepted at leading
hotels and shops but some retailers offer
better bargains for cash.
Clothing: Lightweight summer clothing
is suitable for most of the year, but jackets
or pullovers may be needed for the winter
months. Good quality sunglasses are
advised for all seasons.
Tipping: Practice is similar to most
parts of the world. Some restaurants do
include a service charge; otherwise 10% is
adequate.
Bargaining: Bargaining is expected in
the souks and smaller shops.
Business Hours: The weekend has
tradionally been Thursday afternoon and
Friday, but some organisations now close
on Friday and Saturday, working through
Thursday afternoon instead. Government
8
Dubai International Pharmaceuticals and
Technologies Conference and Exhibition
the world. Internet, E-mail, Fax and Telex
Services are excellent.
Medical Care: Dubai has a number
of highly specialized Hospitals. The
Department of Health and Medical
Services runs the Al Maktoum,
Rashid, Dubai and Al Wasl
Hospitals, in addition to 17 Health
Centers/Clinics distributed all
over Dubai under Primary Health
Care. The Ministry of Health runs
the Medical and Health Services
in the entire UAE.
Money: Money can be exchanged
at banks and most hotels. There
are number of money exchange
centers offering competitive
rates.
offices are open from 7:30 am to 2:30 pm.
Private sector office hours vary, but are
generally from 8:00 am to 1:00 pm,
re-opening at either 3:00 pm or 4:00
pm and closing at 6:00 pm or 7:00 pm.,
depending on the organisation.
Shop hours are similar in their opening
times, but most shops remain open until
9:00 am to 10:00 pm. Department stores,
boutiques, souks and many food shops
remain open on a Friday, apart from
prayer times (between 11:30 am and 1:30
pm), while larger shops re-open on a Friday
afternoon at around 4:00 pm to 5:00 pm.
Communication: Telephone calls within
Dubai are free; International Direct
Dialing is available to most countries in
Shopping
Information:
One
of
Dubai’s
greatest
attractions is indeed its superb
shopping. Apart from the shopping
areas and the traditional souks, there
are a growing number of modern shopping
malls and commercial complexes, besides
the Dubai Duty Free at the airport,
offering a wide range and selection for
eager shoppers. In Dubai shopping is
regarded a pleasure. From the most
modern shopping malls to the traditional
souks (markets), Dubai provides an
endless scope for shoppers. In terms of
sheer variety, quality and services. Dubai
as a shopping center stands second to none.
Customs duties being low, luxury goods
are cheaper. Best buys include clothes and
fabrics (check out the designer label outlets
at Karama and Al Satwa.), carpets and
rugs, electronics, sports goods, perfumes,
jewellery,
ethnic gifts
and novelties,
spices etc. Shopping
complex like Burjuman
Center, Wafi Center, Al Ghurair
and City Center are certainly worth a
visit. The amazing gold souk, one of the
largest retail gold markets in the world is
in Deira.
D U P H A T 2009
www.duphat.ae
9
Message from the Director General of Dubai Health Authority
A
s Dubai conquers international prominence on the world’s health map it has also established itself as the
focal point of the pharmaceutical industry in the region in accordance with the dynamic and revolutionary
vision of H.H Sheikh Mohammed Bin Rashid Al Maktoum, Vice President and Prime Minister of UAE and
Ruler of Dubai and with the continuous support and contribution of H.H Sheikh Hamdan Bin Rashid Al
Maktoum, Deputy Ruler of Dubai, Minister of Finance and President of Dubai Health Authority.
DUPHAT - the Dubai International Pharmaceuticals and Technologies Conference and Exhibition with
its remarkable performance since 1995 launches its 14th edition. Over the years it achieved international
recognition having a significant impact on the pharmaceutical field. This yearly gathering presents an
opportunity for scientists, health care practitioners, pharmaceutical professionals and academia for a cohesive
interaction and exchange of innovative information on the diverse features of Pharmaceutical Science. With
the fervent involvement of pharmacists who through the event gained additional knowledge of the new and
recent discoveries it has evolved and expanded as an event catering to a worldwide audience with speakers from
around the globe. The exhibition has an outstanding participation of top pharmaceutical companies aiming to
increase their market share and venture on new prospects. DUPHAT made a profound contribution to the
development of the pharmaceutical profession in the country and in the world as well.
On behalf of Dubai Health Authority, I sincerely welcome the delegates of DUPHAT 2009.
Qadhi Saeed Al Murooshid
Director General
Dubai Health Authority
Dubai - UAE
10
Message from the Chairman of DUPHAT
T
he science and art of Pharmacy is ever evolving and with it the pharmacist is embracing newer professional
roles. Indeed the patient experience has transformed in the last decade. The Pharmacist is a key player in
the healthcare team providing a more direct and relevant contribution than in the past. The advancement of
Pharmacogenomics, expanded use of automation and information technologies, importance of patient outcomes
research, impact of pharmacoeconomics, concept of disease state management, increasing number of new drugs
and biotech products, the need for clinical interventions, patient focused information and education, and the
changing models of pharmacy practice has resulted in a broader scope for the Pharmacist.
The most important mission of the pharmacist is to improve the quality of patient’s lives, with specialized
services, cultural sensitivity, social commitment and the best drug therapeutic range. Patient safety is of primary
importance. Medication use has never been without risks and new medicines though extremely effective may
be harmful if not properly used. Justification for any risks associated with medicine use is essential. Patient
outcomes have been suboptimal due to drug related problems. A proper understanding, greater knowledge
and skills helps prevent and resolve drug issues. Pharmacists are highly trusted professionals and should be
readily accessible to patients educating them and engaging themselves in direct patient care to provide quality
healthcare services.
DUPHAT is now in its 14th year and the objective of being a continuing pharmaceutical education forum and a
platform for professional interaction and scientific discourse has been sustained and successful maintained due
to the active participation of delegates, the accreditation and patronage of 10 esteemed International pharmacy
organizations and the constant support of the Dubai Health Authority.
DUPHAT 2009 shall feature the distinguished pharmacy professionals from all over the world. Speakers from
USA, UK, Australia, Japan, Europe and the Middle East shall present their latest perspectives on pharmaceutical
science in the 3 – day program. DUPHAT scientific program also comprises Pharmacy Workshops, Exclusive
session on pharmacovigilance and pharmacoepidemiology, managerial skills workshop, parallel scientific
sessions, professional faculty and student poster session, student poster competition and student short oral
presentation competition. The latest technical information from the pharma industry will be highlighted in
the Pharmaceutical Technologies Exhibition participated by multinational pharma companies from the region,
Far East and Europe. DUPHAT has broadened its scope of activities in the last few editions by involving the
community in the activities and consequently contributing to the awareness and interest of the profession. As
in the past schools from Dubai are participating with healthcare exhibits and cultural activities.
DUPHAT is a conference that intends to meet the interests of pharmacists from hospitals and community
pharmacies, professionals from the pharma industry, marketing professionals, researchers, academics, scientists,
biotech experts, clinicians, students and other healthcare professionals.
I welcome you all to participate enthusiastically in DUPHAT 2009 and contribute your best efforts to make it
‘a conference to remember’.
Dr. Ali Al Sayed Hussain, MS, Ph.D.
Chairman – DUPHAT 2009
D U P H A T 2009
www.duphat.ae
11
Message from the President of INDEX HOLDING
The Pharmaceutical Industry is emerging as a major force in the local, gulf and the Arab markets. During the
last two decades, with the Government’s increasing emphasis on diversification, the pharmaceutical sector has
made significant progress in the UAE. It is this growth and development in the industry which necessitates
a forum, through which its professionals convene and exchange ideas. DUPHAT – the Dubai International
Pharmaceuticals and Technologies Conference and Exhibition made this forum possible.
DUPHAT, after 13 successful years is already a recognized pharmaceutical event which exemplifies the
significance of the pharmaceutical industry and new trends and technologies used in manufacturing these
products. Last year DUPHAT witnessed an increase of 30% in the number of exhibiting companies and a
boost of 40% trade professionals. Over 220 companies from 52 countries utilized the event to increase their
market share. More than 2500 conference attendees benefited the discussions by world renowned speakers.
The multifaceted exhibition was well attended by more than 7000 visitors.
This year, DUPHAT 2009 aims to surpass its previous editions as we strive to adapt with the challenges and
demands of the Science of Pharmacy. As substantiated by research, DUPHAT Conference will pioneer innovative
ideas that will facilitate the growth and development of the pharmaceutical profession, with prominent
speakers imparting their expertise and having the support of international pharmaceutical associations. The
exhibition will reveal breakthrough in pharmaceutical technology with exhibitors having worldwide presence
furthering business quests.
On behalf of Index Conferences and Exhibitions Organisations Est., it is my delight to welcome everyone
involved to share in this forum.
Abdul Salam Al Madani
President
INDEX Holding
12
Message from the
American Society of Health-System Pharmacists! (ASHP)
O
n behalf of the Board of Directors, officers and staff of the American Society of Health-System Pharmacists
(ASHP), we congratulate Dr. Ali Sayed Hussain and his colleagues for the continuing success of the Dubai
International Pharmaceuticals & Technologies Conference & Exhibition (DUPHAT).
The work performed by Chairman Hussain and his colleagues during DUPHAT is essential for continued
progress on the scope and quality of pharmacy services in this region. ASHP is proud to offer its continuing
support of the personal and collective efforts made in improving the scope and impact of pharmacy in the
UAE and surrounding region. The monumental strides made by DUPHAT in developing quality educational
programs and focused dialogue on advancing pharmacy practice are exemplary and are hereby commended.
As the professional role of pharmacists continues to expand, we must continue to answer the needs of the
patient and other health professionals. As we are able to use medications in most disease processes, the
accessibility to and appropriate use of medications still remain as important issues. Today more than ever,
we must collectively strive to continuously provide quality care to “every patient, every time” through more
collaborative, interdisciplinary efforts and initiatives.
Everyday, we must strive to help patients make the best use of their medicines, through the nurturing
and development of partnerships with our physician and nurse colleagues in administering the complex
therapeutic cocktails knows as drug therapy. In reaching these goals, we are grateful for DUPHAT’s tremendous
contributions, and look forward to continuing this invaluable partnership.
Henri R. Manasse, Jr., Ph.D., Sc.D.
Executive Vice President and Chief Executive Officer
American Society of Health-System Pharmacists
D U P H A T 2009
www.duphat.ae
13
Message from the
European Federation for Pharmaceutical Sciences (EUFEPS)
The mission of the European Federation for Pharmaceutical Sciences (EUFEPS), founded in 1991, is to serve
and advance excellence in the pharmaceutical sciences and innovative drug research in Europe, and to represent
the interests of scientists engaged in drug research and development, drug regulation and drug policymaking.
Currently, it links 24 Member Societies in 24 countries. In addition, there are around 400 Individual Members
and 15 Member Institutions (universities and research institutions). EUFEPS is the only pan-European body to
represent the interests of scientists in industry, academia, government and other institutions engaged in drug
research, development, regulation and policymaking through Europe.
EUFEPS organises, co-organises, and co-sponsors conferences, courses and workshops. The Pharmaceutical
Sciences Fair & Exhibition (PharmSciFair), for example, is a new such initiative and concept. The 1st
PharmSciFair was successfully held in June 2005, in Nice, France. The 2nd PharmSciFair is scheduled for June
8-12, 2009, again in Nice, France (www.pharmscuifair.org). The Scientific Programme will comprise eight
parallel speaker sessions, during the week, provided by more than 30 European organisations. Obviously, it will
be a true “speakers fair”, plus Poster Sessions, an Exhibition and a Careers Forum. There will also be a European
Students Meeting for and by PostDocs and PhD Students, as pre-satellite.
The EUFEPS New Safe Medicines Faster Project, initiated in 1998 and addressing bottlenecks and hurdles in
drug development, has successfully developed into the Innovative Medicines Initiative (IMI), established by the
European Pharmaceutical Industry and the European Commission together for several years of collaboration.
Final decisions were made in the end of 2007, and eighteen research and education and training projects
(in the first round of calls) are now being prepared and contracted (www.imi-europe.org). IMI represents
a substantial amount of money for medicines research as well as an important avenue for strengthened
European collaboration. The European Union Microdose AMS Partnership Programme (www.eumapp.com)
has been completed, recently, and final reports on the outcomes are in progress. An additional such research
initiative, where EUFEPS engaged, is the BioSim – Biosimulation Network of Excellence (biosim.fysik.dtu.dk),
also making good progress.
EUFEPS (membership) networks include: The Networks on Safety Sciences; The Network on Process
Analytical Technology (PAT) Sciences; The Network on BioAvailability and BioPharmaceutics; the Network on
PharmacoGenetics and PharmacoGenomics Research; and the Network on Environment and Pharmaceuticals
(being established), respectively. All of them make progress, and additional Networks are being considered.
Against this background – and the EUFEPS Strategic Plan 2006-2010 – it is a pleasure to, on behalf of EUFEPS,
bring my greetings to the DUPHAT 2009 in Dubai, United Arab Emirates. Your Programme is an excellent one,
covering important aspects in the pharmaceutical sphere, several of which close to EUFEPS core interests.
EUFEPS’ co-sponsorship of DUPHAT 2009 also reflects interest and involvement in international and global
collaboration, also as member of the International Pharmaceutical Federation (FIP) Board of Pharmaceutical
Sciences (BPS), with links to the FIP Board of Pharmaceutical Practise (BPP). We wish you a successful and
fruitful DUPHAT 2009.
Leiden, The Netherlands, in November 2009
Daan J.A. Crommelin
Professor, EUFEPS President
14
Message from the
European Society of Clinical Pharmacy (ESCP)
Frank Jorgensen
Dear Mr. Chairman,
Dear Guests of Honor,
Dear Colleagues Attendants of the Duphat 2009 Conference,
It is our pleasure to address our message. We want to express our gratitude to the organizers of this 2009
edition of the Duphat Conference for giving ESCP the opportunity to assist at this stimulating meeting.
Gert Laekeman
Duphat Conferences are well known because of their high scientific standard. The conference is an interesting
platform to meet colleagues from all over the world, to discuss and to exchange knowledge in the larger field
of pharmaceutical sciences. All over the world curricula at university are changing, trying to prepare future
pharmacists for new roles and responsibilities. The patient is becoming the most important issue. All efforts
are converging into the caring for patients. Pharmacy was mainly related to fundamental beta-sciences.
Optimizing caring for patients means that gamma (= medical) and alpha (=behavioral) sciences are moving
in. The Bologna declaration inspired European transition from the traditional study curriculum to bachelor (3
years) and master (2 years). It feels like an earthquake for both, students and teachers. It is a very demanding
process not only from the logistic but also from the intellectual side. The question what to keep in the program
and what to leave out of it, is not easy to tackle. This Duphat conference can inspire, as people from the academy
and from the professional practice field are meeting. We especially appreciate the spontaneous meeting of the
Arab and the European world. We keep nice souvenirs of the lively exchange of information during workshops
and poster presentations.
As the president and past president of the European Society of Clinical Pharmacy, we are bringing clinical
pharmacy into the discussion. Within the Society we are reflecting upon a clear definition of Clinical Pharmacy.
One of the definitions could be: Clinical pharmacy is a health science discipline based upon fundamental sciences
like medicinal chemistry, pharmacology, toxicology, pharmacoepidemiology and behavioral sciences. The purpose of the
clinical pharmacist is to improve patient care through optimizing medication therapy and promoting health, wellness
and disease prevention. Clinical pharmacy practice comprises every action from pharmacists that may help fulfilling
this objective: direct patient (pharmaceutical) care, nurses and physicians advising and drugs, medical devices and
nutritional support optimization. Founded in 1979, the European Society of Clinical Pharmacy is ready to act on
the field, but also to stimulate research on the above mentioned issues. The Society has 900 members all over
Europe, and even out of the European continent. We would be glad to welcome your membership in order to
intensify networking and support clinical pharmacy activities and research.
On behalf of the European Society of Clinical Pharmacy we wish all attendants of the Duphat 2009 conference
a fruitful and pleasant event
Frank Jorgensen MSc Pharm
President of ESCP
www.escpweb.org
Gert Laekeman PhD. PharmD.
Past President of ESCP
D U P H A T 2009
www.duphat.ae
15
Message from Neil Keen, Federal President
The Society of Hospital Pharmacists of Australia (SHPA)
It is with great pleasure that I convey greetings and good wishes from Australia to all colleagues attending
Duphat 2009.
I commend the work of the organizing committee members and their efforts to bring together a broad range of
speakers across an important range of topics that are of current interest to pharmacists.
SHPA is committed to ensuring that all pharmacists
have access to a range of continuing professional
development opportunities.
As conveyed in the SHPA CPD logo shown here,
SHPA supports pharmacists to practice as
“current, informed and connected” members of the
health professional team. Conferences such as
Duphat 2009 are important contributions to this goal.
I would also like to take this opportunity to invite you all to join us in Perth, Western Australia for SHPA’s
Medicines Management 2009.
This will be SHPA’s 35th national conference and it will be held during 5-8 November 2009. Further details will
be available soon on the website.
Finally, good wishes again to all colleagues for a very successful educational event with many professional
development opportunities during Duphat 2009.
Yours sincerely
Neil Keen
Federal President
16
Message from the
President of IATDMCT
It is an honor for the International Association of Therapeutic Drug Monitoring and Clinical Toxicology
(IATDMCT) to be associated again with this meeting of the Dubai International Pharmaceuticals & Technologies
Conference 2009.
We are happy to join you this 2009 in Dubai in order to further excellence in drug development, testing
and optimizing clinical drug use. May I extend an invitation to all attendees interested in Therapeutic Drug
Monitoring and Clinical Toxicology to join our Association. Particularly, I invite Ph.D. students and post docs
to actively collaborate with our dynamic Young Scientists Group to pursue our common interests.
I wish the organisers a successful meeting.
Prof. Dr. H.C. Hans Maurer
IATDMCT – President
D U P H A T 2009
www.duphat.ae
17
Message from the
Monash University, Australia
Welcome to DUPHAT 2009 which has become a very important international conference since its
establishment as an annual event in 1995.
DUPHAT 2009 will again provide an excellent forum to discuss a number of issues of importance to pharmacy
and to the pharmaceutical sciences.
And, just as the previous conferences had been resounding successes in providing opportunities for those
attending to explore this very interesting and dynamic part of the world, you will also have this opportunity.
It is an opportunity not to be missed.
DUPHAT 2009 will also allow you to forge new links with pharmacists and other health professionals from
around the world, and to discuss recent developments in the pharmacy profession and how emerging
technologies impact on pharmaceutical science and pharmacy practice.
It has been said for very many years that the profession of pharmacy is “at the crossroads” in relation to its role
in health care. Speakers at this conference will indicate just how many wonderful opportunities await those
who wish to seek out new roles and to extend existing ones in areas such as clinical pharmacy, continuity of
care and pharmacovigilance – and there is more – so that the profession can leave the crossroads well behind.
DUPHAT 2009 will be a conference that facilitates the meeting of the minds.
It is hard to imagine a better place to hold a conference of this sort because Dubai is the gateway to the UAE
and its leaders see it as a “meeting of the minds city”.
I’m sure you will thoroughly enjoy the conference, and I urge you to contribute to its success.
Professor Colin Chapman
Faculty of Pharmacy
Monash University
Australia
18
Message from the
Utrecht University
I
t becomes almost a well-appreciated tradition that Utrecht University is again well repre¬sented at
DUPHAT 2009. Like in previous years the University holds a top position among European Universities and
in the Netherlands, it is the best University according to the Shanghai Index. Particularly in this year, the
Anniversary of the University on March 26 will be celebrated with a special tribute to the Utrecht excellence in
epidemiology and public health research in the medical, pharmaceutical and veterinary sciences. Coming from
this back¬ground it’s a great pleasure and honour to participate and contribute to DUPHAT 2009. DUPHAT
has shown evidence for being a landmark event in the pharmaceutical sciences and practice in the Middle-East
and beyond. The conference has gained sincere recognition all over the world through stimulating cross-cutting
thinking and learning, and exposing bright young students to a wealth of knowledge in the pharmaceutical
sciences and practice.
I wish you all a wonderful conference with inspiring learning, cultural exchange and long-lasting friendship.
Hubert G Leufkens
Chair in Pharmaceutical Sciences
Utrecht University
D U P H A T 2009
www.duphat.ae
19
Message from the
European Society of Oncology Pharmacy (ESOP)
Our capability needs a goal – patients need our competence in Europe and in the whole world
For all health care practitioners, whatever their profession, the patient is the focus of attention. The causes
that induce a need for therapy have to be diagnosed individually and treated in line with generally recognized
methods.
International studies and national surveys alike have pointed out that between 6 and 13% of hospital admissions
relate to conditions whose causes can be attributed to the inappropriate prescription or administration of
medication. The active support of pharmacist is needed.
The situation belonging oncology patient care differs from each country in Europe. The countries with the most
contrary conditions are Belgium and Germany. In particular it is important to reflect the Oncology pharmacy
from the hospital and from the ambulatory aspect.
When we want to be able to serve all patients in future under the same good conditions we have to assume that
three main demands have finally to be fulfilled:
•
Standardisation
•
Specialisation
•
Accreditation
The European Society of Oncology Pharmacy (ESOP) has become a full member of the European CanCer Society
(ECCO) which has more then 45.000 members. Most of them are physicians from different disciplines.
The chance of surviving cancer is increasing all the time. The methods of treatment are changing from
intermittent IV to continuous oral regimens. The safe and effective use of orally administered targeted
treatments for cancer also has to be learned by pharmacists.
The objectives of the “European Society of Oncology Pharmacy – ESOP” are:
•
To promote clinical practice, research and development in drug use and administration for the
treatment of cancer patients.
•
Research results shall be made available to the public by publications, lectures and seminars
•
The Society shall encourage the publication of developments in clinical practice through
professional activities
As early as possible Oncology Pharmacists need to understand their leading role in organising the best support
for patients. Then they will be understood as a supporting pillar in the hall of multi-professionalism.
We are honoured to present our work at this great meeting DUPHAT 2009
Prof. Klaus Meier
President - ESOP
Hamburg, Germany
20
Message from the
Canadian Pharmacists Association (CPhA)
Tremendous change is taking place in the pharmaceutical world. Advances in science are leading to new
drugs, new vaccines and new delivery systems that offer even greater potential for the successful treatment and
prevention of disease. Yet many governments concerned about the escalating expenditures on pharmaceutical
products are revising pharmaceutical policy to help ensure cost-effectiveness of drug programs while maintaining
access to improvements in therapy. This creates both opportunities and challenges for pharmacists and the
pharmaceutical sector in general.
DUPHAT 2009 will provide an important opportunity for experiences from different countries to be shared in
a way that contributes to learning for all. The Canadian Pharmacists Association is pleased to be a supporter of
DUPHAT 2009 and looks forward to an informative conference.
Jeff Poston, PhD., MRPharmS.
Executive Director
D U P H A T 2009
www.duphat.ae
21
Message from the
International Society for Pharmacoepidemiology (ISPE)
I offer you my since best wishes for a successful Dubai International Pharmaceuticals & Technologies
Conference and Exhibition - DUPHAT 2009. The International Society for Pharmacoepidemiology (ISPE) is
pleased to be a joint sponsor of this important scientific meeting.
As an international professional society, ISPE and its members are dedicated to advancing the health of the
public throughout the world. We seek to improve health status by promoting the open exchange of scientific
information in forums such as DUPHAT 2009, while advocating for the field of pharmacoepidemiology,
including pharmacovigilance, drug utilization research, and therapeutic risk management.
I commend the DUPHAT 2009 Organizing Committee and Scientific Committee for another excellent job in
assembling a world class faculty to address today and tomorrow’s pharmaceutical issues. Your participation
is critical to the ultimate success of the meeting. Thank you for taking time from your busy schedules to
participate in DUPHAT 2009.
On behalf of ISPE, I wish you a productive conference
Sincerely,
Prof. Dr. Miriam CJM Sturkenboom
President, International Society for Pharmacoepidemiology
22
General Information
Official Exhibition Date
29 - 31 March 2009
Venue
Dubai International Pharmaceutical and Technologies Conference and Exhibition - DUPHAT 2009 is held at the Dubai International
Convention & Exhibition Centre - Sheikh Maktoum Hall.
Exhibition Inauguration
DUPHAT 2009 will be officially inaugurated on Sunday, 29th March 2009 at 10:00 am.
Exhibition Opening Hours
Sunday
Monday
Tuesday
29th March 2009
30th March 2009
31st March 2009
10:00 am - 6:00 pm
10:00 am - 6:00 pm
10:00 am - 6:00 pm
Admission
For trade visitors only, registration form must be filled up prior to entry. Children below the age of 15 will not be admitted.
Business Center
Business Center is located in the concourse between Halls 3 and 4.
Organiser’s Office
Organiser’s Office is located in front of Sheikh Maktoum Hall.
Catering Facilities
Refreshments, meals and snacks are available from the restaurants and coffee shops located in the lobby of the Dubai International Exhibition
Center and will be open daily from 9:00 am - 7:00 pm.
Conference Hall
The Conference will take place in Sheikh Rashid A.
Disclaimer
The organisers and publisher of the official catalogue will not be held responsibile for the statement made in this catalogue on behalf of the
exhibitors, nor for any errors or ommissions that may have occured, although the utmost care has been taken to ensure that the information
is accurate in this catalogue.
Color Scheme for Name Tags
z
z
z
z
z
z
z
z
Organiser
Scientific Committee
VIP
Speaker
Chairperson
Participant
Professional Poster Presenter
Student (3 days)
Purple
Purple
Red
Red
Red
Green
Green
Light Blue
z
z
z
z
z
z
z
z
Student (March 29)
Student (March 30)
Student (March 31)
Exhibitor
Trade Visitor
Media
Student Poster Presenter
Managerial Skills Workshop
Black
Light Yellow
Brown
Blue
Yellow Gold
Orange
Gray
Pink
Car Parking
Paid Car parking space for exhibitors and visitors is available in front of Halls 1, 2 & 3 - Dubai International Exhibition Center.
Free Car parking space for exhibitors and visitors is available in parking B, C & F
Transportation
Bus C045 is available to and from Dubai International Convention & Exhibition Center.
Taxis are plentiful and reasonably priced. Taxis are available in car park E opposite Ibis Hotel.
Telephones
Public telephones are available in the lobby of the Exhibition Hall.
Prayer Room
The Gents prayer room is located at the second floor opposite Hall 6.
The Ladies prayer room is located at the second floor opposite Hall 7.
Media Office
The Media Office is located in front of Sheikh Maktoum Hall.
Lost and Found
For lost and found item/s please ask the assistance of the security staff or the organisers.
D U P H A T 2009
www.duphat.ae
23
Organizing Committee
Dr. Ali Al Sayed Hussain
Chairman
24
Mr. Mohammed Sameh Ali
Ms. Farida Al Khaja
Ms. Reem AbdulRaoof Al Sayed
Mrs. Nada Ali Amiri
Mr. Mohammed Arfan Asif
Mr. Mohammed Majed Ali
Scientific Committee
Mrs. Mai Mahfouz Al Issa
Mrs. Mahat Hussain Nsaif
Ms. Hana Al Ansari
Mr. Saleem Chittullindavida
Social Committee
Mr. Edwin J. Rajakumar
Mr. Abdel Razik Abdel Aziz
Mr. Ahmad Mohammed Jafar Mehrabi
Mr. Ekrima Khalafallah
Mr. Monickaraj Arulpragasam
Mr. Syed Abdulkadir Barmawar
D U P H A T 2009
www.duphat.ae
25
Volunteers
26
z
Ms. Sumaya Yousuf AlAwadhi
z
Ms. Muna Khalil Al Sammak
z
Mrs. Sara Essam Nawar
z
Ms. Haifa Saeed Mohammed Al Qasimi
z
Ms. Sara Abdulla Al Haj
z
Mr. Syed Mohsin Khadri
z
Mr. Imran Shariff Mahmood Shariff
z
Mr. Chemuthu Moideen Usayn
Chairpersons for the Scientific Presentations
Dr. Abdulla Al Khayat
Prof. Abdel-Aziz Saleh
Prof. Albert I. Wertheimer
Director – Al Wasl Hospital &
Consultant Pediatrician
Dubai Health Authority, Dubai, UAE
Special Adviser to the Regional Director
on Medicines, World Health Orginization,
Eastern Mediterranean Regional Office, Egypt
Director -Center for Pharmaceutical
Health Services Research,
Professor of Pharmacy Practice,
Temple University School of Pharmacy,
Philadelphia, USA
Dr. Mahmoud M. Marashi
Dr. Hans Linden
Prof. Mohamed Yousif Hassan Baniyas
Consultant Haematologist
Rashid Hospital, Dubai Health Authority,
Dubai, UAE
Executive Director, European
Federation for Pharmaceutical Sciences,
Stockholm, Sweden
Vice Dean, College of Medicine, Program
Director, Graduate Studies, Prof- Dept. of
Pharmacology & Therapeutics,
U.A.E. University, Al Ain, UAE.
Dr. Nadia Rashid Al Mazroui
Deputy Commander
Military Medical Services Corps
Zayed Military Hospital
Abu Dhabi, UAE
Dr. Hussain Nasser Al Rahma
Head of Critical Care Department
Dubai Hospital, Dubai Health Authority
Dubai, UAE
D U P H A T 2009
www.duphat.ae
27
Accreditations
“This material in the DUPHAT 2009 program (14.25 hours of content)
has been accredited by SHPA as suitable for inclusion in an individual
pharmacist’s CPD plan as outlined in the SHPA CPD program
at http://www.shpa.org.au/docs/cpd.html”
28
Scientific Program
DUPHAT 2009 SCIENTIFIC PRESENTATIONS – Sheikh Rashid Hall - A
DAY 1 - 29th MARCH 2009
07:30 - 09:00
Registration and Welcome Coffee Break
09:00 - 10:30
Opening Ceremony & Inauguration of the Exhibition
10:30 - 11:00
COFFEE BREAK
Theme
Research & Leadership in Pharmacy Practice
SESSION 1
Chairperson: Dr. Mahmoud M. Marashi, Consultant Haematologist
Rashid Hospital, Dubai Health Authority, Dubai, UAE
11:00 – 11:45
Pharmaceutical Outcomes Research and Its Application to Pharmaceutical Services
Mr. Kevin J. Colgan, MA, RPh, FASHP
President ASHP & Senior Vice President, Health Economics and Outcomes Research, Illinois, USA
11:45 – 12:30
Using consumer medicines information to improve patient outcomes and promote the safe and
effective use of medicines
Prof. DK Theo Raynor, Ph.D., B.Pharm., MRPharmS,
Professor of Pharmacy Practice & Executive Chairman, LUTO Research Ltd, School of Healthcare,
Baines Wing, University of Leeds, UK
12:30 – 13:15
Ethnic difference in drug response and its implications in regional drug use
Prof. Yusuke Tanigawara, Ph.D.,
Department of Pharmacy, School of Medicine, Keio University, Tokyo, Japan
13:15 – 14:30
LUNCH BREAK
SESSION 2
Chairperson: Dr. Nadia Rashid Al Mazroui, Deputy Commander, Military Medical Services Corps,
Zayed Military Hospital, Abu Dhabi, UAE
14:30 – 15:15
Leading Effective Change in Pharmacy Practice
Prof. Jeff Poston, B.Pharm., PhD, MRPharmS.,
Executive Director, Canadian Pharmacists Association (CPhA), Canada
15:15 – 16:00
Quality measurement of pharmacy practice functionality
Dr. Emad El Azazy, Pharm. D., Ph.D.
CEO of Professional Pharma Inc for Pharmaceutical Consulting Training & Quality Management,
Consultant, Egyptian National Training Institute Ministry of Health and Population &
Professional Secretary of EMRO Pharm Forum, Egypt
D U P H A T 2009
www.duphat.ae
29
DAY 2 - 30th MARCH 2009
Theme
Pharmacy Practice
SESSION 1
Chairperson: Dr. Hussain Nasser Al Rahma, Head of Critical Care Department
Dubai Hospital, Dubai Health Authority, Dubai, UAE
09:00 – 09:45
Realigning Pharmacy Practice Goals Towards Effective Patient Care
Prof. Abdulla M. Molokhia, Ph.D.
Chairman, EEPI, Professor, Pharmaceutics, Egypt
09:45 – 10:30
The Community Pharmacist as Smoking Cessation Coach
Prof. Randy P. Juhl, Ph.D.
Vice Chancellor and Distinguished Service Professor of Pharmacy,
University of Pittsburgh, Pittsburgh, USA
10:30 – 11:00
COFFEE BREAK
SESSION 2
Chairperson: Dr. Abdulla Al Khayat, Director – Al Wasl Hospital & Consultant Pediatrician,
Dubai Health Authority, Dubai, UAE
11:00 – 11:45
System Approach to Development of the Pharmacy Practice in the Arab Countries
Prof. Abdel-Aziz Saleh, Ph.D.
Special Adviser to the Regional Director on Medicines, World Health Orginization,
11:45 – 12:30
Directing Future Pharmacy Practice Toward Societal Needs
Prof. Albert I. Wertheimer, Ph.D., MBA
Director -Center for Pharmaceutical Health Services Research,
Professor of Pharmacy Practice, Temple University School of Pharmacy, Philadelphia, USA
12-30 - 13:15
Professional Skills Development in Future Pharmacists: A World-Wide Issue
Prof. Nancy A. Nickman, Ph.D.
Pharmacotherapy and Presidential Teaching Scholar, Department of Pharmacotherapy and
Pharmacotherapy Outcomes Research Center, University of Utah, Salt Lake City, USA
13:15 – 14:30
LUNCH BREAK
SESSION 3
Chairperson: Prof. Mohamed Yousif Hassan Baniyas, Vice Dean, College of Medicine,
Program Director, Graduate Studies, Prof- Dept. of Pharmacology & Therapeutics,
U.A.E. University, Al Ain, UAE
30
14:30 – 15:15
The Pharmacists role in community practice as rapporteur of side effects, especially on new registered
drugs under prescription
Prof. Ole J. Bjerrum, D.MSc.
Department of Pharmacology and pharmacotherapy FARMA,
University of Copenhagen, Copenhagen, Denmark
15:15 – 16:00
Pharmacology of tyrosine kinase inhibitors – optimizing patient outcomes and promoting effective
rational and safe use of medicines
Prof. Alain Astier, PharmD, Ph.D.
Department of Pharmacy and Toxicology, Henri Mondor University Hospital, Créteil, France
DAY 3 - 31st MARCH 2009
Theme
Pharmacogenomics, Quality Measurement Antimicrobial Stewardship & Health Tourism
SESSION 1
Chairperson: Prof. Abdel-Aziz Saleh, Ph.D., Special Adviser to the Regional Director on
Medicines, World Health Orginization, Eastern Mediterranean Regional Office, Egypt
09:00 – 09:45
Developing Quality Use of Medicines indicators/monitoring and measuring
Mr. David Maxwell, BPharm, DipHospPharm, FSHP,
Executive Officer, New South Wales Therapeutic Advisory Group, Sydney, Australia
09:45 – 10:30
Quality Assessment of Drug Therapy by Pharmacy: Finding and using drug use metrics
Prof. Charles E. Daniels, R.Ph., MS, Ph.D.,
Associate Dean for Clinical Affairs & Professor of Clinical Pharmacy, School of Pharmacy and
Pharmaceutical Sciences, University of California, San Diego & Pharmacist-In-Chief,
UCSD Medical Center, USA
10:30 – 11:00
COFFEE BREAK
SESSION 2
Chairperson: Prof. Albert I. Wertheimer, Ph.D., MBA
11:00 – 11:45
Toxicokinetics of Drugs of Abuse: Relevance for Predicting Pharmacogenetic Variations,
Interactions, Detection Time, or Pitfalls in Drug Testing
Prof. Dr. Hans H. Maurer,
President, International Association of Therapeutic Drug Monitoring and Clinical Toxicology &
Head, Department of Experimental and Clinical Toxicology, Institute of Experimental and Clinical
Pharmacology and Toxicology, Saarland University, Germany
11:45 – 12:30
Personalized medicine and faculties of pharmacy: What should be our roles in
pharmacogenetics and pharmacogenomics
Prof. Robert D. Sindelar, Ph.D.,
Professor and Dean, Faculty of Pharmaceutical Sciences, The University of British Columbia, Canada
12:30 – 13:15
Regulatory issues in genomic medicine
Prof. H.G.M. Leufkens, Pharm. D., Ph.D.,
Utrecht University, Faculty of Science, Utrecht Institute for Pharmaceutical Sciences (UIPS),
Division of Pharmacoepidemiology & Pharmacotherapy, Utrecht & Chair of Dutch Medicines
Evaluation Board (MEB), The Netherlands
13:15 – 14:30
LUNCH BREAK
SESSION 3
Chairperson: Dr. Hans Linden, Executive Director, European Federation for
Pharmaceutical Sciences, Stockholm, Sweden
14:30 – 15:15
Antimicrobial Stewardship in Health Care
Dr. David CM Kong, Bpharm., MPharm, Ph.D.,
Department of Pharmacy Practice, Centre for Medicine Use and Safety, Monash University, Australia
15:15 – 16:00
Emerging Trends in Outsourcing Health Care: Health Tourism
Prof. J. Warren Salmon, Ph.D.
Visiting Professor of Pharmacy Practice, University of Sharjah, College of Pharmacy
and Professor of Health Policy and Administration, University of Illinois at Chicago
School of Public Health, Illinois, USA
D U P H A T 2009
www.duphat.ae
31
Pharmacy Workshop Schedule
DAY 1 - 29 MARCH 2009
DUBAI E & F
11:00 – 12:00
W1. New Concept for Chromatographic Peak Purity Assessment and Identification of
Drugs in Multi-Component Pharmaceutical Preparations
Prof. Ismail I. I. Hewala, Ph.D.
Faculty of Pharmacy, University of Alexandria, Egypt
12:15 – 13:15
W2. A Case Study: Why the Concept of Pharmaceutical Care Did Not Survive and
How Such Errors Can Be Avoided in the Future?
Prof. Albert I. Wertheimer, Ph.D., MBA
DUBAI D
11:00 – 13:00
W11. Clinical Pharmacist Establishing and Operating Anticoagulant Clinic in Ambulatory Care
Dr. Maha Al Draimly, MSc
National Guard Comprehensive, Specialized Clinics (NGCSC), Riyadh, Saudi Arabia
DAY 2 - 30 MARCH 2009
DUBAI E & F
9:00 – 10:00
W4: Households Poisoning: An Overview and Ways for Preventions
Dr. Yousif Abdu Asiri, Ph.D.
Dean and Associate Professor, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia
11:00 – 12:00
W5. Pharmacogenomics and Personalized Medicine
Prof. Yusuke Tanigawara, Ph.D.
12:15 – 13:15
W6. Protection Against the Sun, An Important Pharmacy Practice and Research Issue
Prof. Labiba El Khordagui, Ph.D.
Professor of Pharmaceutics, Faculty of Pharmacy, Alexandria University, Egypt
14:30 – 15:30
W7. Medical Tourism and Globalization of Health Care
Prof. Mustafa Z. Younis, Dr.PH., MBA, MA
Executive Committee Member, International Society for
Research of Healthcare Financial Management, USA
DUBAI D
9:00 – 10:00
32
W13. Practical & Clinical Considerations in Intravenous Therapy & Compounding
Dr. Osama Tabbara, R.Ph., BCNSP
Consultant Pharmacist, TPN & IV Therapy, Director,
Pharmacy Services Administration, King Fahad Medical City, Saudi Arabia
11:00 – 12:00
W14. Rational Drug Use in UAE
Dr. Mohammed Abuelkhair, Pharm.D.
Head, Pharma/Medicine and Medical Products Regulation Section,
Health Authority-Abu Dhabi, UAE
12:15 – 13:15
W15. Improving Patient Adherence through Health Behavior Change
Dr. Renée T. Juhl, Pharm.D.
Adjunct Associate Professor, Department of Pharmaceutical Sciences,
School of Pharmacy, Pittsburgh, USA
14:30 - 15:30
W10. Pharmacovigilance and Why Do Drugs Fail?
Dr. Ibrahim Al Khars, MS, MBA
Executive Director, Almana PharmaCare & Coordinator,
Academic and Training Programs in Almana General Hospitals, Al Khobar, Saudi Arabia
DAY 3 - 31 MARCH 2009
DUBAI E & F
09:00 - 10:00
W8. Advances in Transdermal Drug Delivery Technologies
Dr. Nasir Hussain, B.Pharm., MBA, Ph.D.
Head of Pharmaceutical Formulation, Glide Pharma Needle – Free Technologies Limited
Oxford, United Kingdom
11:00 – 12:00
W9. What is Involved in Medication Reconciliation?
Ms. Yvonne Allinson
Chief Executive Officer, The Society of Hospital Pharmacists of Australia, Victoria, Australia
DUBAI D
09:00 – 10:00
W3. Patient education with emphasis on patients with chronic rheumatoid conditions
Mr. Frank Jørgensen, MSc Pharm
Diploma in Clinical Pharmacy, Haukeland Hospital Pharmacy, Bergen, Norway
President of European Society of Clinical Pharmacy
11:00 – 12:00
W12. Clinical Education – Pharmacists Becoming Better Preceptors
Dr. David CM Kong, Ph.D.
Department of Pharmacy Practice, Centre for Medicine Use and Safety,
Monash University, Australia
D U P H A T 2009
www.duphat.ae
33
Chairman: Dr. Ali Al Sayed Hussain, MS, Ph.D.
Co-Chairman: Dr. Qasim Ahmed Al Riyami, B. Pharm, M. Phil, M.Ed
DAY 1 - 29 MARCH 2009
Location : Ajman D
Chairperson: Dr. Qasim Ahmed Al Riyami, B. Pharm, M. Phil, M.Ed
34
11:00 – 12:00
Opening of Session
Presentation 1
Pharmacovigilance: WHO Perspective
12:00 – 13:00
Presentation 2
Dr. Syed Rizwanuddin Ahmad, M.D.,M.P.H., F.I.S.P.E., F.C.P.
Adjunct Assistant Professor, Department of Family Medicine,
Georgetown University School of Medicine, Washington, DC, USA.
Medical Epidemiologist, Division of Epidemiology, Office of Surveillance and Epidemiology,
Food and Drug Administration, Center for Drug Evaluation and Research,
Silver Spring, MD, USA
Pharmacovigilance - An Overview
14:30 – 15:30
Workshop – 1
Dr. Qasim Ahmed Al Riyami, B. Pharm, M. Phil, M.Ed,
Clinical Pharm, Teaching (Univ. Leeds), Assistant Dean for Training,
College of Pharmacy & Nursing, University of Nizwa, Oman
DAY 2 - 30 MARCH 2009
Location : Ajman D
Chairperson: Prof. Robert D. Sindelar, Ph.D.,
Professor and Dean, Faculty of Pharmaceutical Sciences,
The University of British Columbia, Canada
9:00 – 9:45
Presentation 3
Dr. Sahar Abu-Omar, MSc, CPHQ
Senior Clinical Affairs Specialist- Pharmaceutical, Clinical Affairs Division,
Abu Dhabi Health Services Company “SEHA”
Abu-Dhabi, UAE
Adverse Drug Reactions: Classification, Mechanism and Role of Pharmacogenetics on ADR
9:45 – 10:30
Presentation 4
Prof. H.G.M. Leufkens, Pharm. D., Ph.D.
Utrecht University, Faculty of Science, Utrecht Institute for Pharmaceutical Sciences (UIPS)
Division of Pharmacoepidemiology & Pharmacotherapy, Utrecht & Chair of Dutch
Medicines Eva luation Board (MEB), The Netherlands
Pharmacovigilance as a Learning Device in Drug Innovation
10:30 – 11:00
COFFEE BREAK
Chairperson: Prof. Jeff Poston, B.Pharm., PhD, MRPharmS.
Executive Director, Canadian Pharmacists Association (CPhA), Canad
11:00 – 11:45
Presentation 5
Dr. Qasim Ahmed Al Riyami, B. Pharm, M. Phil, M.Ed,
Clinical Pharm, Teaching (Univ. Leeds), Assistant Dean for Training,
College of Pharmacy & Nursing, University of Nizwa, Oman
Role of the Schools of Pharmacy & Medicine in Adverse Drug Reactions (ADR) Monitoring
11:45 – 12:30
Presentation 6
Quality Assurance for Pharmacovigilance: Guidance for Good Pharmacovigilance and
Pharmacoepidemiologic Assessment
12:30 – 13:15
Presentation 7
The Agony and the Ambiguity of Translating Pharmacoepidemiologic Findings into Public Policy
14:30 – 15:30
Workshop - 2
Dr. Syed Rizwanuddin Ahmad, M.D.,M.P.H., F.I.S.P.E., F.C.P.
Food and Drug Administration, Center for Drug Evaluation and Research, Silver Spring, MD, USA
D U P H A T 2009
www.duphat.ae
35
Parallel Session Schedule
DAY 1 - 29 MARCH 2009
Location : Dubai A & B
Chairperson: Prof. Labiba El Khordagui, Ph.D.
Professor of Pharmaceutics, Faculty of Pharmacy, Alexandria University, Egypt
11:00 – 11:30
Dr. Fatima Al Braiki, MHCA, M.Sc.
Registration & Drug Control Department, Ministry of Health, UAE
P001, Update – UAE Regulatory System
11:30 – 12:00
Dr. Rafiq R. A. Abou-Shaaban, Ph.D.
Director of Drug Information and Poison Center
Ajman University of Science and Technology Network
Al Fujairah Campus, United Arab Emirates
P01, Pharmacoeconomics of Therapeutic Managements in Primary Health Care:
Cost Effective Analysis
12:00 – 12:30
Prof. Katerina Goracinova, Ph.D.
Faculty of Pharmacy, Intitute of Pharmaceutical Technology and Biopharmacy,
University of St Cyril and Methodius, Macedonia
P1, Patient Screening and Pharmacist’s Evaluation to Ensure Appropriate “Over-The-Counter”
Advice in Community Pharmacies for Management of Dysmenorrheal and Arthritis Pain
12:30 – 13:00
Dr. Loay Awad
Ludwig Institute for Cancer Research, Lausanne, Switzerland
P2, Synthesis of a Cluster of a C-linked Disaccharide Analogue of the
Thomsen- Friedenreich (TF)-Epitope, precursor of a Potential Anticancer Vaccine
DAY 2 - 30 MARCH 2009
Chairperson: Prof. Ismail I. I. Hewala, Ph.D.
09:00 – 09:30
Dr. Abdel-Azim Zaghloul, Ph.D.
Associate Professor in Faculty of Pharmacy, Kuwait University, Safat, Kuwait
P3, Novel Self-Emulsifying Drug Delivery System of Ibuprofen (IBSEDDS):
Formulation, Optimization and Characterization Study
09:30 – 10:00
Ph. Fatma Ali A. Al-Raisi, M.Sc.
Nephrology Clinical Pharmacist, Royal Hospital - MOH, Sultanate of Oman
P4, Prophylaxis for Opportunistic Infections for Kidney Transplantation Recipients in Oman
10:00 – 10:30
Mr. Michael E. Coughlin, MS, MBA
Founder, President & CEO, ScriptPro, Kansas, USA
P5, Design, Operation, Implementation & Evaluation of Advanced Integrated Robotics-Based
Workflow Systems
10:30 – 11:00
COFFE BREAK
Chairperson: Dr. Emad El Azazy, Pharm. D., Ph.D.
CEO of Professional Pharma Inc for Pharmaceutical Consulting Training & Quality Management,
Consultant, Egyptian National Training Institute Ministry of Health and Population &
Professional Secretary of EMRO Pharm Forum, Egypt
11:00 – 11:30
36
Dr. Imran Fahmi Khudair, BSc.Pharm
Clinical Pharmacist, Medic , Pharmacy Department (Clinical Pharmacy Services),
Hamad General Hospital, Hamad Medical Corporation, Doha, Qatar.
P6, Evaluation of Patient’s Knowledge About Warfarin in Outpatient Anticoagulation
Clinics in a Teaching Hospital in Qatar
11:30 – 12:00
Dr. Khalaf Ali Jumah, M.Sc.
Pharmacy Director, Al Amal Psychiatric Hospital, Riyadh, Saudi Arabia and
Chairman of Continuing Education Committee in Saudi Pharmaceutical Society
P7, The Impact of Public Health Campaign on Awareness, Conception and Behaviors Related to
Asthma Medication “ Saudi Pharmaceutical Society Experience “
12:00 – 12:30
Dr. Manal Zaidan, B.Sc (Pharm)
Director of Pharmacy, Al Amal Cancer Centre, Hamad Medical Corporation, Doha- Qatar
P8, USP Chapter 797: A Management Success Story from Qatar
12:30 – 13:00
Dr. Nehad Mehdi Hamoudi, Ph.D.
Ras Al Khaimah College of Pharmaceutical Sciences,
Ras Al Khaimah Medical & Health Sciences University, Ras Al Khaimah, UAE
P9, Problem Based Learning and Its Impact on Learning Behavior of
3rd Semester B.Pharm Students in Pharmaceutical Analytical Chemistry
DAY 3 - 31 MARCH 2009
Chairperson: Dr. Ibrahim Al Khars, MS, MBA
Executive Director - Almana PharmaCare, Coordinator of academic and
training programs in Almana General Hospitals at Khobar, Saudi Arabia
09:00 – 09:30
Dr. Abdulmohsen AlRohaimi, Ph.D.
Director of Research and Publication, The Food and Drug Authority,
(SFDA) – DRUG SECTOR, Saudi Arabia
P15, Trends in Regulating Biosimilars in kingdom of Saudi Arabia
9:30 – 10:00
Dr. Taleb H. Al-Tel, Ph.D.
Associate Profesor in Medicinal Chemistry, College of Pharmacy, University of Sharjah, UAE
P11, Rational Design of Potent and Novel BACE1 Inhibitors: A Possible Cure for Alzheimer’s
10:00 – 10:30
Dr. Abdullatif Alokifi, B.Sc., R. Ph, MHHA
Chief Pharmacist, Pharmaceutical Care Department, Sultan Bin Abdulaziz Humanitarian City,
Saudi Arabia
P12, How to make your Pharmacy Ready for the Accreditation and Maintain Readiness
“Sultan Bin Abdulaziz Humanitarian City’s experience”
10:30 – 11:00
COFFE BREAK
Chairperson: Dr. Renée T. Juhl, Pharm.D.
Adjunct Associate Professor, Department of Pharmaceutical Sciences,
School of Pharmacy, Pittsburgh, USA
11:00 – 11:30
Mr. Gaspar G. DeViedma
Vice President, International Operations, Health Robotics, Bozen, Italy
P13, Presenting i.v.STATION™: A New Robotic Solution for Aseptic Compounding
of Non-Hazardous Medications
11:30 – 12:00
Dr. Mubarak Nasser Al Ameri
Head of Pharmacy Department, Zayed Military Hospital, Abu Dhabi
Ph.D. Student, Queen Mary University of London, UK
P14, The Pharmaco-economics of Using Generics Versus Brands of Immunosuppressive Drugs
12:00 – 12:30
Dr. Marlene Moukarzel, Pharm.D BCNSP,
ICU Clinical Pharmacist, Mafraq Hospital, Abu Dhabi, United Arab Emirates
P17, Anticoagulants review: a case study approach
D U P H A T 2009
www.duphat.ae
37
Exclusive Parallel Session
DAY 2 - 30 MARCH 2009
Location : Dubai A & B Meeting Room
The Role of Emollients / Pharmacists in Eczema Management
14:00 – 14:30
P10. Wonders of the skin barrier: scientific update
Dr. Ashraf Reda, Doctor degree in Dermatology & Venereology in Shams University, Cairo, Egypt
Mayo Clinic, Rochester, Minnesota, USA & Consultant Dermatologist, Welcare Hospital,
Dubai, UAE
14:30 – 15:00
P10a. Facts and myths of moisturizers
Dr. Makram Nicola, Astellas Europe Int. B.V Near and Middle East Medical Manager.
15:00 – 15:45
P10b. The impact of pharmaceutical care in skin disease management: results from
a large Middle East study
Dr. Hassan El Husseini, Dermato-Venereology and Cosmetology Specialist FRANCE,
Al Hosn Medical Centre Abu-Dhabi, UAE
Sponsored by:
38
DAY 3 - 31 MARCH 2009
Location : Ajman D
Chairperson: Prof. Abdulla M. Molokhia, Ph.D.
Chairman, EEPI, Professor, Pharmaceutics, Egypt
9:00 – 9:30
F03. Design and synthesis of novel β-Carboline Derivatives as potential Phospodiesterase
Inhibitors and Anti-cancer agents
Prof. Dr. Ashraf H. Abadi, Ph.D.
Head, Pharmaceutical Chemistry Department, Faculty of Pharmacy and Biotechnology,
The German University in Cairo-GUC, New Cairo City, Egypt
9:30 – 10:00
F04. Development of sugar decorated nanoparticles targeting activated endothelium
Mr. Emile Jubeli, MSc., (Ph.D.)
Laboratory: UMR CNRS Physico-Chemestry - Pharmacotechology – Biopharmacy.
Institution : School of Pharmacy , University, Paris, France
10:00 – 10:30
F28. Design and Formulation of Candesartan Cilexetil Tablet
Dr. Ahlam A. Khayrollah, Ph.D.
Head of Pharmaceutical Sciences Department, College of Pharmacy, University of Mosul, Iraq
10:30 - 11:00
COFFE BREAK
Chairperson: Dr. Yousif Abdu Asiri, Ph.D.
Dean and Associate Professor, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia
11:00 – 11:30
F15. Targeting DNA repair: Is it a right way for sensitization of tumor cells to 5-FU ?
Prof. Raafat El-Awady, Ph.D.
Associate Professor of Pharmacology, College of Pharmacy, University of Sharjah, UAE
11:30 – 12:00
F16. Effect of Atorvastatin on Oxidative Stress Parameters and Lipid Profile in
Type 2 Diabetic Patients
Dr. Najah R Hadi, Ph.D.
Head Dept. of Pharmacology and Therapeutics, Kufa Faculty of Medicine, Iraq
12:00 – 12:30
F17. Professional satisfaction in a Middle East Country: pharmacist opinions in Qatar
Dr. Maguy El Hajj, BScPharm, Pharm.D
Assistant Professor, Clinical Pharmacy and Practice, College of Pharmacy,
Qatar University, Doha, Qatar
12:30 – 13:00
F23. Polypharmacy among psychiatric outpatients in Kuwait
Prof. Nabeel Eisa Al-Saffar, Ph.D.
Assistant Professor, Director of Pharmacy Students Placements, Department of Pharmacy Practice,
Faculty of Pharmacy, Kuwait University, Kuwait
13:00 – 13:30
F30. Rosiglitazone Medication Utilization Evaluation in Tawam Hospital
Dr. Yasir A. Ibrahim, BS, PharmD (Hons & Dist), MS, BCPS, AQID
Critical Care Clinical Pharmacy Specialist,
Tawam Hospital in Affiliation with Johns Hopkins Medicine, Adjunct Assistant Professor,
Faculty of Medicine and Health Sciences, UAE Univsersity, Al-Ain, UAE
D U P H A T 2009
www.duphat.ae
39
PANEL A
Venue: Dubai D
Time: 14:30 – 16:00
Student Oral Presentations - Panel A
Panel of Jury:
Prof. Charles E. Daniels, R.Ph., MS, PhD.
Associate Dean for Clinical Affairs & Professor of Clinical Pharmacy, School of Pharmacy and
Pharmaceutical Sciences, University of California, San Diego & Pharmacist-In-Chief,
UCSD Medical Center, USA
Prof. H.G.M. Leufkens, Pharm. D., Ph.D.,
Utrecht University, Faculty of Science, Utrecht Institute for Pharmaceutical Sciences (UIPS),
Division of Pharmacoepidemiology & Pharmacotherapy, Utrecht & Chair of Dutch Medicines
Evaluation Board (MEB), The Netherlands
Prof. Yusuke Tanigawara, Ph.D.
Code A1
Aly Mohamed Essam Agamy
Final year student, Faculty of Pharmacy, University of Alexandria, Egypt
Supervised by:
Prof. Labiba K. El-Khordagui, Ph.D.
Professor of Pharmaceutics, Faculty of Pharmacy, University of Alexandria, Egypt
Title: Herbal medicines: from history to the future
Abstract: Since the dawn of time, people have known inherited herbal recipes from their ancestors starting from the mummification
of the ancient Egyptian kings, passing by medicine of the Prophet to modern life health care. Several years ago, herbal medicine
was believed to be unscientific, unproven, ineffective, and possibly dangerous. At the same time chemical drugs were labelled as
modern and efficacious, when so many of them are in fact derived from herbs. Recently, a general trend evolved advocating the use
of herbal medicines to reduce the deleterious side effects of chemical compounds. This led to the widespread use of herbal medicines
but without adequate regulation by the health care system. Accordingly, there is a real need to assess the patterns of use of herbal
medicines in the society in order to promote their rational use.
A survey was conducted on an Egyptian population, about the beliefs and use of herbal medicines. The results indicated a strong belief
of Egyptians in the therapeutic efficacy of herbal medicines with an overestimation of their safety and the knowledge and experience of
local herbalists. The survey outcomes raise great concerns regarding the impact of the inadequately informed use of herbal medicines
on people's health. They also point to the need for regulation of herbal medicines by the health regulatory authority, the fabrication
of standardized herbal products by authorized manufacturers and to advocate the role of the pharmacist as a pharmaceutical care
provider in the informed use of herbal medicines.
More studies should be undertaken to provide the health authority and pharmaceutical education with data to be used as a platform
for regulatory and educational changes.
40
Code A2
Co-Author:
Sana Ghalib
Supervised by:
Dr. Nihal Abdulla, Faculty of Pharmacy and Health Sciences, Ajman University of Science and Technology, UAE
Student Oral Presentations - Panel A
Nisreen Nabil
Faculty of Pharmacy and Health Sciences, Ajman University of Science and Technology, UAE
Title: The Silent Thief
Abstract: Osteoporosis is a silent thief that you won’t be able to feel or see your bones while becoming weaker, so it’s very important
to increase people’s awareness about such a disease.
The aim of our project is mainly to discuss the risk factors of osteoporosis, diagnosis, types, management, and treatment.
A questionnaire was formulated based on extensive research, where it was used as the primary tool for data collection in addition
we visited hospitals in Dubai {American Hospital}, Sharjah {Al Zahra Hospital}, and Ajman {Khalifa Hospital}, to gather the required
statistics and information about our topics.
Code A3
Farah M. Anas
4th year Dubai Pharmacy College, Dubai, UAE
Co-Authors:
Alaa Attaallah, , Hanan Shaban and Zainab Mijbil
Supervised by:
Dr. Saeed A Khan and Dr. Fazilatun Nessa
Dubai Pharmacy College, Dubai, UAE
Title: A process for producing of Chitosan from shrimp shell waste
Abstract: Chitosan is a natural carbohydrate derived of chitin. Chitin is a major component of crustacean shells. Chitosan is a nontoxic, biodegradable and biocompatible polymer. Over the last several years, chitinous polymers, especially chitosan, have received
increased attention as one of the promising renewable polymeric materials for their extensive applications in the pharmaceutical,
food and biomedical industries. Therefore, a process has been developed for the production of chitosan by utilizing shrimp shell
waste. Chitosan is made from chitin by a chemical process involving demineralization, deproteinization, and deacetylation. Very little
work has been done to demonstrate the effects of altering or excluding any of the processing steps on chitosan characteristics. The
present study was undertaken to develop a process and to evaluate the effects of process modification during chitosan production on
the physiochemical and functional properties of shrimp shells chitosans. Results indicated that process modification of shrimp shell
chitosan production yielded some differences on each characteristic. This study demonstrated that process modification of chitosan
production affected physicochemical and functional properties. The optimal chitosan production may vary depending on the intended
final usages in food systems as well as in pharmaceutical, and biomedical industries.
D U P H A T 2009
www.duphat.ae
41
PANEL B
Venue: Dubai A & B
Time: 14:30 – 15:30
Panel of Jury:
Student Oral Presentations - Panel B
Prof. Robert D. Sindelar, Ph.D.,
Professor and Dean, Faculty of Pharmaceutical Sciences, The University of British Columbia, Canada
Code B4
Mahmoud Abd-El Rahman Bakir
Supervised by:
Professor of Pharmaceutics, Faculty of Pharmacy, University of Alexandria, Egypt
Title: Just Influenza but this time it’s deadly!!!
Abstract: Avian influenza (AI) is a virus-caused disease usually infecting birds. The virus strains are divided into two groups based on
pathogenicity. Most strains are classified as low pathogenicity (LPAI) which can mutate to the more highly pathogenic forms (HPAI)
which is more virulent. People can get HPAI from birds, but it requires extensive close contact with infected birds.
The virus posses a great risk to the whole world as it is still spreading and casualties are still falling, so it is very important for every
human being living on this earth to be aware of the strategic actions taken to stop the virus from spreading.
The strain that is currently a problem is H5N1 HPAI and has spread from Southeast Asia to at least 55 nations around the world.
Egypt is one of the top six nations in facing the invasion of the virus. Of the 51 cases confirmed to date in Egypt, 23 have been fatal. A
survey was conducted to assess the situation in Egypt. Results showed that some of the decisions taken were hasty but most of them
were very successful in containing the virus and in retaining normal life of the Egyptian society. Results also indicated an important
public awareness role played by community pharmacists in this respect.
The Egyptian experience and the significant role played by the pharmacist both in rural and urban areas may be of great interest to
other countries as the current situation really concerns every person around the globe.
42
Code B5
Co-Authors:
Hawra Ali, Sara Majdi and Nadin Numan
Supervised by:
Director, Pharmceutical Services Department, Dubai Health Authority, Dubai, UAE
Student Oral Presentations - Panel B
Saba Khan
4th Year, Dubai Pharmacy College, Dubai, UAE
Title: Rational use of NSAIDs with Gastroprotective drugs
Abstract: To investigate to what extent recommendations for co-prescribing gastro-protective agents in prevention of NSAIDinduced gastrointestinal complications are followed in clinical practice, since there is an occurrence of neglect. The aim of our study
is to evaluate the prevalence of concomitant use of gastroprotectives with NSAIDs in patients, because chronic NSAID use has been
implicated in the development of severe and potentially life-threatening gastointestinal complications, emphasis were made on age
over 65 years, prolonged use and other drugs like COX-2 selective NSAIDS. If people have at least one of these risk factors, and have
to take an NSAID then some form of gastroprotection is recommended!!
D U P H A T 2009
www.duphat.ae
43
PANEL C
Venue: Dubai E & F
Time: 14:30 – 15:30
Panel of Jury:
Prof. Nancy A. Nickman, Ph.D.
Pharmacotherapy and Presidential Teaching Scholar, Department of Pharmacotherapy and
Pharmacotherapy Outcomes Research Center, University of Utah, Salt Lake City, USA
Student Oral Presentations - Panel C
Prof. Ole J. Bjerrum D.MSc.
Department Pharmacology and pharmacotherapy, FARMA, University of Copenhagen,
Copenhagen, Denmark
Prof. DK Theo Raynor, Ph.D., B.Pharm., MRPharmS
Professor of Pharmacy Practice & Executive Chairman, LUTO Research Ltd,
School of Healthcare, Baines Wing, University of Leeds, UK
Code C6
Mohamed Saad Tawfik El Yamany
Supervised by:
Professor of Pharmaceutics, Faculty of Pharmacy. University of Alexandria, Egypt
Title: Throw it away the proper way
Abstract: Home cabinets are usually filled with unused or expired medications. Whether these are a few extra pills from a prescription
or a medicine that just did not work properly, it does not matter. What does really matter is how unused medicines are disposed of.
Improper medicinal disposal is harmful to the environment, not mentioning its effect on antibiotic resistance, disease transmission
and drug misuse. The way of disposal of medicinal products varies at each stage in the pathway of the product cycle starting from the
factory passing by hospitals and pharmacies till reaching the patient's home; depending on the nature of the product as well as the
scale of disposal. Thus, it is of great importance to raise awareness among health care professionals and the public of the proper ways
of disposal of unused medicines in all stages of the product cycle.
A survey about disposal of unused medicines was conducted at the different stages of the product cycle. The current medicinal
disposal practices were compared with those recommended in guidelines. Data analysis indicated that the current practices are nonoptimal bearing in mind that perfection cannot be accomplished.
Outcomes of the survey are of great importance to the health regulatory authority, health care community, patients and the public.
More necessary actions should be taken at educational, pharmacy practice and health policy levels to improve medicine disposal
practices in order to reduce the impact of improper practices on public health and the environment.
44
Code C7
Co-Authors :
Eman M. Hassan Ahmed, Reem S, Marwa Ghani
Supervised by :
Dr. Heyam Saad Ali
Dubai Pharmacy College, Dubai, UAE
Student Oral Presentations - Panel C
Mai Bakr
4th Year, Dubai Pharmacy College, Dubai, UAE
Title: The Effects of light exposure on Silver Sulfadiazine cream Comparative studies of
different types of container
Abstract: Objective: The experiment was designed to find the reason of changing color of Sulfadiazine cream manufactured by
Julphar packed in plastic container. 500 gm
Methods: The prepared cream was filled into 1) White plastic container. 2) Black plastic container and 3) white plastic container
covered with white cap along with aluminum foil liner (inside) and all the samples were kept in normal condition and under exposure
to light to examine the effect of container to protect the exposure of light to the product. After seven days samples were examined
visually and transmittance of light through different containers were examined as per UPS method. Experimental samples were
compared against reference samples packed in Black plastic container.
Results: On exposure to light the color of the sample in black container was not changed. The color of the sample kept in white
container with cap along with aluminum foil was not changed remarkably It was observed that light mostly affect the surface (top of
the container) of the cream not inside.
Conclusion: Findings indicate that the black container is a suitable container as a primary packaging material of Silver Sulphadiazine
cream (SSD).
D U P H A T 2009
www.duphat.ae
45
29, 30 & 31 March 2009
Dr. Medhat Sweillam
International Trainer, Egypt
Dr. Sweillam is renowned international trainer who is developing & delivering programs to international
organizations in various management, skills and leadership topics. He is a pharmacist and has a Master
degree in business administration (MBA) from the American University in Cairo
Venue: Dubai C
Time: 09:00 - 13:00 (all 3 days)
Getting Results Without Authority
Introduction:
Nowadays more things get done through influence than through giving orders. The days of commandand-control and management by decree are quickly disappearing. Largely from cross-functional teams
populated by people who show little tolerance for unquestioned authority. Executives and managers
need influence skills to make things happen. The three-day seminar, you are about to attend, gives
participants practical, hands-on experience in influence skills. Participants will go home with several
tools and actual practice to help them become better influencers.
Program objectives:
•
Assess your own profile and understand how it affects your communication and
ability to influence.
•
Determine another person’s profile and speak in a way that honors his or her preferences
and better enables that person to understand your message.
•
Assess your listening style and improve listening capabilities.
•
Use various types of arguments when advocating a position, tailoring them to the other
person’s profile or readiness.
•
Use tools to help you understand your own needs and the needs and interests of bosses,
colleagues, reports.
•
Learn how to establish credibility when you lack authority.
•
Appreciate the possibilities inherent in conflict and learn how to settle conflicts in
a no-lose fashion.
•
Identify various win/lose negotiating techniques and how to promote win/win
negotiations.
•
Negotiate in a collaborative manner.
Program content:
46
•
Rank (Authority vs. Influence)
•
How Personal Preference Can Enable or Hinder Influence
•
Understanding Others
•
Persuasion
•
The Role of listening in Influence
•
Conflict
•
Negotiation
29, 30 & 31 March 2009
Dr. Roger Saba
Training & Development Manager, Eli Lilly Co.
Venue:
Dubai C
Timings: 14:00 – 16:00 (all 3 days)
The Art of Coaching
Brief course description
The art of coaching workshop is designed to introduce you to the international Coaching Model,
including terms, processes and techniques to ensure coaching is consistent with people development .
This 8 hour workshop is designed to be highly interactive and engaging. It draws upon techniques such
as stories, visuals, hands-on demos, and memory cues to help the learner discover, explore and practice
peer coaching.
Course outline
1- Leadership Behaviors and coaching:
•
Thoughts on leadership behaviors
•
The self development process: From diagnosing development needs to providing self
development support.
2- The International coaching model:
•
STEP 1 - Observing, listening and mutual diagnosis: bench marking with
standard expectations.
•
STEP 2 – Exchanging feedback: Motivational, evaluative & developmental feedback;
rules of effective feedback; conflict resolution with transactional analysis.
•
STEP 3 – Determine next steps: standards of an action plan
•
STEP 4 – Follow up: Standards of effective follow up
D U P H A T 2009
www.duphat.ae
47
Acknowledgment
48
Acknowledgment
D U P H A T 2009
www.duphat.ae
49
50
DAY - 1
29TH MARCH 2009
SUNDAY
D U P H A T 2009
www.duphat.ae
51
Abstract
(Day - 1) - Sunday 29th March 2009
Pharmaceutical Outcomes Research and Its Application to Pharmaceutical
Services
Day 1 29th March 2009
Mr. Kevin J. Colgan. MA, RPh, FASHP, President ASHP. USA
Senior Vice President, Health Economics and Outcomes Research, Oak Brook, Illinois, USA
Venue: Sheikh Rashid Hall - A
Time: 11:00 - 11:45
Healthcare outcomes are often considered when making healthcare policy decisions at both the local
and national level. Numerous outcomes research studies are often required to make one decision, be it
a formulary decision or a clinical guideline decision. In general, outcomes are described in one or more
of three broad categories, namely those that are clinical, economic, or humanistic.
Clinical outcomes research explores issues of drug safety, utilization, efficacy, and effectiveness typically
utilizing randomized control trials for pre-approval analysis and observational data for post-approval
analysis. One of four pharmacoepidemiologic study designs are commonly used, including cohort
studies, case-control studies, case-crossover studies, and case-time control studies.
Economic outcomes research identifies relevant alternatives for treatment or services and the cost
of their outcomes utilizing one of five analysis methods, including cost-minimization analysis, costbenefit analysis, cost-effectiveness analysis, cost-utility analysis, and cost-consequence analysis. The
perspective of the study and the weighing of different outcomes by the decision-maker are of particular
importance.
Patient-reported outcomes is an all-encompassing term to describe humanistic research used to
recognize and value the patient’s perception of a therapeutic intervention. This research includes the
patient’s subjective assessment of symptoms and treatment satisfaction based on what is important to
the patient.
Each of these broad categories of research will be described and case studies will be utilized to
demonstrate their application to pharmaceutical services. Models for clinical benchmarking and
national performance measures will also be illustrated and discussed.
52
Abstract
Using consumer medicines information to improve patient outcomes and
promote the safe and effective use of medicines
Prof. DK Theo Raynor, Ph.D., BPharm., MRPharmS, Professor of Pharmacy Practice &
Executive Chairman, LUTO Research Ltd, School of Healthcare, Baines Wing, University of Leeds, UK
Time: 11:45 - 12:30
Most medicines will not produce acceptable patient outcomes without an informed medicine-taker.
To be able to use medicines safely and effectively, people need understandable and accessible spoken
and written information.
A recent review of the research on consumer medicine information[1] showed that people need
information for two main reasons:
a) when deciding whether a medicine is right for them
b) to help them take such medicines safely and effectively.
A further key finding was that spoken information remains the priority of patients (written information
should support, and not replace, spoken information).
Getting people to become more involved in the decision-making about their medicines may make them
more likely to take them as prescribed. Such partnership in medicine taking depends on being able to
access the information they need and being able to understand it.
Stakeholders need to make sure that the written information supplied to patients is accessible and
understandable. However, patients have long complained that the leaflets that come with their
medicines do not meet their needs. This is being addressed in the European Union through mandatory
“user-testing” of patient information leaflets by lay people. This is transforming the usability of leaflets
in the European Union and has the potential to do the same elsewhere. The process could also be
applied to other patient materials such as those accompanying medical devices or clinical trials patient
information sheets.
Future developments will include increasing used of the internet as a source of medicines information.
However, there is limited research on the impact of such information. Other priorities include improving
the way we describe the likelihood of side-effects, and including more positive (‘benefit’) information to
balance the mainly negative information in leaflets). Only then can people truly start to make informed
decisions about whether a medicine is right for them.
D U P H A T 2009
www.duphat.ae
53
Abstract
Ethnic difference in drug response and its implications in regional drug use
Prof. Yusuke Tanigawara, Ph.D., Department of Pharmacy, School of Medicine,
Keio University , Tokyo, Japan
Time: 12:30 - 13:15
A
greater deal of attention has been given to the multi-national global drug development to save
time and cost of drug development, to avoid redundant clinical trials and for minimal delayed launch
at the major drug markets. However, on the other hand, differences in response to medical products
have been observed in different populations with different racial and ethnic origins. Japan is the
most experienced country for such ethnic differences in the process of drug development and new
drug registration for the last decade. The approved doses for some widely prescribed drugs have been
different in Japan and the Western countries.
The ethnic difference in drug response and consequently recommended doses and dosing regimens,
may be caused by intrinsic and extrinsic factors. The intrinsic ethnic factors include genetic variations
and metabolic activity with respect to different races, while the extrinsic ethnic factors are associated
with environmental and social/cultural differences such as medical practice, diet, concomitant drug use,
and local regulatory environment. The ICH guideline “E5: Ethnic factors in the acceptability of foreign
clinical data” issued in 1998, discusses how to deal with the ethnic difference in drug development and
approval.
The framework of pharmacokinetics (PK) and pharmacodynamics (PD) is particularly useful when we
consider an appropriate regional dose for new populations. As a scientific rationale for optimal regional
dose setting, a “bridging” data package has been used successfully which compares PK and PD together
with efficacy/safety profiles between Japanese (new) and Western (original) populations. This means
that the Western doses are not automatically applied to Japanese patients. The pharmacogenomic data
is also useful for considerations related to ethnic factors.
In conclusion, science-based consideration is recommended to provide the highest quality of medication
service with optimal dose and dosage regimen for patients with different ethnic backgrounds.
54
Abstract
Leading Effective Change in Pharmacy Practice
Dr. Jeff Poston, B.Pharm., Ph.D., MRPharm S., Executive Director, Canadian Pharmacists
Association (CPhA), Canada
Time: 14:30 - 15:15
P
harmacy practice is changing. The profession is working to strengthen its alignment with the health
care needs of populations and to respond to stresses on the health care system. This change will
result in new roles for both pharmacists and pharmacy technicians that take full advantage of their
knowledge and skills. Pharmacists must shift more attention to patient-centred, outcomes-focused care
to optimize the safe and effective use of medications. Regulated pharmacy technicians will assume
greater responsibility for drug distribution activities.
A major change management initiative in Canada to lead and support practice change is the Blueprint
for Pharmacy project (www.pharmacists.ca/blueprint), led by the Canadian Pharmacists Association
(CPhA) in collaboration with a large number of other pharmacy organizations and stakeholders.
In 2007, pharmacists, pharmacy students and technicians were surveyed on the need for a common
vision for the future of pharmacy. Survey results (n=718) found that 85% definitely see the need for
a common vision and action plan, and 90% think that the profession needs to change and respond
to future changes in the health care system. It is recognized that change will not come easily—an
integrated approach is needed to support change in pharmacy practice. Such change requires a common
vision, leadership and collaboration.
The Task Force on a Blueprint for Pharmacy was established by CPhA in December 2006 to define a
vision for pharmacy and to develop a strategic action plan for the future of the profession. In February
2008, the Task Force established five expert working groups to further develop the implementation
plan to realize the Vision for Pharmacy. The Blueprint process aligns with the eight critical steps offered
by John Kotter, a leading expert in organizational change, in achieving practice change in pharmacy.
In June 2008, following extensive consultations with individual pharmacists and pharmacy
organizations across Canada, the Task Force launched the document “Blueprint for Pharmacy: The
Vision for Pharmacy”. It puts forth a new Vision for Pharmacy: Optimal drug therapy outcomes for
Canadians through patient-centred care. This document reviews medication use challenges and the
current and future role of pharmacists and pharmacy technicians in the health care system. It also
outlines the key elements and proposed strategic actions in five key areas required to achieve the Vision
and meet the future health care needs of Canadians:
•
•
•
•
•
pharmacy human resources
education and continuing professional development
information and communication technology
financial viability and sustainability
legislation, regulation and liability
The process of implementing the Blueprint will be inclusive, involving the broadest range of pharmacy
stakeholders (pharmacists, pharmacy technicians, national and provincial organizations, pharmacy
chains, and faculties) and the engagement of patients, governments, other health care providers, policy
makers and private payers. Pharmacy organizations across Canada are currently being asked to formally
support the Vision for Pharmacy by signing a Commitment to Act, a pledge to help move the profession
forward by referring to the Blueprint in their own strategic planning and working collaboratively to
implement a pan-Canadian action plan for the future.
D U P H A T 2009
www.duphat.ae
55
Abstract
Quality measurement of pharmacy practice functionality
Dr. Emad El Azazy, Pharm.D., Ph.D., CEO of Professional Pharma Inc for Pharmaceutical
Consulting, Training & Quality Management,, Consultant, Egyptian National Training Institute,
Ministry of Health and Population & Professional Secretary of EMRO Pharm Forum, Egypt.
Time: 15:15 - 16:00
B
ackground: Recently, a great deal of health routines and initiatives have drawn much attention to
quality assurance concept in pharmacy in view of the fact that it being a wide-ranging conception
covering all matters that individually or collectively influence the quality of pharmaceutical product
and services.
Quality management schemes and their value generated into the pharmacy practice can be considered
as the prime benefit for patient and community welfare for many reasons due to heterogeneous
dimensions of controls can be exerted.
To the greatest extent pharmacists are practicing their profession in various ways variably comparable
to their own conduct, habits, knowledge, in addition to the health system, prescribers and/or patients.
Moreover the pharmacy practice decision making processes are sometimes being imposed or proposed;
and in most circumstances endure economical intervention.
On the other hand the unique nature of the pharmaceutical product as an ethical and research or
evidence based product, plus its need for assessment, registration, and accredited facility for service
delivery add more controls.
Objectives:

To understand the quality monitoring concept in pharmacy practice. And make quality
monitoring, improvement and audit plans, as activities in the community pharmacy management
course of action.

To describe planning and implementation dimensions of quality that must be built and measured
into the organization’s mission.

To illustrate the value and methodologies of quality measurement.

To establish key performance metrics and appropriate documentation structure hierarchy.

To demonstrate different methodologies to standardize and accredit pharmacy practice.
Scope: Pragmatically, quality monitoring or auditing is the provision of providing indicator to establish
measures to prove that professional and technical requirements will be met endlessly all the way
through the practice. Thus, management and leadership roles create the foundation of quality functions’
evaluation in professional pharmacy framework.
Eventually the architecture of continuous improvement, services design/redesign, performance
indicators, and outcomes’ analysis as well as the corrective actions significantly enhance the capabilities
and efficiency of the pharmacy practice.
56
Pharmacy Workshops
W1. New Concept for Chromatographic Peak Purity Assessment and
Identification of Drugs in Multi-Component Pharmaceutical Preparations
Prof. Ismail I. I. Hewala, Ph.D., Faculty of Pharmacy, University of Alexandria, Egypt
Venue: Dubai E & F
Time: 11:00 - 12:00
A considerable number of pharmaceutical preparations contains more than one active pharmaceutical
ingredient (API) i.e. multi-component pharmaceutical preparations. The ICH state that there must be
identification tests for each API in their final products and the compendial monographs of the official
multi-component preparations include identification tests for each API.
The common identification tests in most compendia include infrared spectra, melting point, UV spectra
and chromatographic techniques such as TLC, HPLC and GC. Such identification tests could be classified
into two categories. The first category includes tests that depend on absolute characteristic features of
APIs such as melting point, IR and UV. The application of these tests needs tedious, lengthy and timeconsuming extraction procedures for purification of the individual API. The second category includes
tests which depend on arbitrary features of APIs such as retention time (HPLC and GC) and RF values
(TLC). The application of this class of chromatographic identification is limited by compliance with one
or more elements of chromatographic system suitability.In all chromatographic procedures, peak purity
assessment has become a crucial step in the analysis to assure the reliability of the results. In HPLC and
HPTLC analyses, two closely related compounds may not be resolved and hence eluted or migrated as
a single peak or single spot respectively. This situation would result into seriously misleading results in
quantitative analysis, especially if the non-resolved compound is an unknown impurity or degradation
product.
The new concept for testing the chromatographic (HPLC and HPTLC) peak purity uses HPLC or HPTLC
instrument hyphenated with photodiode array detector. The test for peak purity in both techniques
includes the following steps;
(a) Extraction of the UV-absorption spectra at different time intervals throughout the elution time of
each peak on the chromatogram
(b) The construction of the relative absorption spectra of the extracted absorption spectra for each
peak on the chromatogram.
(c) The construction of log A versus the wavelength plots of the extracted absorption spectra for each
peak on the chromatogram.
(d) The construction of the derivative (first, second, third and fourth) spectra of the extracted
absorption and examination of their intersection. The wavelengths of absorption and derivative
optima and their ratios also computed
The identification of the drugs in their multi-component pharmaceutical preparations without prior
separation depend on extraction of the absorption spectra and construction of derivative spectra
at different time intervals throughout the elution of each peak on the HPLC chromatogram. The
wavelengths of derivative optima and derivative ratios are used as characteristic fingerprint of each
drug.
The workshop would include presentation of the new concept using binary mixtures as a model for HPLC
and HPTLC. Two chromatographic conditions are used. The first is chosen so that the two compounds
would elute as a single sharp peak (impure peak). The second is chosen to result into complete
separation and high resolution of the two compounds as sharp peaks (pure peak). The workshop would
also include presentation of the application of the new concept for testing the purity and identity of
multi-component mixtures containing intact drugs, their degradation products and related compounds
using both HPLC and HPTLC techniques.
D U P H A T 2009
www.duphat.ae
57
Pharmacy Workshops
W2. A Case Study Why the Concept of Pharmaceutical Care Did Not Survive and
How Such Errors Can Be Avoided in the Future ?
Prof. Albert I. Wertheimer, Ph.D., MBA,
Venue: Dubai E & F
Time: 12:15 - 13:15
In this workshop we will perform two functions; we will critically analyze the decision making and
mistakes that were made in the marketing of the concept of Pharmaceutical Care, and secondly, we
will take a different concept, one selected by the workshop participants, check its suitability and then
devise a plan to successfully sell it to the public, to health insurers and other payers, to other health care
professions, and to ourselves – the profession of pharmacy.
In this day and age, it is incredible to learn that a proposed new product or service has not been
thoroughly scrutinized in a market research type of investigation, and yet, that appears to be the case
of Pharmaceutical Care. It is essential to determine whether the expected market wants the product
or service, sees it as valuable, and it is necessary to determine what approximate price the target
audience would be willing to pay for it. From that basic data, one may estimate the likely market size
and make a preliminary judgment as to whether or not the product or service might be successful in
the marketplace.
For example, if someone offered to sell me horseshoes, I do not own a horse and there is no price at
which the product would be attractive to me. If many others gave the same response, it would be most
wise for the product developer to swallow his or her pride and go back to the drawing board.
Together, we will go through the process of evaluating a potential professional pharmacy service or
product, using a methodology that is applicable to any and all future proposed pharmacy practice
innovations.
58
Pharmacy Workshops
W11. Clinical Pharmacist Establishing and operating Anticoagulant Clinic in
Ambulatory care
Dr. Maha Al Draimly, MSc, KSA National Guard Comprehensive Specialized Clinics (NGCSC),
Riyadh, Saudia Arabia
Venue: Dubai D
Time: 11:00 - 13:00
The discipline of clinical pharmacy has been involving in the anticoagulant service for over 20 years
in over seas, the role of clinical pharmacist, include providing therapeutic monitoring, warfarin dosage
adjustment, triage of warfarin related and unrelated problems, patient counseling and education, and
co-ordination anti coagulation clinic activities. monitoring parameters include INR,signs and symptoms
of hemorrhage and thromboembolic events, drug-drug interaction, drug-food interaction, drug- disease
interaction and patient compliance. Descriptive reports and comparative trials had indicated that
clinical pharmacist managed anti coagulation services significantly lowered incidence of hemorrhagic
and thrombo embolic events and improved INR control when compared to patient received routine
medical care.
Aim : To update clinical pharmacist and pharmacist for establishing and operating anticoagulant clinic
for achieving the optimum patient care in term of INR control, educate and counseling, reducing drug
related events and improving patient out come.
Contents: Introduction
Pharmacy experience with anticoagulation clinic. (ACC)
Aim of (ACC).
Objectives of (ACC)
I. Organization and management:
a)
b)
c)
d)
Personal.
Care management and coordination.
Communication and documentation.
Laboratory monitoring
II. Process of patient care:
a)
b)
c)
d)
e)
f)
Patient selection and assessment.
Initiation of treatment.
Maintenance and management of therapy.
Dosage adjustment.
Patient education.
Management and triage of patients
III. Guidelines for the evaluation of patients’ outcomes, organization components
D U P H A T 2009
www.duphat.ae
59
Exclusive Session
Presentation 1
Pharmacovigilance: WHO Perspective
Venue: Ajman D
Time: 11:00 - 12:00
Ssafety
afety of medicines is one of the main components of WHO medicine strategy, which emphasizes that
should be assured throughout the process of medicines research and development, production,
registration and also monitored following marketing.
It was not until the disaster caused by thalidomide in 1961 that the first systematic international efforts
were initiated to address drug safety issues.
From these beginnings emerged the practice and science of pharmacovigilance. Systems were developed
in WHO Member States for the collection of individual case histories of ADRs and evaluation of them.
Since the start of the International Programme in 1968. The pilot project has developed into the WHO
Programme for International Drug Monitoring now coordinated by the Uppsala Monitoring Centre
(UMC) in Uppsala, Sweden, with oversight by an international board
The principal function of the Uppsala Monitoring Centre is to manage the international database of
ADR reports received from National Centres. In 2002 this database held nearly three million case
reports. The UMC has established standardized reporting by all National Centres and has facilitated
communication between countries to promote rapid identification of signals.
Pharmacovigilance has developed and will continue to develop in response to the special needs and
according to the particular strengths of members of the WHO Programme and beyond. Such active
influence needs to be encouraged and fostered; it is a source of vigour and originality that has contributed
much to international practice and standards.
WHO has recently published the Guidelines on Safety Monitoring of Herbal Medicines in
pharmacovigilance Systems. The inclusion of herbal medicines in pharmacovigilance systems is becoming
increasingly important given the growing use of herbal products and herbal medicines globally.
In order to encourage WHO member states in the WHO Eastern Mediterranean Region to establish
national pharmacovigilance system, a workshop was organized in Cairo 9–12 May, 1994.
The main recommendations of the workshop include:
Ministries of health should encourage the establishment of national centres for
pharmacovigilance. Collaboration with the drug manufacturing industry, academic institutions
and professional organizations should be taken into consideration. A national plan of action
should be developed with clear objectives, responsibilities, source of funding and a time frame.
Coordination and collaboration of national pharmacovigilance activities with existing activities of
poison and drug information centres on technical matters should be developed.
The national centres for pharmacovigilance should communicate, on a regular basis, with drug
regulatory authorities to support regulatory action, if required; and for example, through
participation in meetings of the regulatory board or committee.
Academic institutions, medical and pharmacy schools should support, and, where necessary, take
the initiative in the development of a drug monitoring system which should include the
introduction of pharmacovigilance in undergraduate courses and in continuing education
programmes, and research studies related to regional conditions.
Unfortunately, little has been done to implement these recommendations in most WHO EMR
countries
Reference:
1. World Health Organization, The Importance of Pharmacovigilance:
Safety Monitoring of Medicinal Products, 2002.
2. Report on the WHO Intercountry Workshop on Post-Marketing Surveillance Cairo,
Egypt, 9-12 May 1994.
60
Exclusive Session
Presentation 2
Pharmacovigilance - An Overview
Dr. Syed Rizwanuddin Ahmad, M.D., M.P.H., F.I.S.P.E., F.C.P.
Food and Drug Administration, Center for Drug Evaluation and Research, Silver Spring, MD, USA
Venue: Ajman D
Time: 12:00 - 13:00
When a new therapeutic product is approved for marketing, its full safety profile is unknown because
of limitations of clinical trials. Typically, these clinical trials are of short duration and involve small
sample size with many restrictions and hence the participants in these trials may not be representative
of the real world where the approved product is eventually used. Many methods exist to further elucidate
the safety profile of a product after approval including spontaneous reporting systems. Spontaneous
reporting system is the process of reporting of unsolicited reports of adverse events from health care
professionals or consumers to any appropriate authority.
In this session, I will define adverse drug reactions, its type; and describe the magnitude of the problem;
define spontaneous reporting system; describe its goals, strengths, limitations, and share some case
examples.
D U P H A T 2009
www.duphat.ae
61
Parallel Session
P001. Update – UAE Regulatory System
Author:
Dr. Fatima Al Braiki, MHCA, M.Sc.
Registration & Drug Control Department, Ministry of Health, UAE
Venue: Dubai A &B
Time: 11:00 - 11:30
P01. Pharmacoeconomics of Therapeutic Managements in Primary Health Care: Cost Effective Analysis
Author:
Dr. Rafiq R. A. Abou-Shaaban, Ph.D.
Director of Drug Information and Poison Center, Ajman University of Science and
Technology Network, Al Fujairah Campus, United Arab Emirates
Venue: Dubai A &B
Time: 11:30 - 12:00
I
ntroduction: The healthcare system is the only system that touches the life of every individual of the society regardless of his or her
status, life style, origin or gender. This may reflect the level of impact that the structure of the healthcare system has on the outcomes
of the process of healthcare giving to the different members of the society.
The Aim of this article is to perform national survey on prescription errors to justify the implementation of IT-Solution to reduce
patient morbidity, mortality and national health cost.
Methodology: The analysis of 23886 prescriptions obtained randomly from primary clinics, pharmacies and hospitals from all Emirates
in United Arab Emirates was done using Greenrain drug database program published by Aroma Software.
Results: The analysis shows that prescriptions with duplication in drug therapy represent 47%. This error was due to prescribing
different trade names with either same therapeutic class (41.83%) or same generic names (5.05%). The survey also revealed that the
total drug-drug interactions with different significances are about 14.63%. About 0.85% of the prescriptions are with significant # 1
which considered to be fatal. The serious ADEs that might lead to hospitalization in both ICU and normal Ward are about 6.26%. In
addition the survey revealed that prescription analyzed with Pregnancy Precautions of Category X, D or C, Breastfeeding Precautions,
Liver Disease Precautions and Renal Impairment Precautions are 77.04%, 93.96%, 89.63% and 90.84% respectively.
Conclusion: The medication errors in UAE cause at least 22000 serious ADEs and mortality of 1600. The pharmacoeconnomics of
this survey indicates that the average cost of a prescription in UAE is about 158.51 AED. The loss due to duplication in drug therapy
equivalent to about 56.61 AED/prescription and the loss due to errors in dispensing 1000 prescription within UAE per year is 44
million AEDs. Therefore IT solution with customized drug database, decision support system and E-pharmacy should be adopted
within UAE health care facilities to reduce medication errors and their consequences.
Learning Objectives:
Upon the completion of this activity, participants should be able to know:
62
•
Types of prescription errors and their route cause analysis
•
Consequences Prescription Errors in United Arab Emirates on Patient safety,
Mortality and National Cost.
•
Different Information Technology solution s that should be adopted within
UAE health care facilities to reduce medication errors and their consequences
Parallel Session
P1. Patient screening and pharmacist’s evaluation to ensure appropriate “over-the-counter” advice in
community pharmacies for management of dysmenorea and arthritis pain
Author:
Prof. Katerina Goracinova, Ph.D.
Intitute of Pharmaceutical technology and Biopharmacy, Faculty of Pharmacy,
University of Sts Cyril and Methodius, Skopje, Macedonia
Venue: Dubai A &B
Time: 12:00 - 12:30
T
oday’s healthcare challenges fosters the development of new and renewed roles for pharmacists in community-based healthcare
system as a highly accessible community-based drug therapy experts who are often the first point of contact with the healthcare
system for patients. Excellence in professional development, application to practice, and evaluation of innovative healthcare delivery
methods are crucial in order to integrate theory and evidence-based practice to practical application in the workplace and serve as an
ongoing resource to promote practice change.
With the continued growth of the elderly population, osteoarthritis is becoming a major medical and financial concern compounding
the growing problem of the enormous economic obligation for treating arthritis, its complications, and resulting disability. Due to the
prevalence of chronic conditions and comorbidity in the elderly population special care has to be taken for coordinating medications
and increased risk of adverse drug reactions and drug interactions. The pharmacist response to the needs of elderly patients with
osteoarthritis as well as patient response to pharmaceutical care was evaluated through questionnaire surveys conducted by researchexperienced community pharmacy specialist in collaboration with pharmacist academic. Patient care for diagnosed patients was
evaluated in terms of quality of collection of patient information, patient advising on OTC therapy and coexisting illness and
medication.
Premenstrual syndrome as a complex psychoneuroendocrine disorder is estimated to affect up to 40% of women of reproductive age.
Improved treatments for these disorders expand the opportunities for pharmacists to contribute to this important area of women’s
health and become a first health care professional patient consults for PMS. Questionnaire designed research on patient care for PMS
pointed that pharmacist can help to identify those who meet the criteria for PMS (advising further help from a clinician), and working
as a team (patient, physician and pharmacist) can help women to better understand their symptoms and benefit from a rational,
individualized treatment plan.
1. Wertheimer A.I., Serradell J. A discussion paper on self-care and its implications for pharmacists. Pharmacy World & Science 2008;
30, 309-315.
2. Mobach M.P. From the laboratory to pharmaceutical care research - Part I. Pharmacy World & Science 2001; 23(6), 205-209(5)
D U P H A T 2009
www.duphat.ae
63
Parallel Session
P2. Synthesis of a Cluster of a C-linked Disaccharide Analogue of the
Thomsen- Friedenreich (TF)-Epitope, precursor of a Potential Anticancer Vaccine
Author:
Dr. Loay Awad
Ludwig Institute for Cancer Research, Lausanne; Switzerland
Co-Author:
Pierre Vogel
Venue: Dubai A &B
Time: 12:30 - 13:00
T
he Thomsen-Friedenreich antigen (T antigen) is a cancer-associated disaccharide which plays an important role in tumor cell-cell
recognition. The immuno dominant part of the T antigen consists of the disaccharide Gal∝1➞3GalNAc∝➞O linked to serine or
threonine. The great potential of clustered antigen motifs such as 1 for anti-tumor vaccines has been demonstrated. [1]
C-linked disaccharide analogues offer stability towards hydrolysis which is catalysed by ubiquitous glycosidases. We wish to present
here the extension of our previous efforts [2] towards the synthesis of C-disaccharide analogues of the T antigen based on a BaylisHillman type of condensation between a D-galactose-derived aldehyde and isolevoglucosenone. [3-4]
[1] S. D. Kuduk, J. B. Schwarz, X.-T. Chen, P. W. Glunz, D. Sames, G. Ragupathi,
P. O. Livingston, S. J. Danishefsky, J. Am. Chem. Soc. 1998, 120, 12474.
[2] Y.-H. Zhu, P. Vogel, Synlett 2001, 79.
[3] Y.-H. Zhu, P. Vogel, Tetrahedron Lett. 1998, 39, 31; Y.-H. Zhu, R. Demange, P.
Vogel, Tetrahedron: Asymmetry 2000, 11, 263;
[4] L. Awad, J. Riedner, P. Vogel, Chem. Eur. J. 2005, 11, 3565 – 3573
64
PUBLICATIONS
D U P H A T 2009
www.duphat.ae
65
66
DAY - 2
30TH MARCH 2009
MONDAY
D U P H A T 2009
www.duphat.ae
67
Abstract
(Day - 2) - Monday 30th March 2009
Realigning Pharmacy Practice Goals Towards Effective Patient Care
Prof. Abdulla M. Molokhia, Ph.D., Chairman, EEPI, Professor, Pharmaceutics
Time: 09:00 - 09:45
The fast development in pharmaceutical sciences and the technological advancement in pharmaceutical
industry have opted the trend of changes in pharmacy practice over the past four decades. The original
focus of pharmacy practice on medicine and its supply has moved towards an explicit focus on patient
care. The role of the pharmacist had developed from a compounder and supplier of medication to service
and information provider.
The implementation of pharmaceutical care approach in service provision had not only added to the
pharmacist challenges within the medical team but lead to significant improvements in patient quality
of life.
In practice, the pharmaceutical care, being new, requires, in addition to old assignments, active pharmacist
participation in documentation, monitoring and review of the care given to patients. The international
bodies like WHO, FIP see the new pharmacy practice to include care-giving, communication, decisionmaking, teaching, life-long learning, leadership, management and research. Programs that include
knowledge, skills and attitudes represent the core in current pharmacy practice training to old pharmacists
and form the base for curricula in pharmacy schools. Public health interventions, pharmaceutical care,
rational medicine use and effective medicine supply management are key components in achieving
effective patient care. Along these lines, the intent of Pharmaceutical Public Health Practice would be to
prevent disease, prolong life, promote, protect and improve health for all.
The introduction of the evidence-based medicine led to integrating best research evidence with clinical
expertise and patient values. The pharmacist is expected to use the “best evidence” in pharmacy practice
including pharmaco-economic analysis. Major challenges in realigning pharmacy practice process
include rising cost of healthcare, limited financial resources, shortage of trained personnel, inefficient
health systems, the huge disease burden and the changing social, technological, economic and political
environment.
68
Abstract
The Community Pharmacist as Smoking Cessation Coach
Prof. Randy P. Juhl, Ph.D., Vice Chancellor and Distinguished Service Professor of Pharmacy,
Time: 09:45 - 10:30
The health consequences of smoking are well known. Heart disease, stroke, complications of pregnancy,
chronic obstructive pulmonary disease (COPD), multiple cancers, and many other diseases are all linked
to smoking or to second hand smoke. In the US more than 400,000 premature deaths occur attributable
to smoking, nearly $100B is lost in productivity of the workforce, and a similar amount is spent on
tobacco related healthcare costs.
Despite more than 50 years of knowledge about the dangers of smoking, the availability of effective
methods to quit smoking and the dramatically higher prices for cigarettes and other tobacco products,
more than 20% adult Americans continue to smoke. This is similar to the rate in the Emirates of 18%.
In general, health professionals all around the world have not been as helpful as we could be to the
approximately 75% of smokers who wish they could quit. Studies have shown that even a very brief
encouraging interaction with clinicians, including pharmacists, can very positively influence a patient’s
chances of successfully fighting this very difficult addiction.
Beginning in 1997 the University of Pittsburgh School of Pharmacy, with the support of Glaxo
SmithKline launched a program to train pharmacists to effectively assist smokers who frequent
community pharmacies in their efforts to become tobacco-free. The program trained over 80,000
pharmacists throughout the United States, and has played an important role in promoting the
pharmacist as a partner in this difficult public health problem.
D U P H A T 2009
www.duphat.ae
69
Abstract
System Approach to Development of the Pharmacy Practice
in the Arab Countries
Time: 11:00 - 11:45
The World Health Report 2000 on Health systems: improving performance conveyed a clear message
about the importance of health system development in achieving the goals of health systems.
The World Bank report Reforming public institutions and strengthening governance and results of
other studies have indicated that the failure of some sound technical interventions addressing specific
problems in various sectors is mainly due to weak systems and institutions.
According to ISO 9000, a system is defined as “the organizational structure, responsibilities,
procedures, processes and resources for implementing quality management.” This can be the case in the
pharmaceutical sector.
The boundary of the pharmaceutical sector can be determined by the sector objective as decided by the
national drug policy activities or by the scope of pharmacy profession. In both cases the basic institutions of
pharmaceutical sector are:
a)
b)
c)
d)
e)
f)
Ministry of Health, pharmacy administration;
Pharmacists syndicated and/or societies;
Pharmacy schools and other academic institutions;
Local drug industry;
Drug supply systems;
Professional pharmaceutical services in public, private and health insurance sectors.
According to this model the following features are of great importance:
•
•
•
•
70
The pharmaceutical system has to function within a clearly defined national
policy framework.
The well-functioning pharmaceutical system should be based on a well defined
organizational structure with clear and enforced legal framework, institutional
responsibilities and set-up, post description and working relationship.
Professional systems, particularly those in the services sector, should ensure confidence
and satisfaction of their beneficiaries.
The pharmaceutical system should provide good working conditions for staff and
incentives for good performance.
Abstract
Directing Future Pharmacy Practice Toward Societal Needs
Prof. Albert I. Wertheimer, Ph.D., MBA,
Time: 11:45 - 12:30
In recent years many simultaneous events have changed the practice of pharmacy. For example,
technology has brought automated dispensing equipment, electronic prescription communication
and electronic medical records; education has brought pharmacy technicians, continuing education
and specialty practice certification; lobbying (political pressure) has brought permission to administer
injections and under certain cases, to prescribe or refill prescription drugs. The leaders of the profession
are advocating MTM – Medication Therapy Management, patient education and counseling, and what
some call pharmaceutical care practices.
But what do patients want and what are health insurers willing to pay for? These appears to be a huge
gap between what the profession wants to provide and be paid for and what the lay public wants or
expects from the pharmacists, and similarly, what insurers are willing to pay for.
This report examines some of the studies on patient satisfaction and preferences and compares them to
the words of our pharmacy profession leaders. The surprising results should give us a roadmap toward
where we should direct the future of pharmacy education and practice.
In essence, if the profession of pharmacy is to survive, prosper and grow in stature, respect and utility, it
must be valued, respected and seen as beneficial by the public. Otherwise, the technicians or others will
take over our responsibilities at a lower cost. From listening to our patients’ opinions, we can defend
and facilitate the profession’s bright future existence.
D U P H A T 2009
www.duphat.ae
71
Abstract
Professional Skills Development in Future Pharmacists: A World-Wide Issue
Prof. Nancy A. Nickman, Ph.D., Pharmacotherapy and Presidential Teaching Scholar, Departement
of Pharmacotherapy and Pharmacotherapy Outcomes Research Center, University of Utah, Salt Lake
City, USA
Time: 12:30 - 13:15
Pharmacists continue to be one of many types of healthcare workers who are potentially broadly and
inexpensively available to the public. However, common world-wide problems including 1) practitioner
shortages, 2) wrong practitioner mix available to provide basic care, 3) public-private disagreements on
educational requirements and places of training, and 4) migration of healthcare workers to practitionerrich areas hamper accessibility and add to public health needs for basic medical care. Globally, pharmacy
education has attempted to solve these issues by producing more places of training and ultimately,
pharmacists, to meet unsolved demand. Educational program development has sought not only
to rectify short-term workforce needs, but increasing emphasis has also been placed on substantial
changes in professional skills training. More sophisticated clinical skills certainly lead to the potential
for pharmacists to have a larger world-wide impact on health and disease. However, the emphasis on
building additional clinical skills often comes at the expense of basic socioeconomic, cultural, and public
health knowledge and skills that would allow pharmacists to function competently at both patientcentered and population-centered levels. Recent reports from the World Health Organization (WHO),
International Pharmaceutical Federation (FIP), and United States health-focused organizations such
as the Institute of Medicine (IOM), practice-focused organizations such as the American Society of
Health-System Pharmacists (ASHP) and Joint Commission of Pharmacy Practitioners (JCPP), and
education-focused organizations such as the American Association of Colleges of Pharmacy (AACP)
will be reviewed as related to global health human resource strategies and population health indicators.
Training to a realistically agreeable public health knowledge level with provision of life-long learning
skills will provide practitioners with the flexibility to adapt to new situations without compromising
public well-being. A framework of public health practitioner responsibilities relative to social justice in
healthcare will be presented in order to facilitate a discussion of potential solutions.
72
Abstract
The Pharmacists role in community practice as rapporteur of side effects,
especially on new registered drugs under prescription
Prof. Ole J. Bjerrum, D.MSc., Department of Pharmacology and Pharmacotherapy, FARMA,
University of Copenhagen, Copenhagen, Denmark
Time: 14:30 - 15:15
The spontaneous reporting of adverse drug reactions (ADRs) forms an essential part of post-marketing
surveillance of medicines since reports on ADRs play a crucial role in the generation of new signals
(1). Traditionally the reporting relies on Medical Doctors’s but in Denmark also healthcare personnel
and patients are allowed to report directly to the Medicines Agency. Community pharmacists have a
potential unique position as both detectors and rapporteurs of ADRs due their daily widespread patient
contact and pharmacotherapeutic encountering (2). In spite of an easy access to online reporting to
the authorities the annual numbers of reports submitted is about 1% of the total reports received. This
contrasts to The Netherlands with a well-functioning community pharmacy reporting system standing
for 40% of all spontaneous reports (3). Research communication from Norway (4) and Sweden have
also documented the benefits of community pharmacists’ ADRs reporting.
An initiative towards increased reporting incl. improved report processing from community pharmacists
addressing professional engagement, importance and responsibility in relation to ADRs. This academic
initiative is to progress stepwise and will make extensive use of pharmacy students as rapporteurs in
relation to their 6 months community pharmacy internship; a pilot phase addresses the feasibility of
increased reporting through testing of the effectiveness of the reporting models in selected community
pharmacies. Based on the outcome the developed reporting model will be tested on a larger number of
pharmacies. Finally a formal National study is intended to be conducted.
A new route is opened for intensive monitoring of early drug introductions if a robust and reliable ADR
reporting system can be established for prescribed medicines in community pharmacy setting. This
might justify an earlier market introduction of new medicines (with limited marketing authorization)
thus supporting the “New Safe Medicines Faster/Innovative Medicines initiative” to the benefit of both
patients, societies and manufacturers.
D U P H A T 2009
www.duphat.ae
73
Abstract
Pharmacology of tyrosine kinase inhibitors – optimizing patient outcomes and
promoting effective rational and safe use of medicines
Prof. Alain Astier, PharmD, Ph.D., Departement of Pharmacy and Toxicology, Henri Mondor
University Hospital, Créteil, France
Time: 15:15 - 16:00
Molecular targeted therapies are major advances in modern cancer care. Their mechanisms of action
and side effects profiles are very different from classical cytotoxic drugs. Among these new drugs,
tyrosine kinase inhibitors (TKI) such as imatinib, erlotinib, gefitinib or dasatinib are recognized as major
improvement in severe diseases such as chronic myeloid leukaemia, gastrointestinal stromal tumors,
renal and bronchic carcinomas. Very differently from classical chemotherapy regimens, these drugs are
usually administered by oral route, at home and for long time, mimicking classical treatments in chronic
diseases. Therefore, comparable “chronicity” problems are observed such as poor compliance, severe or
badly accepted side effects, and various interactions with food, alcohol, smoking or co-administered
drugs.
TKI are strongly metabolized by cytochomes P450, explaining complex metabolism interactions. As
example, some co-administered drugs can severely affect nilotinib metabolism such as ketoconazole
which acts as inhibitor and increases AUC by 300 % or rifampicin as activator, reducing AUC by 80 %.
Particularly over-exposure can induce serious effects, possibly life-threatening. Half-life of erlotinib is
strongly reduced by smoking due to CYP1A1 induction. Plasmatic peak of nilotinib can be increased by
more than 110% when taken less than 30 min after a high fat meal.
Since they act more as cytostatics, efficient plasmatic level must be maintained continuously. Therefore,
it is critical to limit all cause of plasmatic variability which reduce efficacy and induce resistance.
Self-medication is also an important and underestimated problem. Particularly, alternative (herbal)
medicines, OTC products (e.g. vitamins, NSAIDs), nutritional supplements and foodstuffs (grapefruit…)
can be cause of unexplained toxicities
Pharmacists should play an unique and important role to limit interactions problems and to improve
compliance.
74
Pharmacy Workshops
W4. Households Poisoning: An Overview and ways for preventions
Dr. Yousif Abdu Asiri, Ph.D., Dean College of Pharmacy, Associate Professor of Clinical Pharmacy,
College of Pharmacy, King Saud University, Saudi Arabia
Venue: Dubai E & F
Time: 09:00 - 10:00
I
t is beyond the shadow of the doubt that poisoning is considered a worldwide public problem especially
among children. Statistics shows that more around 60 % of the poisoning case occurs in children less
than 5 years of age. In addition, poisoning can occur by accidents, suicidal attempts, from households
products, drugs use, exposure to chemical either at work or home, environmental population, herbal
products, and bites and stings. Moreover, the most common households ingested by children are
cleaning substances, analgesics, plants, cosmetics, and cough and cold preparations. Among drugs
acetaminophen is the most drugs that cause toxicity in children. Among household products, kerosen
and cleaning substances.
Further more,
Herbal products considered serious categories of materials that cause toxicity in children and adults
these days.
In this workshop the following topics will be discussed:
•
•
•
•
To familiarize the audience with the different types of households products that might
cause poisoning.
To illustrate the different types of poisoning management available in the literature.
To elaborate on the available procedures for poisoning diagnosis related to drugs and
poisonous materials, and
The role of pharmacists in educating and preventing poisoning especially herbal and
household products.
D U P H A T 2009
www.duphat.ae
75
Pharmacy Workshops
W5. Pharmacogenomics and Personalized Medicine
Prof. Yusuke Tanigawara, Ph.D., Department of Pharmacy, School of Medicine,
Keio University, Tokyo, Japan
Venue: Dubai E & F
Time: 11:00 - 12:00
O
ne dose does not fit all. The inter-individual variability in the responses to drugs is one of important
problems in medication therapy. Differences in response to medicines have been observed in association
with genetic variations, in addition to pathological and physiological factors such as age, gender, severity
of illness and organ dysfunction. These genetic variations include single-nucleotide polymorphisms
(SNP) or expression of the genes coding drug metabolizing enzymes or drug target molecules.
Pharmacogenomics (PGx) deals with the influence of genetic variation on drug response in patients
by correlating gene expression or SNPs with a drug’s efficacy or toxicity. PGx aims to develop rational
means to optimize drug therapy, with respect to individual patients’ genotype, to ensure maximum
efficacy with minimal adverse drug reactions. PGx-based approaches create a new paradigm of
treatment regimen for “personalized medicine”, in which drug selection and its dose are optimized for
each individual patient.
Numerous studies have observed the correlations or associations between therapeutic outcomes and
genetic polymorphisms in target molecules or enzymes that activate or detoxify drugs. The reported
evidence includes omeprazole, warfarin, tamoxifen, 6-MP, 5-FU, irinotecan, and many anti-cancer
agents. This pharmacogenomic information is useful to predict responders/non-responders or to
identify a risk population that can suffer from severe adverse effects. Optimization of drug therapy
is highly beneficial not only for public health but also to reduce the social medication cost by avoiding
meaningless drug dosage to non-responders.
My talk focuses on the recent progress made in the field of pharmacogenomics and personalized
medicine. This information is quite important for health care professionals, particularly medical doctors
and pharmacists.
76
Pharmacy Workshops
W6. Protection against the sun, an important pharmacy practice and
research issue
Prof. Labiba El-Khordagui, Ph.D., Professor of Pharmaceutics, Faculty of Pharmacy,
University of Alexandria, Egypt
Venue: Dubai E & F
Time: 12:15 - 13:15
Solar radiation is the essential thermal energy source for the planetary surface. As part of our everyday
life, sunlight is generally regarded as having beneficial effects on health and well-being. However,
unprotected sun exposure during usual daily activities, especially in high insolation parts of the world
may lead to damage of DNA with the generation of cellular, molecular and clinical changes in human
skin, ranging from skin ageing, photodermatoses to skin cancers. Ultraviolet B (UVB, 290-320 nm) is
the major active terrestrial waveband region that causes direct photochemical damage to DNA, from
which gene mutations arise. Ultraviolet A (UVA, 320-400 nm) have more indirect effects on DNA via
the generation of reactive oxygen species. The most lethal of the skin cancers, cutaneous malignant
melanoma, is more commonly associated with sporadic burning exposure to sunlight, especially early
in life.
Authorities are recommending primary prevention programs to reduce cutaneous photodamage and
skin carcinogenesis. These include the integral components: raising public awareness, environmental
photoprotection, behavioural changes to avoid overexposure to the sun and to use protective clothing
and the use of sunscreen products.
Sunscreen products contain as their active ingredients inorganic and organic agents which are treated
as drugs by the US FDA and cosmetics by other regulatory agencies. A proper sunscreen product must
provide efficient protection against acute and long-term UV-induced skin damage, be stable to heat and
to UV radiation (UVR), be user-friendly to encourage frequent application, provide reliable protection
and be cost-effective. The FDA upgraded sunscreen labeling in 2007 to include UVA star rating in
addition to SPF as indicators of the level of UVA and UVB protection respectively.
Extensive research efforts are directed to the development of more photoprotective, broader spectrum
sunscreen materials and products. These are based on nano and drug delivery technologies. In addition,
the inadvertent effects of sunscreens on the environment and the health of human populations is a
research area of great public health importance. Practicing pharmacists have an important role to play
regarding both wise exposure to the sun and safe use of sunscreen products.
Public education, provision of sunscreen-related care, environment protection and pharmaceutical
research are important domains of commitment of the pharmacy profession.
D U P H A T 2009
www.duphat.ae
77
Pharmacy Workshops
W7. Medical Tourism and Globalization of Health Care
Prof. Mustafa Z. Younis, Dr.PH., MBA, MA, Executive Committee Member, International Society for
Research of Healthcare Financial Management, USA
Venue: Dubai E & F
Time: 14:30 - 15:30
The escalating cost of major surgery in the United States and other industrial counties has opened the
door for medical tourism. Such industry is in its infancy and is expected to grow rapidly over the next
decade.
Very few studies have been conducted regarding the cost/benefit analysis and quality of care of treatment
in foreign countries. Furthermore, the ministries of health in coordination with the ministries of tourism
in countries such as Brazil, Malaysia, India and Thailand have begun regulation and accommodation for
this nascent flourishing industry.
This presentation (workshop) will discuss issues related to the advantages and disadvantages of traveling
abroad for medical treatment.
78
Pharmacy Workshops
W13. Practical & Clinical Considerations in Intravenous Therapy &
Compounding
Dr. Osama Tabbara, R.Ph., BCNSP, Consultant Pharmacist, TPN & IV Therapy Director, Pharmacy
Services Administration, King Fahad Medical City, Saudi Arabia
Venue: Dubai D
Time: 09:00 - 10:30
B
ackground: Literature support revealed that nursing-based intravenous (IV) computing and admixture
leads to significant medication errors and may increase the chance of nosocomial infections.
Methods: Literature Medline search from 2000 to March 2008 to critically evaluate the evidence for
the practical & Clinical considerations of pharmacy-based practice for IV admixture and for assuring
pharmacy competencies in IV therapy.
Results: To assure core competencies of pharmacists practicing IV therapy and admixture, the pharmacist
should be well aware of the concept of safe admixture that includes but not limited to: USP 797 guidelines
for sterile compounding, pharmaceutical calculations, osmolarity, physiological pH., sterility, pyrogen
and particulate free admixtures, types of peripheral/central catheters, and compatibilities. Moreover,
the pharmacist should be well aware of conditions requiring IV push versus intermittent IV infusion as
well as knowing the various significance of physical, chemical and microbial stabilities.
Conclusion: Structural and formal training programs are essentials to generate competent pharmacists
specialized in IV therapy and admixtures. Redesigning the pharmacy curriculum at faculty level to
include more IV therapy and training courses is crucial.
D U P H A T 2009
www.duphat.ae
79
Pharmacy Workshops
W14. Rational Drug Use in UAE
Dr. Mohammed Abuelkhair, Pharm.D., Head, Pharma/Medicine and Medical Products Regulation
Section, Health Authority-Abu Dhabi, UAE
Venue: Dubai D
Time: 11:00 - 12:00
Rational use of drugs is considered as a one of the highest priority in healthcare practice in all
countries. Proper prescribing and rational use f drugs will improve the quality of the healthcare services
and develop the healthcare systems.
Overuse of medicine, misuse and overuse of medicines, lack of consultation to patients, poor patient
compliance and other issues can cause inefficiency and ineffective use of drugs, malpractice and
irrational drug budget. There is a need to identify the patterns of irrational use of drugs in UAE and a
need to develop and adopt the medical interventions in the healthcare practice for UAE. In addition, a
national plan to cover the educational need to healthcare professionals and to adopt the regulation for
developing the medical intervention are important to adopt and implement through out the country.
Role of the Health Authority in UAE in regulating the medicines, current activities of rational drug use
in Ministry of Health’s facilities, in addition to, challenges and future plan to improve prescribing and
rational drug use will be presented through the conference.
An impact of strengthen and coordination between the health authorities in UAE to improve the
prescribing of the right medicine for the right patient and right instruction is serious mandate toward
rational drug use in UAE.
80
Pharmacy Workshops
W15. Improving Patient Adherence through Health Behavior Change
Dr. Renée T. Juhl, Pharm.D., Adjunct Associate Professor, Department of Pharmaceutical Sciences,
School of Pharmacy, Pittsburgh, PA, USA
Venue: Dubai D
Time: 12:15 - 13:15
The Health Behavior Change communication process has become a key component in the patient
counseling session for all health care providers. It is a collection of methods geared to the brief patientcentered consultation and is based on the Motivational Interviewing and Stages of Change models
of patient counseling. Health Behavior Change is a patient-centered, directive method of counseling.
Because patients must be motivated to decide for themselves whether they will adhere to their
medication regimen, the pharmacists’ role is to support and encourage the willing and nearly willing
patient. This communication technique uses various strategies and principles to guide the patient
counseling session, which should take less than 5 minutes once the pharmacist is skilled with the
Health Behavior Change methods.
The purpose of this workshop is to offer a training program in the process and techniques of Health
Behavior Change. If time permits, several short case studies will also be included. The objectives are as
follows:
Review recent medication adherence research
Explore methods of communicating with patients to improve their adherence
to the treatment plan
Assist patients to commit to a plan appropriate to their stage of change
Develop an empathic, yet directive counseling style
Utilize key principles of motivational interviewing

Roll with resistance
Express empathy
Develop discrepancy
Support self-efficacy
Discuss strategies to negotiate behavior change with patients
D U P H A T 2009
www.duphat.ae
81
Pharmacy Workshops
W10. Pharmacovigilance and why do drugs fail?
Dr. Ibrahim Al Khars, MS, MBA, Executive Director - Almana PharmaCare,
Coordinator of academic and training programs in Almana General Hospitals at Khobar, Saudi Arabia
Venue: Dubai D
Time: 14:30 - 15:30
Undesirably, medical disasters have shaped the history and development of drugs. A series of cases
of damage caused to the health of a large number of people owing to the adverse effects of “super”
drugs such as Vioxx (rofecoxib), Agreal (veralipride), Lipobay (Cerivastatin). Such situation has made
drug safety a major issue for governments, regulatory authorities and the pharmaceutical industry and
improves the management of global pharmacovigilance.
The workshop will answer important questions: Why do drugs fail? Are drugs safer today? As drugs
move into the marketing setting, the question turns from one of safety and efficacy “can it work” to one
of “does it work” in actual practice?” and Why the need for Effectiveness Research?
Workshop Objectives
The primary objectives are to (1) provide standard definitions of terms relating to pharmacovigilance
and safety monitoring of drugs, (2) discuss the stages of drug development and identify the relationship
with drug failure, and (3) provide technical guidance on the principles of good pharmacovigilance and
the inclusion of drugs in existing national drug safety monitoring systems.
This workshop will allow participants to apply pharmacovigilance tools, and give examples of serious
medical events, which change the history of drug’s regulations. This interactive session will provide
insight into the following areas:
•
•
•
•
82
Why clinical trials fail to detect some side-effects?
Can postmarking surveillance tell whether a drug is safe?
Examination of the future of pharmacovigilance in the US, EU and Arabian Gulf countries.
Recommendations on how we can optimize pharmacovigilance studies.
Exclusive Session
Presentation 3
Adverse Drug Reactions: Classification, Mechanism and Role of
Pharmacogenetics on ADR
Dr. Sahar Abu-Omar, MSc, CPHQ
Senior Clinical Affairs Specialist- Pharmaceutical, Clinical Affairs Division, Abu Dhabi Health Services
Company “SEHA” Abu-Dhabi, UAE
Venue: Ajman D
Time: 09:00 - 09:45
Adverse drug reaction is defined as a response to a drug that is noxious and unintended and that
occurs at doses used in humans for prophylaxis, diagnosis, or therapy of disease, or for the modification
of physiologic function. When adverse drug reactions are the 4th to 6th leading cause of death among
hospitalized patients, 30% to 60% are preventable. Different classifications of ADR’s are in place.
Generally they are classified according to onset, severity or type.
Much of current clinical interest is at the level of pharmacogenetics, involving variation in genes
involved in, drug metabolism with a particular emphasis on improving drug safety. The wider use of
pharmacogenetic testing is viewed by many as an outstanding opportunity to improve prescribing
safety and efficacy. Driving this trend are the 106,000 deaths and 2.2 Million serious events caused
by adverse drug reactions in the US each year (Lazarou 1998). As such ADRs are responsible for 5-7%
of hospital admissions in the US and Europe, lead to the withdrawal of 4% of new medicines and cost
society an amount equal to the costs of drug treatment (Ingelman-Sundberg 2005). Comparisons of the
list of drugs most commonly implicated in adverse drug reactions with the list of metabolizing enzymes
with known polymorphisms found that drugs commonly involved in adverse drug reactions were also
those that were metabolized by enzymes with known polymorphisms (see Phillips, 2001).
D U P H A T 2009
www.duphat.ae
83
Exclusive Session
Presentation 4
Pharmacovigilance as a Learning Device in Drug Innovation
Prof. H.G.M. Leufkens, Pharm.D., Ph.D.
Utrecht University, Faculty of Science, Utrecht Institute for Pharmaceutical Sciences (UIPS)
Division of Pharmacoepidemiology & Pharmacotherapy, Utrecht & Chair of Dutch
Medicines Eva luation Board (MEB), The Netherlands
Venue: Ajman D
Time: 09:45 - 10:30
Despite extensive testing of medicines during drug development, unexpected, severe and rare adverse
drug reactions may occur when the medicine is used after marketing in normal daily practice. Premarketing findings regarding safety of medicines are commonly based on the ex¬pe¬rience of a limited
number of patients, who have been treated in controlled randomised trials. These trials have important
limitations in terms of that they [a] usually include rather homo¬ge¬neous po¬pulations (no elderly
patients with other diseases, no impaired renal or liver function, etc), [b] they are too small to detect
very rare events, [c] they are usual too short to detect long-term effects, [d] they are unable to predict
the real world of clinical practice. The characterization of the full safety profile of a medicinal product
is a dynamic continuum, starting at the bench with in-vitro and in-vivo pharmacology and toxicology,
clinical development and extensive, increasingly in a pro-active fashion, postmarketing follow-up. This
continuum is being challenged constantly as many molecules are developed further during their lifecycle for second, third or even more indi¬ca¬tions, attracting consequently very often new and different
patient populations, demanding for a wide array of risk management strategies.
The cyclic nature of pharmacovigilance is reflected is a constant learning loop from report-signal-data
to (if needed) regulatory action and communication. Medicines may have unforeseen side effects when
used in patients with multiple morbidities, impaired organ function or used in an inappro¬priate or
off-label fashion. Determining the signal-noise ratio is a key activity in pharma¬co¬vigilance and is
nowadays an essential part of public health and drug innovation. After new medi¬ci¬nal products
have been approved for usage in normal clinical practice the real practice-based benefit-risk balance
should be established. There is increasing evidence that the likelihood of the majority of the problems
we face in pharma¬covigilance is in certain patients more at risk than others. There¬fore a critical part
is seen in charac¬terizing, also coined ‘landscaping’, the patient population in order to identify patients
and patterns of drug usage susceptible to increased risk. As part of this, pharmacogenetic and other
molecular biomarkers are increasingly considered as important tools to identify proactively possible
non-responders due to ADRs or other reasons. All these developments show that phar¬ma¬covigilance
is not only an activity of ‘bad news’, but also an essential building block in the lear¬ning curve of drug
development. Bringing a medical product to the market is one step, keeping a drug with a favourable
B/R profile on the market another one.
84
Exclusive Session
Presentation 5
Role of the Schools of Pharmacy & Medicine in Adverse Drug Reactions (adr)
Monitoring
Dr. Qasim Ahmed AlRiyami, B. Pharm, M. Phil, M.Ed, Clinical Pharm, Teaching (Univ. Leeds)
Assistant Dean for Training, College of Pharmacy & Nursing, University of Nizwa, Oman
Venue: Ajman D
Time: 11:00 - 11:45
Oman is the only country within the Eastern Mediterranean Region (EMRO) which subscribes as a full
member, to the WHO’s ADR database in Uppsala. Considering that up to 3% of hospital admissions are
drug induced, it is obvious that numerous adverse events are not reported within EMRO. Traditionally
pharmacovigilance has been the responsibility of the pharmaceutical companies which have taken this
task.
Pharmacoepidemiology recently introduced scientific discipline aimed at looking into the use of
pharmaceuticals in the society.
Doctors, pharmacists and nurses regularly encounter the adverse effects of pharmaceuticals during
their practice. Unfortunately these professionals have not been properly couched in the concepts of
pharmacoepidemiology and pharmacovigilance. Education these professionals at undergraduate and
at graduate levels will improve patient care in this region. There is a need to develop awareness of
these concepts, so as to eliminate the idea that reporting ADR is “Witch hunting”.
Our patients regularly combine the use of pharmaceuticals with traditional health care systems.
Teaching Pharmacopeidemiology to medical and pharmacy students will assist in determining
causality of an adverse event, non-compliance and rational use of medicines.
D U P H A T 2009
www.duphat.ae
85
Exclusive Session
Presentation 6
Quality Assurance for Pharmacovigilance: Guidance for Good
Pharmacovigilance and Pharmacoepidemiologic Assessment
Prof. Ismail I. I. Hewala, Ph.D., Faculty of Pharmacy, University of Alexandria, Egypt
Venue: Ajman D
Time: 11:45 - 12:30
The goal of quality assurance in pharmaceutical industry is the implementation of GXP (GMP, GLP,
GSP, GDP, … etc). This is performed through designed protocols for each process and SOP for each
activity included in such protocols according to the guidelines of international organizations such as
ICH and FDA.
The WHO definition of the term Pharmacovigilance as the science and activities relating to the detection,
assessment, understanding and prevention of adverse effects, or any other drug related problems. The
definition encompasses the use of pharmacoepidemiological studies.
The WHO, ICH and other international organizations propose guidelines which are intended to aid in
planning Pharmacovigilance activities especially in preparation for the early post-marketing period of
a new drug. The main focus of the guidelines is on a safety specification and Pharmacovigilance plan
that might be submitted at the time of licence application. The guidelines can be used by sponsors to
provide guidance on incorporation of elements of the safety specification and Pharmacovigilance plan
into common technical document.
The achievement of GPvP could be performed according to the following;
1. The guidelines describe a method for summarizing the important identified risks of a drug,
important potential risks and important missing information, including the potentially atrisk populations and situations where the product is likely to be used that have not been
studied pre-approval.
2. The guidelines for proposing a structure for a Pharmacovigilance plan and set out principle
of good practice for the design and conduct of observational studies.
3. The guidelines for Pharmacoepidemiologic assessment and safety signal interpretation.
4. The guidelines for inspection (auditing).
86
Exclusive Session
Presentation 7
The Agony and the Ambiguity of Translating Pharmacoepidemiologic
Findings into Public Policy
Vice Chancellor and Distinguished Service Professor of Pharmacy, University of Pittsburgh,
Pittsburgh, USA
Venue: Ajman D
Time: 12:30 - 13:15
Collecting and analyzing pharmacoepidemiologic data presents a series of methodological and data
integrity issues, but once the scientific report is written, an equally difficult phase begins; using the
findings to take corrective action. Conflicting studies, scientific disagreements between honorable
experts, unintended consequences, economic concerns, patient advocacy groups and other social
factors must be assessed before a policy decision is made. The agency assigned the task of overseeing the
safety of drugs and devices will consider a range of options from taking no action to removing a product
from the market. At each point along that decision spectrum, assumptions must be made about the
effect and effectiveness of the corrective action, which will in most cases depend upon the ability or
willingness of consumers/patients and the health care community to alter their behaviors or practices.
Instructive case studies involving aspirin and Reye’s Syndrome, selective serotonin re-uptake inhibitors
and suicidal thoughts and actions, rosuvastatin and kidney damage, troglitazone and liver damage and
other recent examples will be presented for consideration and discussion.
Ultimately, the same degree of rigor is needed in planning and implementing the public policy corrective
action plan as was expended on the scientific collection and analysis of the numeric data.
D U P H A T 2009
www.duphat.ae
87
Parallel Session
P3. Novel self-emulsifying drug delivery system of ibuprofen (IBSEDDS): Formulation, optimization
and characterization study
Author:
Dr. Abdel-Azim Zaghloul, Ph.D.
Department of Pharmaceutics, Faculty of Pharmacy, Kuwait University, SAFAT, Kuwait
Venue: Dubai A & B
Time: 09:00 - 09:30
O
bjectives: Ibuprofen (IB) has poor dissolution and many gastrointestinal side effects. SEDDS has proved its efficacy to improve the
solubility and dissolution of poorly soluble drugs. The objectives of this study were to formulate and optimize a IBSEDDS applying
experimental design.
Methods: The solubility of IB in different oils, surfactants and co-surfactants was investigated. Ingredient showing high drug solubility
were used to formulate several IBSEDDS after being tested for physical and chemical compatibility with the drug. A three factor,
three level Face Centered Experimental Design was used for the optimization process. The prepared formulations were evaluated for
dissolution , turbidity and droplet size and referred to as the responsesY1, Y2 and Y3 respectively. Results: The results showed high
solubility and compatibility of IB with soybean oil, Cremophore EL and Capmul MCM-C8 which are referred to as the variables X1,
X2 and X3 respectively. The amounts of X1- X3 showed significant effects on the responses Y1-Y3.The polynomial equation relating
the response Y1 and variables X1-X3 was obtained. The optimized and predicted values of Y1 were found to be in close agreement.
According to the design, 50% oil, 40% surfactant and 10% co-surfactant were shown to maximize Y1up to 100% after 60 min.
Conclusions: The findings indicated that IBSEDDS with high drug release and reasonable physical properties could be prepared and
the experimental design applied helped in understanding the effects and the interaction effects between the three variables applied.
The optimized formulation is expected to show high absorption with minimal side effects.
P4. Prophylaxis for opportunistic infections for kidney transplantation recipients in Oman
Author:
Ph. Fatma Ali A. Al-Raisi, M.Sc.
Nephrology Clinical Pharmacist, Royal Hospital - MOH, Sultanate of Oman
Venue: Dubai A & B
Time: 09:30 - 10:00
Background: Opportunistic infections (pneumocystic carnii/jiroveci, toxoplasmosis) remain the most common life-threatening
infection among immnuocompromised patients such as HIV patients and patients underwent solid organ transplantations.
Prophylactic therapy with trimethoprim/sulfamethoxazole (TMP/SMX) should be prescribed soon after the kidney transplantation
for a period of no less than 6 months.
Prior to initiation of PCP prophylaxis there are several pharmaceutical care issues to be tackled by the clinical pharmacist to make sure
all transplant patients received individualized suitable medication. The aim of this study is to highlight those issues and ensure all
legible kidney transplant recipients receive appropriate PCP prophylaxis.
Objective: The main objective of this mini study is to ensure all patients undergone kidney transplantation receives appropriate
standard PCP prophylaxis soon after transplantation, unless contraindicated.
Methodology: A prospective study included all kidney transplantation recipients from January 2008 to August 2008. The subjects
were followed-up during the admission for transplantation to the date of discharge. The discharge prescriptions were screened to
ensure all the kidney transplantation recipients were prescribed appropriate PCP prophylaxis before discharge. All prescriptions with
NO PCP prophylaxis were intervened by the clinical pharmacist.
Results: Almost 80% of the prescriptions did not included (TMP/SMX) for PCP among which 20% of the prescriptions were for
patients with G6PD deficiency. The clinical pharmacist’s interventions resulted that all discharge prescriptions were modified and
(TMP/SMX) was prescribed for patients who were legible for a PCP prophylaxis.
88
Parallel Session
Conclusion: In the absence of prophylaxis, the incidence of PCP in solid organ transplant recipients ranges from 6.8% to 22%,
necessitating PCP prophylaxis for at least 6 months following transplantation. Despite the widespread knowledge on PCP prophylaxis,
most of the patients were discharged with no prophylactic treatment for PCP. After pharmacist’s intervention the prescriptions were
edited and PCP prophylaxis was added.
Author:
P5. Design, Operation, Implementation & Evaluation of Advanced Integrated Robotics-Based
Workflow Systems
Mr. Michael E. Coughlin, MS, MBA
Founder, President & CEO, ScriptPro, Kansas, USA
Venue: Dubai A & B
Time: 10:00 - 10:30
C
ommunity and ambulatory pharmacies are a vital link in providing the best outcome for patients while controlling healthcare costs.
Integrated, robotics-based workflow systems greatly enhance the safety and efficiency of these pharmacies and enable them to deliver
the highest level of medication therapy management to their patients. The design and operation of these advanced systems will be
discussed along with approaches for cost justification, implementation and evaluation.
P6. Evaluation of Patient’s Knowledge About Warfarin in Outpatient Anticoagulation Clinics in a
Teaching Hospital in Qatar
Author:
Dr. Imran Fahmi Khudair, BSc.Pharm
Clinical Pharmacist, Medic , Pharmacy Department (Clinical Pharmacy Services),
Co-Author:
Dr. Yolande Hanssens, Pharm. D
Venue: Dubai A & B
Time: 11:00 - 11:30
Background: Warfarin is the main oral anticoagulation therapy and has a narrow therapeutic window. Therefore monitoring patients'
INR, dietary vitamin K, usage of other drugs, patient’s compliance and patient’s knowledge about possible complications are key
elements to ensure an optimal efficacy/safety ratio.
Objectives: 1) To evaluate the extent of warfarin patient education and its possible impact on INR, warfarin-drug interaction and the
management of missing dose.
2) To identify the strengths and weaknesses of the current patient education system and modify/adjust it accordingly.
Setting: Medical and cardiology warfarin outpatient clinics in Hamad General Hospital, Hamad Medical Corporation, Doha, Qatar.
Method: All patients being on warfarin for at least 2 months and attending medical and cardiology warfarin clinics between August
and November 2008 were asked to complete a 20-item questionnaire. A score of 75% was considered “pass”.
Results: A total of 140 patients completed the questionnaire and 116 (83%) got warfarin education on initiation of treatment. Seventy
nine patients (56%) passed. Education is mainly performed by doctors (49%) followed by pharmacists (18%). Patients with a passing
score kept their target INR in for 89% compared to 45% in patients who did not pass (p<0.001). Warfarin-drug interaction knowledge
got the lowest score (36%) followed by the management of a missing dose (42%).
Conclusions: Controlled INR values do not guarantee patient’s knowledge about warfarin-drug interactions and the management of
a missing dose.
Improving the current warfarin education practice before and after discharge is needed to optimize patient management in our
hospital.
D U P H A T 2009
www.duphat.ae
89
Parallel Session
P7. The Impact of Public Health Campaign on Awareness, conception and Behaviors Related to Asthma
Medication " Saudi Pharmaceutical Society Experience "
Author:
Dr. Khalaf Ali Jumah, M.Sc.
Pharmacy Director, Al Amal Psychiatric Hospital, Riyadh, Saudi Arabia and
Chairman of Continuing Education Committee in Saudi Pharmaceutical Society, Saudi Arabia
Venue: Dubai A & B
Time: 11:30 - 12:00
Background: Public campaign is a series of activities and communication materials that happened during an extended period of
time. The beneficial of this kind of activity is to develop a good relationship with target public plus achieve a specific behavior toward
a common disease. The Saudi Pharmaceutical Society realized that our society in a tremendous need for such activity . The SPS
conducted two campaigns during 2008. The first one covered the asthma disease, with emphasized on the use of asthma medication
plus patient counseling. The second campaign related to diabetic and the role of pharmacist in the management of the disease. Both
campaigns were organized and supervised by local organization and other health authority in KSA .
Presentations Outlines
1. The definition and beneficial of the public campaigns.
2. The Need for public campaign.
3. The Current status of public campaigns in KSA.
4. The challenges of public health educational campaign in KSA.
5. The SPS and public campaigns ( our experiences ).
6. The Outcome of the asthma public campaign which include :
a) The number and type of patient which received an active educational and
counseling during the campaign.
b) The type of common mistakes regarding the use of medication.
c) The type of confused concepts regarding asthma medication and treatment.
d) The campaign feedback.
A documentary video will be displayed about our SPS campaigns in 2008. Also the response from patients, media official, pharmacists,
physicians and others.
90
Parallel Session
P8. USP Chapter 797; A Management Success story from Qatar
Author:
Dr. Manal B. Al-Zaidan, B.SC (Pharm)
Director of Pharmacy, Al Amal Cancer Centre, Hamad Medical Corporation, Doha, Qatar
Venue: Dubai A & B
Time: 12:00 - 12:30
Compliance with USP Chapter 797 does not need to be complex or cumbersome, but it will require leadership, vigilance, and
consistence from the Pharmacists and Technicians who carry out critical compounding activities on a duty basis, as well as their
Managers and Supervisors.
This presentation will help leaders, managers and pharmacy staff in designing, operating a new room for compounding sterile
preparations to meet the institution’s needs and improve facility compliance with USP Chapter 797, thus ensuring a safe work place
and reduced risk of contaminating with increased staff awareness of safe facility design.
The revised, 2008 USP 797 Chapter focuses on the employees involved in the compounding of Compounded Sterile products (CSPs)
as the primary source of contamination and recommendations are specifically aimed to reduce this possibility. Accordingly the
presentation will focus on the importance of assuring core competencies of pharmacy staff practicing sterile compounding required
to perform their job in a safe and efficient manner.
However, the presentation will highlight a successful team work story with a multidisciplinary team approach which consists of, but
not limited to pharmacists , administrators, engineers, infection control practitioners and housekeepers .
P9. Problem Based Learning and its impact on learning behavior of 3rd semester B.Pharm students in
Pharmaceutical Analytical Chemistry
Author:
Dr. Nehad Mehdi Hamoudi, Ph.D.
Ras Al Khaimah College of Pharmaceutical Sciences, Ras Al Khaimah Medical & Health Sciences University,
Ras Al Khaimah, UAE.
Co-Author:
Prof. BG Nagavi, Ph.D.
Dean, RAK College of Pharmaceutical Sciences, Ras Al Khaimah, UAE
Venue: Dubai A & B
Time: 12:30 - 13:00
T
he objective of the study was to evaluate the impact of Problem Based Learning (PBL) on the knowledge (K), Skill (S), and Attitude
(A) of 2nd year, 3rd semester students of B.Pharm in Pharmaceutical Analytical Chemistry. Twenty (20) students participated in the
study in 3 groups of 7, 7 & 6 each and assisted by faculties as facilitators. Three sessions of 2 hours each were designated for the PBL,
with a gap of 2 or 3 days between the session in the course Pharmaceutical Chemistry. Study site was class room and total duration
of PBL was 2 weeks with 3 sessions. Standard questionnaires containing about 33 questions on K, S, and A were administered during
the study.
Significant improvement was observed in the K, S, and A of students between the base line and end of PBL assessment. Four phased
assessment of students was done by self, peer, facilitator and course faculty. First session was meant for brain storming on the
problem, 2nd session was for discussion and 3rd session was devoted to presentation and assessment. Facilitator and Course faculty
assessments were more reliable than self and peer assessments as students invariably over-graded themselves.
Students however showed significant improvements in oral and written communication, group behavior and team skills. Students
knowledge about the topic discussed in the PBL improved significantly as learning was participative, explorative and team based than
regular class room based lecture. PBL showed positive impact on individual students K, S and A. All the relevant data will be presented
and discussed.
D U P H A T 2009
www.duphat.ae
91
92
DAY - 3
31ST MARCH 2009
TUESDAY
D U P H A T 2009
www.duphat.ae
93
Abstract
(Day - 3) - Tuesday 31st March 2009
Developing Quality Use of Medicines indicators/monitoring and measuring
Day 3 31st March 2009
Mr. David Maxwell, BPharm, DipHospPharm, FSHP,
Executive Officer, New South Wales Therapeutic Advisory Group, Sydney, Australia
Time: 09:00 - 09:45
Developing Quality Use of Medicines indicators - Monitoring and measuring.
Medicines are a valuable intervention in the overall delivery of healthcare. Quality use of medicines
(QUM) involves judicious selection of treatment options, appropriate choice of medicine when medicine
is required, and safe and effective use of medicines. But how do you know if medicines are being used
wisely?
Indicators (measurement of structures, processes and outcomes) can be used to guide and monitor
the appropriateness of healthcare delivery. Indicators related to medicines use will assist clinicians in
identifying specific areas of practice that may be problematic and that may require further analysis and/
or intervention. Hence these indicators can be used to drive improvements to achieve QUM.
However measurement of practice should not be undertaken in isolation. In order to achieve sustained
improvements in medicines use, indicator measurement should be part of an ongoing, multidisciplinary
continuous quality improvement program. Indicator measurement should be embedded in routine
clinical care, with feedback used by clinicians to guide their everyday practice; and interventions should
be undertaken in a supportive environment that includes appropriate structures, policies, leadership
and organisational culture.
This presentation will outline the development of two key QUM tools in Australia, the Indicators for
Quality Use of Medicines in Australian Hospitals and the Medication Safety Self Assessments for
Australian Hospitals and Medication Safety Self Assessment for Antithrombotic therapy in Australian
Hospitals. Current uptake and use of these tools will also be discussed.
These tools were developed by New South Wales Therapeutic Advisory Group (NSW TAG) and the
Clinical Excellence Commission (CEC) and are available on the NSW TAG website (www.nswtag.org.au)
and the CEC website (www.cec.health.nsw.gov.au).
94
Abstract
Quality Assessment of Drug Therapy by Pharmacy: Finding and
using drug use metrics
Prof. Charles E. Daniels, R.Ph., MS, Ph.D., Associate Dean for Clinical Affairs, Professor of Clinical
Pharmacy, School of Pharmacy and Pharmaceutical Sciences, University of California, San Diego &
Pharmacist-In-Chief, UCSD Medical Center, USA
Time: 09:45 - 10:30
M
edication system design and the principles of medication use evaluation provide the basis for
improving medication use quality in the institutional setting. There is expanding information which
documents an opportunity to improve the quality of medication use within the hospital or clinic
environment. The objectives of this presentation are to 1) review the published data on problems
with safety and quality outcomes; 2) present tools to analyze the opportunities for improvement in
medication use in a hospital or health care system; 3) discuss methods to improve quality of medication
use. Medication errors and poor medication use outcomes result in morbidity and mortality to patients.
They also result in added costs to the payer and lost productivity to society. Quality improvement tools
and pharmacist clinical service activities applied to the medication use system may offer important
improvements in results. Standard approaches to analysis at different levels will be presented for
consideration. This will include discussion of therapeutic class analysis and use of comparative data
between hospitals. Several types of interventions will be reviewed as potential tools to improve
quality of medication use. This will include pharmacist clinical interventions, automation of ordering
and dispensing, and other activities to improve medication use. Examples of how these tools may be
incorporated into hospital or broader medication use will be discussed.
D U P H A T 2009
www.duphat.ae
95
Abstract
Toxicokinetics of Drugs of Abuse: Relevance for Predicting Pharmacogenetic
Variations, Interactions, Detection Time, or Pitfalls in Drug Testing
Prof. Dr. Hans H. Maurer, President , International Association of Therapeutic Drug Monitoring
and Clinical Toxicology & Head, Department of Experimental and Clinical Toxicology, Institute of
Experimental and Clinical Pharmacology and Toxicology, Saarland University, Germany
Time: 11:00 - 11:45
Individual variations in the pharmacological responses to the same drug dose may be caused by a variety
of factors such as body mass, age, sex, kidney and liver function, drug-drug (food-drug) interactions,
or genetic variability [1]. Detailed knowledge of the metabolism of drugs allows to predict possible
interactions with other xenobiotics because of e.g. inhibition or induction of individual metabolic
isoenzymes by poisons, drugs (of abuse), alcohol, or ingredients of tobacco or food [2-4]. Hence,
understanding pharmaco-/toxicokinetics and pharmacogenetic variations is a prerequisite for evidencebased case interpretation, for toxicological risk assessment, for developing toxicological analysis
procedures, and for understanding pitfalls in drug testing. In the presentation, the major metabolic
pathways and the involved isoenzymes in humans will be summarized for the major drugs of abuse.
It will also provide an overview on the implications of the presented data for possible interactions of
drugs of abuse with other xenobiotics, i.e. inhibition or induction of individual polymorphic and nonpolymorphic isoenzymes.
96
Abstract
Personalized medicine and faculties of pharmacy: What should be our roles in
pharmacogenetics and pharmacogenomics
Prof. Robert D. Sindelar, Ph.D., Professor and Dean, Faculty of Pharmaceutical Sciences,
The University of British Columbia, Canada
Time: 11:45 - 12:30
Drug safety issues can arise throughout the life of a drug. No single patient is “average,” but rather
represents a genetically unique individual. In the very near future, more and more drugs will be
prescribed based on the results from pharmacodiagnostic testing. How can clinical pharmacy care
providers assure cost-effective, optimal drug therapy and improve patient outcomes? The answer may
be found in personalized medicine approaches that will include pharmacogenetics, pharmacogenomics
and health informatics. The practical consequences of the application of biotechnology and information
technology to pharmaceutical care and healthcare delivery are only beginning to be felt in the health
care environment. Future patterns of pharmaceutical care will involve new linkages among therapeutics,
diagnostics, and information. The genotyping methods and bioinformatics tools being deployed in
today’s research laboratory are being designed with a view to their utilization in investigational clinical
trials within a very short time and, once validated, for incorporation into routine clinical pharmacy
practice. Capitalizing on British Columbia’s strong infrastructure for genomic and bioinformatic research
to provide new insights into individualized drug therapy, the Faculty of Pharmaceutical Sciences at The
University of British Columbia is promoting the health and wellbeing of Canadians by developing costeffective interventions to reduce life-long disabilities and deaths caused by severe ADRs. The model to
be described is expected to provide numerous synergistic benefits in education, healthcare provision,
discovery and innovation, and translation of discoveries into products and practice. This presentation
will highlight the contribution academic pharmacy programs can make to this environment, identify
challenges that must be meet, and explore opportunities for synergistic collaboration and partnering.
Keywords: drug safety, personalized medicine, pharmacogenetics, pharmacogenomics health
informatics, ADRs. Oral Presentation
D U P H A T 2009
www.duphat.ae
97
Abstract
Regulatory issues in genomic medicine
Prof. H.G.M. Leufkens, Pharm.D., Ph.D., Utrecht University, Faculty of Science,
Utrecht Institute for Pharmaceutical Sciences (UIPS) Division of Pharmacoepidemiology &
Pharmacotherapy, Utrecht & Chair of Dutch Medicines Eva¬luation Board (MEB), The Netherlands
Time: 12:30 - 13:15
P
harmacogenetics focuses on the question of the extent to which genetic variants are responsible for
inter-individual variability in drug response among reci¬pients of a specific drug therapy. The ultimate
goal of pharmacogenetics is to shape therapy with available and new medicines in an individualised
fashion, e.g. ‘tailor-made pharmacotherapy’. Knowledge about individual drug-gene inter¬actions
is increasing rapidly. Disco¬very of genes determining the response to drugs is an emerging area of
genomic research. This research parallels the surge in discoveries of genes and protein expression
patterns affecting the suscep¬tibility to disease. There is evidence that certain disease susceptibility
genes are also determining drug action, and thereby therapy response. It becomes apparent that single
polymorphisms of genes coding for metabolism enzymes (CYP450, NAT2, etc) may have large clinically
significant effects. In this area of what we could call ‘first-phase pharmaco¬genetics’, genetic variants
affecting the drug dose needed to achieve an effi¬cacious and safe effect, have been inves¬ti¬gated
thoroughly in numerous studies and have resulted in the identi¬fica¬tion of categories of ‘slow’, or
‘fast-meta¬bolisers’, or other grouping formats. Already dozens of polymorphisms of genes coding for
the dopamine-receptor (rele¬vant for pharmacogenetics of psychiatric diseases) or the angiotensinconverting enzyme (relevant for pharmacogenetics of cardiovascular diseases) have been described
abundantly in the international literature.
The inclusion, both by FDA and EMEA, of HLA-B(*)5701 testing in the product label of the HIV drug
aba¬cavir has been a major breakthrough event in bridging genomic medicine and regulating medicinal
products. HLA-B(*)5701 is a highly predictive biomarker for abacavir treated patients who will develop
hyper¬sensitivity reactions, a severe syndrome seen in about 4-5% of exposed patients. From a risk
management perspective, preventing severe ADRs through genomic medicine seems to be a very
attractive scenario, both from the perspective of the treated patient as the market sustainability of
the medicinal product itself. However, although, there has been ample progress over the last decade
in the area of individual pharmaco¬genetic markers of a drug’s fate and action in the human body
(metabolism enzymes, trans¬porters, receptors, ion channels, nucleic acid and protein repair,
insertion/¬deletion (I/D) of the ACE, HLA proteins, and the like), so far the case of abacavir is rather an
exception. There seems to be a critical gap between the available science base on genomic medicine and
what drug regulators so far have adopted in their role as assessors of benefit-risk of medicinal products.
This presentation will address this gap from different perspectives and aims to provide a number of
thoughtful learning aspects.
98
Abstract
Antimicrobial Stewardship in Health Care
Dr. David CM Kong, BPharm., MPharm, Ph.D.,
Department of Pharmacy Practice, Centre for Medicine Use and Safety, Monash University, Australia
Time: 14:30 - 15:15
Antimicrobial resistance is a growing threat to public health due to increased mortality, morbidity and
cost. It has been prioritized for international action by the World Health Organisation. The key driver
for the development of resistance is the inappropriate use of antimicrobials.
The diminishing development of new antimicrobials (especially those active against multi-drug resistant
gram-negative bacteria) is of significant concern. This, coupled with the emergence of resistance,
highlights the need to prolong and optimise the use of existing antimicrobials. Strategies or programs
to optimise antimicrobial use fall under the broad heading of antimicrobial stewardship.
Antimicrobial stewardship in hospitals is recommended by professional societies and public health
authorities. The primary goal of Antimicrobial Stewardship Programs (ASP) is to improve patient care
through appropriate antimicrobial selection, dosage, route and duration of therapy, whilst minimising
the selection of pathogenic organisms, development of resistance and toxicity. This presentation will
discuss some of the strategies used in Antimicrobial Stewardship Programs and potential roles for
pharmacists.
D U P H A T 2009
www.duphat.ae
99
Abstract
Emerging Trends in Outsourcing Health Care: Health Tourism
Prof. J. Warren Salmon, Ph.D.
Visiting Professor of Pharmacy Practice, University of Sharjah, College of Pharmacy and Professor of
Health Policy and Administration, University of Illinois at Chicago School of Public Health,
Illinois, USA
Time: 15:15 - 16:00
"Health tourism” encompasses all health-seeking behaviors by consumers into another country.
This definition includes getting lower cost conventional health services, tourism for indigenous
and alternative medical treatments, and any other form of tourism undertaken with the purpose of
addressing a health concern, usually motivated by seeking cheaper care. The phenomenon of medical
tourism has attracted much attention in the lay press across the United States and Europe, but is surely
not confined to just Western societies. Citizens traveling abroad hold many implications for their
respective health care systems.
Hot destinations for medical tourism include Singapore, India, Thailand, Mexico, Costa Rico, China,
and more. Rich Europeans opting out a national health program queue, or uninsured or underinsured
Americans seeking cheaper care join with Middle Easterners, all enticed by clever marketing campaigns
to get dental services, specialty pharmacy, cosmetic services, or high tech surgeries at “bargain prices”
arranged with “customer care.” owever, However, how safe is medical tourism, is patient care quality
assured, what about complications when returning home? Such concerns persist with a need for a policy
discussion about other cautions over an unregulated entrepreneurial medical tourism industry seeking
high profits amidst their concurrent drains on their respective national public health care systems.
This presentation examines health tourism and assessing potential issues surrounding its varying
impact on certain societies, as well as the implications for patients and other stakeholders.
100
Pharmacy Workshops
W8. Advances in Transdermal Drug Delivery Technologies
Venue: Dubai E & F
Time: 09:00 - 10:00
N
ovel drug delivery systems are increasingly being demanded by patients, physicians, payers and
pharmaceutical manufacturers for a variety of reasons: patient compliance, clinical cost-effectiveness
and life-cycle management are commonly cited reasons. Transdermal drug delivery technologies
(TDDT) offer a non-invasive solution to many of these requirements, but additionally offer scope for
the delivery of molecules that cannot be delivered by the oral route, and more recently for cosmetology
products as worldwide affluence and ageing increases.
Dr. Nasir Hussain, B.Pharm., MBA, Ph.D.
Head of Pharmaceutical Formulation, Glide Pharma Needle – Free Technologies Limited
Oxford, United Kingdom
In this workshop, I will attempt to cover this rather diverse subject matter in three broad sections:
1. A review of skin anatomy: to correctly tilize the variety of TDDT.
2. Current and prototype TDDT: e.g. Patches vs. Needle-free systems
3. Regulatory considerations in the product development of TDDT: e.g. endotoxin
calculations, excipient selection, content of uniformity calculation
Note: All Registered Workshop Participants should bring a Scientific Calculator with them for this
Workshop
D U P H A T 2009
www.duphat.ae
101
Pharmacy Workshops
W9. What is Involved in Medication Reconciliation ?
Ms. Yvonne Allinson, Chief Executive Officer, The Society of Hospital Pharmacists of Australia,
Victoria, Australia
Venue: Dubai E & F
Time: 11:00 - 12:00
M
edication reconciliation is the standardised process of obtaining a complete and accurate
medication history and, in the context of the plan for care, comparing it to the current medication
order. Discrepancies are brought to the attention of the prescriber and if changes are made, they are
documented.
Medication reconciliation is a four step process: undertaking an accurate medication history;
confirmation of the medication history, reconciliation against the medications prescribed; and transfer
of verified information to other members of the healthcare team.
A medication history is a record of all the medicines actually taken by the patient in the period before
admission or presentation for the episode of care and includes information about previous adverse drug
reactions and allergies, and any recently ceased or changed medicines.
Undertaking a medication history is a core clinical pharmacy service. A recent US study of more than 14
million hospital admissions identified an association between pharmacists undertaking a medication
history on admission with reduced drug cost, length of stay, medication errors, adverse drug reactions
and most importantly a reduced mortality rate.
The purpose of medication reconciliation is to ensure patients receive all intended medicines and avoid
errors of transcription, omission, duplication of therapy, drug-drug and drug-disease interactions.
Medication reconciliation is a vital part of the pharmaceutical review process.
A reconciliation of current medication should be completed whenever the patient has a change in
their health status or when undertaking a medication review. For example diagnosis of a new disease,
admission or discharge to or from a residential care facility or hospital.
Workshop Objectives:
1. To understand the concept of medication reconciliation
2. To understand the role of patients’ medication history in the medication
reconciliation process
3. To be able to identify patients who would benefit from a reconciliation between their
medication history and current medication order
4. To consider the pharmacy services undertaken by workshop participants and determine
how medication reconciliation can best be used to improve patient outcomes.
102
Pharmacy Workshops
W3. Patient education with emphasis on patients with chronic
rheumatoid conditions
President of European Society of Clinical Pharmacy
Venue: Dubai D
Time: 09:00 - 10:00
The Workshop will be focused towards how best to achieve that the patients will feel safe and motivated
towards the use of their own medicines. A learning model developed at the local rheumatology ward will
be presented. In this model the educational needs of the patient is addressed throughout his or her stay
at the hospital; from admission to discharge and beyond. Ideally, at admission the level of knowledge
and beliefs towards medicines are mapped. The results from this assessment, forms the basis for the
content and form of further counseling during the stay and at discharge. During the stay much effort is
directed towards making the patient safe and motivated towards using newly prescribed medicines. As
it is custom not to start any new medicine unless the patient is willing to do so, this is a very important
issue to address. At discharge, ideally it is made sure that the patient is feeling comfortable and safe with
the medicines to be used at home.
Mr. Frank Jørgensen, MSc Pharm, Diploma in Clinical Pharmacy,
Haukeland Hospital Pharmacy, Bergen, Norway
The evidence informing the model will be reviewed; with special focus on research concerning
concordance and compliance related to the use of medicines.
D U P H A T 2009
www.duphat.ae
103
Pharmacy Workshops
W12. Clinical Education - Pharmacists becoming better Preceptors
Dr. David CM Kong, BPharm, MPharm, Ph.D., Department of Pharmacy Practice,
Centre for Medicine Use and Safety, Monash University, Australia
104
Venue: Dubai D
Time: 11:00 - 12:00
P
harmacists are highly trained professionals. Increasingly, they are being called upon to fulfil the role
of clinical educator (ie. preceptor) in-addition to their role in delivering patient-centred pharmaceutical
services. Whilst their undergraduate training will prepare pharmacists to deliver effective pharmaceutical
services to patients, sadly, not all pharmacists are well prepared or adequately trained to become good
clinical educators or prceptors for undergraduate students or pre-registrants. Indeed, little attention is
given with respect to equipping practitioners to become good preceptors. Accordingly, this presentation
will focus on a number of aspects which a pharmacist would need to consider if he or she intends to
become a preceptor. This includes preparing for the student’s placement, monitoring the student during
placement and provision of feedback/assessment to students.
Parallel Session
P15. Trends in Regulating Biosimilars in Kingdom of Saudi Arabia
Author:
Dr. Abdulmohsen AlRohaimi, Ph.D.
Director of Research and Publication, The Food and Drug Authority, (SFDA) – DRUG SECTOR, Saudi Arabia
T
he term “biosimilar product” is a new European term which was coined with the 2004 review of EU legislation regarding regulation
of biotechnology-derived medicines among other issues. Authorities are very aware of potential for immunogenecity and other safety
problems with biologica in general and biosimilars in particular. The Saudi Food and Drug Authority (SFDA) established a legal framework
for biosimilars (which are also known as follow-on proteins in the United States and as subsequent entry biologic in Canada).
According to this new legislation, all pre-clinical and clinical studies for biosimilars should be comparative in nature. Studies must be
designed to detect differences in response between the biosimilar and the reference product and not just the response (efficacy) per se.
The comparability exercise requires not only a comparable physicochemical profile but also pre-clinical studies and clinical trials showing
similarity between biosimilar and reference product. The chosen reference product must be the original medicinal product that has been
authorized in the community, on the basis of a complete dossier. The same reference product should be used throughout the whole
comparability studies.
Venue: Dubai A & B
Time: 09:00 - 09:30
The purpose of this talk is to explain the concept and basic principles of biosimilar products, show how to find relevant scientific
information for various aspects of regulations in order to substantiate the claim of similarity, introduce the guideline that is being
prepared by SFDA, and provide the stakeholders with most relevant issues.
P11. Rational Design of Potent and Novel BACE1 Inhibitors: A Possible Cure for Alzheimer’s
Author:
Dr. Taleb H. Al-Tel, Ph.D.
Associate Profesor in Medicinal Chemistry, College of Pharmacy, University of Sharjah, United Arab Emirates
Co-Authors:
Dr. Mazen Qato, College of Pharmacy
Dr. Salim S. Sabri, College of Science,
University of Sharjah, United Arab Emirates
Venue: Dubai A & B
Time: 09:30 - 10:00
A
lzheimer's disease (AD) is a progressive, neurodegenerative disorder for which no current treatment is available. It affects more
than fifteen million people worldwide, and has become one of the leading cause of dementia and death in elderly people. The sociofinancial cost brought about by the prolonged nature of AD, is estimated at over 100 billion USD a year in the US alone. A key hallmark
of AD is deposition of aggregated β-amyloid peptides (Aβ-40 and Aβ42) as plaques in the brain. Over the past 20 years or so, there has
been tremendous progress in understanding the etiology and pathology of this devastating disease. A key advance in this regard was
the identification of two proteases, β- and γ-secretase that are involved in the sequential proteolysis of membrane-anchored amyloid
precursor protein (APP). An interesting finding was that, BACE1 knockout homozygote mice show a complete absence of the plaques
resulted from the production Aβ in the brain and the lack of BACE1 have been reported to have no side-effects. Thus, BACE1 which
is highly expressed in the CNS compared to the peripheral system became an attractive target for drug discovery through designing
inhibitors of Aβ production.
In this presentation, we are describing the discovery of novel small molecules BACE1 inhibitors (Figure 1) as a possible treatment for
Alzheimer’s disease.
Figure 1. Three dimensional docking of our lead compound in the BACE1 active site
D U P H A T 2009
www.duphat.ae
105
Parallel Session
P12. How to make your Pharmacy ready for the accreditation and maintain readiness; "Sultan Bin
Abdulaziz Humanitarian City's experience"
Author:
Dr. Abdullatif Alokifi, B.Sc., R. Ph, MHHA
Chief Pharmacist, Pharmaceutical Care Department, Sultan Bin Abdulaziz Humanitarian City,
Saudi Arabia
Venue: Dubai A & B
Time: 10:00 - 10:30
Joint Commission International (JCI), is recognized as a global leader in providing technical assistance, education, and quality
evaluation services. JCI focuses on health care quality improvement and patient safety, with expertise in infection control, medication
management, standards compliance, and systems development. The accreditation of a healthcare organization helps both new and
experienced healthcare organizations to design and implement the clinical, facility, and management structures to achieve operational
improvement goals. In more than sixty countries around the world, JCI helps healthcare organizations to achieve their process
improvement goals.
In Sultan Bin Abdulaziz Humanitarian City (The City), we planned to go for accreditation as the true benefits of accreditation lies in
improved medical service quality, providing patients with safe, efficient and effective treatment. This allowed us to stand out from
others healthcare organizations nationally and internationally in terms of professionalism and quality of service.
My presentation will cover the role of Pharmaceutical Care Department as part of The City's accreditation readiness activities. Our
experience in the preparation of Pharmaceutical Care Department and the challenges with the new Medication Management and Use
standards will be discussed. I will also cover other related professionals and their collaborative roles to be an accredited healthcare
organization.
I will also discuss the need to maintain and continuously improve the existing culture of survey readiness and The City’s commitment
to maintain continuous performance improvement as an organizational priority.
P13. Presenting i.v.STATION™: a New Robotic Solution for Aseptic Compounding of Non-Hazardous
Medications
Author:
Mr. Gaspar G. DeViedma
Vice President, International Operations, Health Robotics, Bozen, Italy
Venue: Dubai A & B
Time: 11:00 - 11:30
T
he primary challenges in today’s IV Admixture operations are serious medication errors, high costs, turn-around time, waste,
regulatory issues, lack of audit trails, motion injuries, space constraints and difficulty in maintaining adequate and trained staff.
i.v.STATION™ was designed to address these issues and overcome the fact that until now, the range of products and technology
available to mitigate these challenges has consisted of variations on the IV “piggyback” bag, outsourcing of IVs, and partial automation
solutions that have seen very limited adoption and success over the past decade. i.v.STATION™ represents a revolutionary approach
in the quest for safe, accurate, efficient, and cost effective IV Admixtures. It offers unprecedented IV container flexibility, life-critical
patient safety, and robotic precision and performance, all within a scalable and fail-safe architecture.
106
Parallel Session
P14. The Pharmaco-economics of Using Generics versus Brands of immunosuppressive drugs
Dr. Mubarak Nasser Al Ameri, (Ph.D.)
Head of Pharmacy Department, Zayed Military Hospital, Abu Dhabi, United Arab Emirates
Ph.D. Student, Queen Mary, University of London, UK
Venue: Dubai A & B
Time: 11:30 - 12:00
T
he rising health care costs have received significant attention from both public and political arenas. Most policy makers are
looking desperately to reduce health expenditures while maintaining the quality healthcare. They often find it easier to intervene on
pharmaceutical expenditures since most of the health care budget consists of fixed costs (i.e., hospital services). Generally, the cycle
of healthcare consists of physicians prescribe, pharmacist dispense and/or substitute, patients consume, and increasingly throughout
the world, third parties (government, insurance companies) pay the bill with the money reluctantly contributed by healthy members
of the public. It is very important at this point to differentiate between drug prescribability and drug switchability. Drug prescribability
is the physician’s choice for prescribing between a brand and its counterpart generic drugs for a new patient. Drug switchability is
related to the switch from a brand drug to its alternative generic copy within the same subject whose concentration of the drug
product has been titrated to a steady, efficacious and safe level [1]. This indicates that drug switchability can be considered more
critical than drug prescribability for patients who have been on brand medication for a while. Therefore, there are some safety and
ethical issues around switching patients from a brand to generic drugs. In order to assure drug switchability, bioequivalence within
individual subjects should be assessed. This is known as the individual bioequivalence.
Author:
For example, switching between brands and generic cyclosporine may have a clinically-relevant impact on co-administered sirolimus
pharmacokinetics. Both drugs are immunosuppressants used in combination after transplantation. John M., et al, indicate that
sirolimus Cmax was significantly lower by 29% and AUC was 28% lower in the presence of generic versus brand cyclosporine [2].
Therefore, if this switch is initiated by the physician, monitoring of blood levels should be performed. However, if this switch was made
without informing the physician, potentially significant changes in sirolimus exposure may not be observed by the patient and the
clinician. Stephen P., et al, stated that ‘standards bioequivalence criteria do not address differences in cyclosporine pharmacokinetics
between transplant recipients and healthy volunteers, or between subpopulations of transplant recipients’ [3]. Current practice for
the assessment of bioequivalence is based on the fundamental bioequivalence assumption that when two formulations of the same
drug product or two drug products are equivalent in the rate and extent of drug absorption, it is assumed that they will reach the same
therapeutic effect or they are therapeutically equivalent. This article is not against generic prescribing or substituting but it is with the
ethical and effective use of generic drugs.
D U P H A T 2009
www.duphat.ae
107
Parallel Session
P17. Anticoagulants review: a case study approach
Author:
Dr. Marlene Moukarzel, Pharm.D BCNSP
Clinical Pharmacist, ICU department, Mafraq Hospital. Abu Dhabi, UAE
Venue: Dubai A & B
Time: 12:00 - 12:30
Anticoagulant therapy in special patient population (case studies)
Safe and effective use of anticoagulant therapy may require consideration of genetics, obesity, renal impairment, or the potential
for Heparin-Induced Thrombocytopenia (HIT); selecting anticoagulant therapy on the basis of these considerations can present a
challenge.
These special considerations in using antithrombotic therapy in special patient were described through two case studies, one in obese
patients and the other in renal failure patients.
In the obese patients, given LMWH prophylaxis or treatment, weight based dosing is suggested and dose capping is not warranted;
twice-daily enoxaparin is preferred over once-daily dosing. Anti-Xa monitoring is perhaps not necessary for patients weighing less
than 190 kg, but it may be useful to adjust the dose in heavier patients.
In patients with severe renal impairments, bleeding during anticoagulant therapy may be attributed to the uremic state, excessive
doses, or both. If creatinine clearance (CrCl) is < 30 mL/min and therapeutic anticoagulation is required, unfractionated heparin
(UFH) is suggested instead of LMWH. If LMWH are used dosage reduction(50%) and anti-Xa monitoring are recommended for
patients with severe renal impairmen
Major references:
108
1
Parenteral anticoagulants. American College of Chest Physicians evidence-based clinical practice guidelines (8th edition).
2
Considerations in using anticoagulant therapy in special patient populations, Katherine W. Phillips, Paul P. Dobesh, and
Stuart T. Haines, Am J Health-Syst Pharm—Vol 65 Aug 1, 2008 Suppl
PROFESSIONAL POSTERS
D U P H A T 2009
www.duphat.ae
109
Location : Sheikh Rashid Hall - B
Poster Code F01
Author:
Dr. Homan Kaghazian, MSc, Recombinant Biopharmaceuticals Production Department,
Research and Production Complex, Pasteur Institute of Iran, Tehran, Iran
Co-Author:
Dr. Abdol-Reza Varasteh
Immunology Research Center, Mashhad University of Medical Science, Iran
Title: Specific IgG Antibodies (Total and Subclasses) against Saffron Pollen:
A Study of Their Correlation with Specific IgE and Immediate Skin Reactions
Abstract: Saffron (Zaaferan), botanical name Crocus sativus, is the most expensive spice in the world. It is derived from the dried
stigma and pistil of the purple saffron crocus flowers. Iran is the largest saffron producer accounting for more than 80% of the world’s
production. Saffron contains an aeroallergen that causes reactive respiratory allergic reactions in atopic subjects. IgG antibody to
allergens in the serum of allergic patients is not routinely measured. In this study in order to find out more about mechanism of
allergy against saffron pollen, specific antibodies (IgE and IgG, total and subclasses) in atopic subjects were assayed.
We used an ELISA assay for measuring specific IgE and IgG against saffron pollen extract in the sera of 38 atopic subjects (test
group) and 20 non allergic subjects (control group). The optical densities were compared between allergic subjects and non-allergic
individuals. The prick test with saffron pollen extract was used to evaluate the cutaneous and specific antibody responses in the
allergic subjects. The correlation was determined by statistical analysis.
Specific saffron pollen IgE and IgG subclasses were found significantly higher in the allergic subjects than the control group. The
immediate skin reaction was found positive in 70% of the test group. We report here, the existence of a positive correlation between
specific IgE and skin reaction by prick test in atopic subjects (R=0.433). A negative correlation between specific IgE and IgG4 subclass
was also found (R=-0.576).
These data may be useful to understand the mechanism of allergy to saffron and may help in clarifying clinical manifestations and to
prevent IgE production as well as therapeutic application.
Key words: Allergy; Saffron pollen; Specific IgE; Specific IgG; Specific IgG subclasses; Skin prick test
Poster Code F02
Author:
Dr. Bassim Irheim Mohammad, MBChB, MSc, Ph.D., Chairman and Senior Lecturer Physician,
Department of Clinical Pharmacology and Therapeutics, College of Medicine, University of Diwaniyah,
Diwaniyah, Iraq
Co-Author:
Dr. Najah R Hadi, Ph.D.
Department of Pharmacology and Therapeutics, Kufa College of Medicine, Iraq. Kufa, Iraq.
Title: The effects of Allopurinol and Vitamin C on fracture healing
Abstract: Background: Oxidative stress has recently been shown to play a role in bone metabolism, osteoclast activation and damage
to osteoblast. Therefore this study was carried out to clarify the effect of allopurinol and vitamin C on the healing of experimental
fractures.
Materials and methods: A total of fifteen adult New Zealand rabbits, weighing 2.5~3.0 kg, were used in this study. Animals were
divided into three groups, assigned 1, 2 and 3 (five animals in each group). Bilateral closed femoral fracture was constructed manually
in all groups. Group 1 received no treatment (control) while groups 2 and 3 were treated with allopurinol and vitamin C, respectively
for four weeks, beginning one day after production of the femoral fracture. Radiographic and histopathologicl examinations were
performed to evaluate fracture-healing.
Results: Radiographs showed significantly more advanced healing of the allopurinol and vitamin C treated fractures compared with
the fractures in the control group. Histopathological examination revealed that average healing grades (degrees) of the allopurinol and
vitamin C treated groups were higher than the control group. Mean healing grades of the groups were as follows: allopurinol (7.1) and
vitamin C (7.6) and control (4.2).
Conclusions: Due to their possible antioxidant effects, allopurinol and vitamin C enhanced fracture healing and callus formation in
rabbits.
Key Words: Fracture healing, allopurinol, vitamin C, antioxidant, rabbits
110
Poster Code F03
Author:
Prof. Dr. Ashraf H. Abadi, Ph.D., Head, Pharmaceutical Chemistry Department,
Faculty of Pharmacy and Biotechnology, The German University in Cairo-GUC, New Cairo City, Egypt
Co-Authors:
Mohamed Abdel-Halim1, Bernard D. Gary2, Heather N. Tinsley2, Gary A. Piazza2
1
Department of Pharmaceutical Chemistry, Faculty of Pharmacy and Biotechnology,
German University in Cairo, Cairo, Egypt
2
Title: Design and Synthesis of Novel ß-Carboline Derivatives As Potential Phosphodiesterase
Inhibitors And Anticancer Agents
Abstract: Tadalafil is a ß-carboline with PDE5 inhibitory properties that is
marketed for the treatment of male erectile dysfunction. Its local vasodilatation
action is mediated through high levels of cGMP. Recent studies showed that
PDE5 and other PDE isozymes are over-expressed in malignant tumors whereby
inhibition and consequent high levels of cGMP may be associated with anticancer
and apoptotic activities. Herein, we report novel tadalafil related analogues in which
tadalafil chiral carbons swing from R,R to R,S, S,R and S,S, the piperazinedione ring
is maintained or reduced to imidazolidinedione or thioxoimidazolinone. For all
derivatives the benzodioxole moiety of tadalafil was replaced by 2-bromophenyl. The
prepared analogues were evaluated for their capacity to inhibit PDE5 and tumor cell
growth using the human HT-29 colon adenocarcinoma tumor cell line . Compound
(5R,11aS)-5-(2-Bromophenyl)-2-ethyl-5,6,11,11a-tetrahydro-1H-imidazo[1’,5’:1,6]
pyrido[3,4-b]indole-1, 3(2H)-dione exhibited the strongest PDE5 inhibition
with IC50 = 38 nM, while compound Methyl (1R,3S)-1-(2-bromophenyl)-2-(2chloroacetyl)-2,3,4,9-tetrahydro-1H-ß-carboline-3-carboxylate was the most active
in growth inhibition with IC50 of 1.6 μM. The stereochemical aspects of C-5 in the hydantoin series and C-6 in the piperazinedione
derivatives seem to be the most crucial for the PDE5 inhibition. For this class of compounds, there does not appear to be a correlation
between the PDE5 inhibition and the anticancer activity, which leads us to hypothesize that other PDE isozymes or possibly PDE5
splice variants may be involved.
Division of Drug Discovery, Department of Biochemistry and Molecular Biology,
Southern Research Institute, The University of Alabama at Birmingham, Birmingham, USA
Poster Code F04
Author:
Mr. Emile Jubeli, MSc., (Ph.D.)
Co-Authors:
Dr. Gillian Barratt and Dr. Laurence Moine
Title: Development of sugar decorated nanoparticles targeting activated endothelium
Abstract: Introduction: E-selectin, also known as CD62E, is a cell adhesion molecule expressed only on endothelial cells activated
by cytokines. Like other selectins, it plays an important part in inflammation and in the adhesion of metastatic cancer cells to the
endothelium. E-selectin recognises and binds to sialylated carbohydrates present on the surface proteins of certain leukocytes.
AIM: The aim of this work was to develop an amphiphilic block copolymer linked by its hydrophilic part to a monosaccharide
(glucopyranoside) which was used as a model for a carbohydrate ligand of E-selectin. Then stealth nanoparticles were prepared from
this copolymer, as a drug delivery system targeting activated endothelium.
Methods: The construction of the amphiphilic block copolymer was achieved by a combination of click chemistry, ring opening
polymerization and atom transfer radical polymerization. The preparation of nanoparticles was done by nanoprecipitation methods.
The characterisation of the resulting nanoparticles was achieved by Quasi-Elastic Light Scattering transmission electronic microscopy.
Detection of the glucopyranoside on their surface was done by their interaction with the Concanavalin A.
Results: The synthesis of glucopyranoside grafted copolymer was done successfully which allowed us to prepare particles of nanometric
size (50-150 nm). The formation of aggregates by these nanoparticles in presence of concanavaline A confirmed the presence and the
D U P H A T 2009
www.duphat.ae
111
accessibility of glucopyranoside on the surface of the nanoparticles.
Conclusion: We have confirmed the feasibility of well defined block amphiphilic polymer from which we have prepared nanoparticles
bearing molecules of monosaccharide. In the future, this monosaccharide can be substituted by more complicated carbohydrate
molecules like sialyl Lewis X which is the natural ligand of E-selectin.
Poster Code F05
Dr. Linda Tahaineh, Ph.D., MS, Assistant Professor of Clinical Pharmacy, Department of Clinical
Pharmacy, College of Pharmacy, Jordan University of Science and Technology, Irbid, Jordan
Co-Authors:
Mayyada Wazaify (PhD)2, Abla Albsoul-Younes (PhD)1,
Yousef Khader (ScD)3, Manal Zaidan (BSc Pharm)4
Author:
1
Department of Clinical Pharmacy, Faculty of Pharmacy, Jordan University of Science &
Technology (JUST), Irbid, Jordan
2
Department of Biopharmaceutics and Clinical Pharmacy, Faculty of Pharmacy,
The University of Jordan (JU), Amman, Jordan.
3
Department of Public Health, Community Medicine, and Family medicine, Faculty of Medicine,
Jordan University of Science & Technology (JUST), Irbid, Jordan
4
Al-Amal Cancer Centre, Doha, State of Qatar.
Title: Physicians’ Perceptions, Expectations and Experiences of the Clinical Role of
Pharmacists in Hospital Settings in North of Jordan
Abstract: Background: Physicians’ perceptions, expectations and actual experiences of pharmacists need to be determined in order to
develop a collaborative working relationship between the two health care providers.
Objectives: The goal of this study is to investigate the nature of the relationship between physicians and pharmacists including
physicians’ perceptions, expectations and experiences in hospital settings in Jordan.
Methods: A questionnaire was distributed randomly to 284 physicians working in four main hospitals in north of Jordan. The
questionnaire constituted of four parts investigating physicians’ perceptions, expectations and experiences of pharmacists.
Results: Two hundreds and forty-five questionnaires were returned, response rate (83.6%). More than half of the physicians were
comfortable with pharmacists educating patients about their treatment (53.9%). Around half of physicians were not comfortable
with pharmacists suggesting the use of prescription medications like antibiotics to patients (48.2%). Most physicians (62.5%) expect
pharmacists to council their patients about safe and appropriate use of drugs, nevertheless, around one-third of them (33.9%) do not
expect pharmacists to be available during rounds for consultation.
Conclusion: Physicians in Jordan hospitals accept the traditional role of pharmacists. However, they are skeptical to the implementation
of more clinical services. In order to initiate a collaborative working relationship between physicians and pharmacist, pharmacist need
to increase physicians’ awareness of clinical services they can offer.
Poster Code F06
Author:
Dr. Azza T. Taher, Department of Organic Chemistry, Faculty of Pharmacy,
Cairo University, Cairo, Egypt
Co-Authors:
Dr. Nadia A. Khalil, Dr. Eman M. Ahmed
Department of Organic Chemistry, Faculty of Pharmacy, Cairo University, Cairo, Egypt
Title: Design, Synthesis of 4-oxo-1,2,4-Triazolo[4,3-a] quinoxaline Derivatives
For Evaluation of in –vitro Antitumor and Antimicrobial Activities
Abstract: Triazolo[4,3-a]quinoxalinones derivatives are an important class of nitrogen -containing heterocycles. Fused quinoxalines
are common structural arrays that are found in a variety of biologically important and medicinally useful agents as antibacterial,
antifungal, anti-HIVand anticancer activities. Novel series of quinoxalinones derived from 4-oxo-5H-1,2,4-triazolo[4,3-a]quinoxalin-
112
5-yl-acetic acid hydrazide have been synthesized in order to evaluate their antitumor and antimicrobial activites. Certain selected
newly synthesized compounds were tested in- vitro for cytotoxic activity on human breast carcinoma cell line (MCF-7) and on liver
carcinoma cell line (HEPG-2) .
On the other hand , in-vitro microbiological data revealed that novel compounds exhibited moderate antibacterial and antifungal
activity compared to reference tetracycline and amphotricine.
Author:
Dr. Sayer Ibrahim Al-Azzam, Pharm. D, M.Sc , Assistant Professor, Department of Clinical Pharmacy,
Faculty of Pharmacy. Jordan University of Science and Technology, Irbid, Jordan
Co-Author:
Dr. Khalid K. Al-Ani, Ph.D., Associate Professor, Department of Clinical Pharmacy, Faculty of Pharmacy,
Jordan University of Science and Technology, Irbid, Jordan
Title: The nephroprotective effects of pioglitazone and glibenclamide against
Gentamicin-induced nephrotoxicity in rats: A comparative study
Abstract: Background: Gentamicin is a commonly used antibacterial drug that can cause significant nephrotoxic effects in both
humans and animals. Gentamicin-induced nephrotoxicity is the result of oxidative reactions.
Poster Code F07
Objective: The aim of the current study is to comparatively examine the nephroprotective effects of two different commonly used oral
hypoglycemic agents (pioglitazone, and Glibenclamide) in a rat model subjected to Gentamicin-induced nephrotoxicity.
Method: Three groups of rats were given; gentamicin (100 mg/kg/day) alone, gentamicin (100 mg/kg/day) plus pioglitazone (10 mg/
kg/day), and gentamicin (100 mg/kg/day) plus glibenclamide (20 mg/kg/day), in addition to the control group.
At the end of the experimental study, the toxicity as well as the nephroprotective effects of the drugs were assessed biochemically and
histopathologically.
Results: The results of this study indicated that gentamicin and gentamicin plus pioglitazone groups had a significant reduction in
antioxidant enzymes activity, a significant elevation in lipid peroxidation level and plasma creatinine levels, while histopathological
examination showed severe to moderate necrosis. While in gentamicin plus glibenclamide group showed a significant elevation
in antioxidant enzymes activity, a significant reduced in lipid peroxidation level, and a significant reduced in creatinine level. Also
showed mild necrosis in histopathological finding as a compared with gentamicin group alone.
Conclusion: Our study showed that glibenclamide (20 mg/kg/day) have a nephroprotective effects against gentamicin-induced
nephrotoxicity in rats.
Poster Code F08
Author:
Dr. Shadi Faiz Gharaibeh, Ph.D. in Pharmaceutics, Assistant Professor,
Department of Pharmaceutical Technology, Jordan University of Science and Technology, Irbid, Jordan
Co-Author:
Dr. Ibaa N. Chick Al-Ard (MS.)
Department of Pharmaceutical Technology, Jordan University of Science and Technology, Irbid, Jordan
Title: The Mechanical Energies (work) Associated with the Compaction of both the
Monoclinic and the Orthorhombic forms of Paracetamol Powder
Abstract: Introduction: paracetamol in the solid state is reported to have three polymorphic forms. The monoclinic form (form I), the
orthorhombic form (form II), and form III. The monoclinic form is the most stable form and has poor compaction behavior. On the
other hand, the orthohrohmbic form has been reported to have better compaction behavior which in turn could be utilized in a direct
compression formulation. In this work the work associated with the compaction of both forms of paracetamol was estimated and
correlated to the extent of plasiticity and elasiticity of the compacted powders.
Methods: the orthorhombic form of paracetamol was successfully produced in appreciable quantities by melting the monoclinic
form in a test tube immersed in a heated paraffin oil bath. The melted paracetamol was then cooled in a water bath at 60-70°C.
Powder samples of both the monoclinic and the orthorhombic forms of paracetamol were stored for 3 weeks at 25°C at relative
humidity conditions of 23%, 43%, 57%, 75%, and 93%. The stored powder samples were then characterized and analyzed using a
D U P H A T 2009
www.duphat.ae
113
Roell+Korthaus compression machine.
Results: it was found that for generating compacts of equal volumes of the two forms then the plasticity index would be larger for the
orthorhombic form and the EE/PE ratio would be larger for the monoclinic form at any given compression force.
Conclusions: the orthorhombic form of paracetamol has higher tendency to deform by a plastic mechanism and lower degree of elastic
component when compared with the monoclinic form.
Poster Code F09
Author:
Dr. B. J. Mahendra Kumar, M Pharm, Ph.D., Associate professor,
KLES College of Pharmacy, Karnataka, India
Co-Author:
Prof. B. G. Nagavi, M Pharm, Ph.D., Dean, Ras Al Khaimah College of Pharmaceutical Sciences
RAKMHS University, Ras Al Khaimah, UAE
Title: Assessment of Quality of Life of Diabetic Patients in selected Community
Pharmacies in South India
Abstract: Objectives: To assess the impact of patient counseling on Quality of Life (QOL) of diabetic patients.
Methods: A cohort, prospective, randomized controlled study was conducted in three independent selected community pharmacies
of South Indian city for a period of two years. Patients diagnosed to have diabetes mellitus type II were enrolled as per the inclusion
and exclusion criteria. All test group patients were counseled and educated regarding their disease state, diet, life style modifications.
Ferrans and Powers QOL index Diabetes Version-III a validated, disease specific questionnaire was distributed among all enrolled
patients and filled questionnaire collected at baseline and at subsequent follow-ups to assess the QOL. Parameters included in QOL
questionnaire were total QOL index score, health and functioning subscale, social and economic subscale, psychological/spiritual
subscale and family subscale scores. The scores were compared between control and test group using ‘ANOVA’ test.
Results: One hundred eighty diabetic patients were enrolled (control 90, test 90). Of these, 102 (56.66%) patients completed the
study [control 48(47.05%), test 54(52.94%)]. On statistical analysis health and functioning subscale score had shown significant
(P<0.05) difference between control and test group. It was also found that there was improvement in QOL scores in test group (from
baseline to subsequent follow-ups), whereas no significant (P>0.05) difference was observed in control group.
Conclusion: The study concluded that the community pharmacist mediated patient counseling have significant impact leading to
improvement in QOL of diabetic patients.
Poster Code F10
Author:
Dr. P. K. Kulkarni, M.Pharm., Ph.D., J.S.S. College of Pharmacy, Mysore, India
Title: Spherical crystallization of ibuprofen for direct tabletting
Abstract: Ibuprofen, an anti-inflammatory drug exhibits poor flow and compressible properties. It is poorly water-soluble and the
present investigation was envisaged to study the influence of spherical crystallization on the dissolution behaviour of Ibuprofen.
Spherical crystallization of Ibuprofen was carried out using solvent change and neutralization methods. Spherical crystals of
ibuprofen were prepared using Isopropyl alcohol: isopropyl acetate and water system (21:7:72). Isopropyl acetate acted as bridging
liquid. Spherical crystals prepared were evaluated for their primary properties by IR spectroscopy X-ray diffraction and scanning
calorimetry. Micromeritic and dissolution behaviour studies were carried. Process variables and amount of bridging liquid were
114
optimized. Particle size, bulk density and drug release were significantly affected by amount of bridging liquid, speed of rotation and
temperature differences. Spherical crystals exhibited decreased crystallinity and improved micromeritic and mechanical properties.
Amount of bridging liquid, speed of agitation and duration of agitation affected the yield, mechanical properties and micromeritic
properties of spherical crystals. The dissolution of the drug is improved significantly (99.2% at 60th min compared to 73% for pure
sample). Hence this technique can be used for formulation of Ibuprofen tablets by direct compression with directly compressible
tablet excipients.
Author:
Ms. Banan Mukhalalati, BSc (Pharmacy), MBA
Medication Safety Manager, Al-Amal Hospital, HMC, Doha, Qatar
Co-Authors:
Dr. Michael Fahey, MSc, PhD, MRPharmS, Pharmacy Advisor, HMC &
Ms. Manal Zaidan, BSc (Pharmacy), Pham D candidate, Pharmacy Director, Al-Amal Hospital, HMC
Title: A Report of Medicines Use in Hamad Medical Corporation (HMC) hospitals,
Qatar 2006 to 2008
Abstract: Background Qatar is an independent State in Arabian Gulf. It has the fastest growing economy in the world and its wealth
from Gas and Oil is transforming it into an education based society.
Poster Code F11
HMC is the government provider of health within Qatar, HMC is composed of five hospitals: Hamad General Hospital, Rumailah
Hospital, Women Hospital, Al-Khor Hospital and Al-Amal Cancer Hospital.
Objectives: This study describes medicines cost in relation to therapeutic category and formulary versus non formulary.
This study describe the cost of opioids dispensed at Al-Amal Cancer Hospital and compares those opioids quantities in Daily Defined
Dose (DDD) against quantities consumed in Clínica Universidad de Navarra in Spain
Method: Records of medications dispensed within HMC hospitals were produced from the Pharmacy Management System for years
2006-2008; it included 1,955 medications.
Each medication was categorized as per the BNF classification and the current formulary status.
Data was analyzed utilizing Microsoft Excel, the analysis comprised comparisons of year on year data and Paretto analysis to identify
the most significant areas of medicine cost.
The WHO ATC DDD was used to estimate the quantity of opioids utilized at Al-Amal Hospital in 2008. Those quantities are compared
against the opioids quantities in the study that was conducted in the Clínica Universidad de Navarra by calculating DDD per 1000
hospital stays.
Results:
·
The increase in cost was 34% from 2006 to 2007and 10% from 2007 to 2008.
·
Medicines for Cardiovascular system diseases are the highest in cost followed by infections for years 2006-2008
·
For year 2008, medicines for Cardiovascular system diseases are the highest in cost (22%) followed by infections (16%)
then Central nervous system (11%)
·
For year 2008, formulary items accounted for 87% of cost.
·
Quantities as DDD per 1000 Hospital stay for opioids consumed at Al-Amal Hospital are higher than Clínica Universidad
de Navarra except for Methadone.
D U P H A T 2009
www.duphat.ae
115
Poster Code F12
Author :
Dr. Nohad A Al Omari, Medicinal Chemistry (Ph.D.), Department of Pharm. Chemistry,
College of Pharmacy, University of Mosul, Mosul, Iraq
Co-Authors:
Adnan O. Omar & Iklas M. Taher,
College of Science, University of Mosul, Iraq
Title: Preliminary Cytotoxic Study of Some Novel Furo-2-quinolone Compounds
Abstract: New series of Furo-2-quinolone [FQ] compounds have been synthesized in this research. These novel [FQ] compounds are
prepared from coumarin derivatives (Furocoumarins: psoralen and isopsoralen).
Identifications of these FQ compounds were performed by using infrared spectrum (I.R), Ultraviolet spectrum (U.V) and Nuclear
Magnetic Resonance spectrum (H1-NMR) besides some physical data.
The cytotoxic screening involves ;using HEP-2 cell line which give differential responses against tested compounds :
4,6-Dimethyl psoralene (C1), 1-(P-Hydroxybenzyliden imino)-2,6- dimethyl furo [3,2-g] quinolin-2-one (C3) and 1-(2`,4`Dimethoxybenzylidenimino)4,6-dimethyl-Furo[2,3-g]quinoline-2-one(C3A).
These preliminary studies with using different cell lines in addition to full cytotoxic screening may facililate generation of better
structural activity relationship & then shed the light for new lead promising anticancer compounds.
Keyword Coumarin, Angelicin, HEP-2 Cell line, cytotoxicity
Poster Code F13
Author :
Dr. Sonia Driss Chaieb, Ph.D., Principal Specialist Pharmacist, Head of Pharmacy Department
Centre National de Greffe de Moelle Osseuse, Bab Saadoun , Tunis, Tunisia
Co-Authors:
Jean-Claude Chaumeil 1, Sami Jebnoun 2, Naima Khrouf 2,
Abderrazek Hedhili 3, Souad Sfar 4
1
Laboratoire de pharmacie galénique, Faculté des Sciences pharmaceutiques et Biologiques,
Université Paris-Descartes et A.G.E.P.S., Paris, France
2
Neonatology department of the Maternity Centre of Tunis
3
Emergency and Anti poison Centre (CAMU) - Tunis
4
Laboratoire de Pharmacie Galénique, Faculté de Pharmacie de Monastir, Tunisia
Title: Effect of additives on the physicochemical properties of two intravenous lipid
emulsions used as total parenteral nutrition
Abstract: Background: Several factors can affect the stability of intravenous lipid emulsions intended to be administered as total
parenteral nutrition.
Objective: To study the effect of additives on two intravenous lipid emulsions (Clinoleic® 20% and Ivelip® 20%) using Primene® 10%
as source of amino acids and simulating clinical conditions.
Methods: Two series of experiments for each lipid emulsion were carried out. One using separate nutriments (water, glucose or amino
acid) with various Ca-P (calcium gluconate and glucose-1-phosphate) concentrations, and second using TPN admixtures with varied
amino acid (1%, 2% or 3.5%) and glucose (8% or 14%) concentrations. Samples were stored 24 hours at 37°C.
Results: Investigations of lipid-nutrient admixtures showed a significant decrease of the pH with Primene® and a visual instability
when mixing with sterile water alone, wile total parenteral nutrition (TPN) admixtures made of Clinoleic® 20% or Ivelip® 20% were
stable regarding to pH, particle sizing and zeta potential after storage conditions. Also the evaluation of calcium-phosphate solubility
showed a significant decrease of the calcium concentration after filtration of the PN samples containing highest concentrations of Ca
(up to 30mmol/l).
Conclusions: Our data indicated that total parenteral nutrition admixtures could contribute to protect the lipid emulsion from its
physicochemical degradation when using high Ca-P concentrations in their organic form, but the use of inline-filters remains necessary
during the administration of TPN regimens.
Key words: parenteral nutrition, stability, compatibility, calcium, phosphate.
116
Poster Code F14
Author :
Co-Author:
Dr. Manal Al-Sharawi, B.Pharm, MSc
Department of Pharmacology & Pharmaceutics, College of Pharmacy, University of Sharjah, UAE.
Prof. Suleiman I. Sharif, B.Pharm, Ph.D.
Department of Pharmacology & Pharmaceutics, College of Pharmacy, University of Sharjah, UAE.
Title: Influence of Methylene Blue on Oxotremorine – induced Parkinsonism
Parkinson’s and
In the present investigation, experimental Parkinsonism was induced in mice by the IP injection of oxotremorine in a dose of 3 mg/kg.
Mice exhibited severe tremor at an average of 2 minutes following the drug administration together with profuse salivation, urination
and diarrhoea. Administration of methylene blue IP at a dose of 0.25 ml of either 0.1 and1% solution was without any appreciable
effect on oxotremorine. Moreover, intraventricular injection of methylene blue at 5 μl and 20 μl (0.1% or 1%) though immediately
produced sedation, mice exhibited circular movement that continued till oxotremorine was administered. In these animals the
onset of tremor was delayed in presence of methylene blue but once precipitated it was more severe than in absence of methylene
blue. Our preliminary results suggest that methylene blue injected intraventricularly may increase central dopaminergic activity as
demonstrated by circling behaviour reminiscent of that produced by apomorphine. It is also tempting to suggest that Parkinsonism
consequent to increased cholinergic activity is resistant to methylene blue despite its possible dopaminergic influence.
Abstract: Recently it has been claimed that methylene blue may have a therapeutic potential in treatment of
Alzheimer’s diseases.
Poster Code F15
Author :
Prof. Raafat El-Awady, Ph.D., Associate Professor of Pharmacology, College of Pharmacy,
University of Sharjah, UAE
Co-Author:
Ekram M. Saleh
National Cancer Institute, Cairo University, Cairo, Egypt
Title: Targeting DNA repair: is it a right way for sensitization of tumor cells to 5-FU?
Abstract: Disrupting DNA repair in tumour cells is a new approach for improving their response to anti-cancer agents and to
overcome resistance of some tumours. The aim of this study is to investigate the effect of targeting DNA repair on other biological
processes that may also affect response of tumour cells to anti-cancer drugs
An isogenic pair of cell lines was used in this study differing only in the expression of XRCC3 protein which is required for an efficient
DNA repair . Their sensitivity to 5-FU was determined by colony-formation assay, their ability to repair 5-FU-induced DNA damage
was assessed by western blot analysis of γ–H2AX protein and cell cycle regulation and apoptosis were measured by flow cytometry.
Results showed that cells defective in XRCC3 protein were more resistant to 5FU than wild-type cells . XRCC3-deficient cells had
reduced ability to repair 5FU-induced DNA damage than wild-type cells. Induction of apoptosis after treatment with 5-FU was evident
in XRCC3-wild type but not XRCC3-deficient cells. Both cells were found to be arrested at the G1/S phases of the cell cycle after
treatment with 5-FU.
These results indicate that caution should be warranted upon targeting DNA repair because other biological processes like apoptosis
and cell cycle may be affected as well which may influence the overall response of cells to anti-cancer agents.
D U P H A T 2009
www.duphat.ae
117
Poster Code F16
Author :
Dr. Najah R. Hadi, Head Department of Pharmacology and Therapeutics,
Kufa Faculty of Medicine, Iraq
Co-Authors:
Dr. Mohammad Abdelhusein, Dr.Hussein S Mohammad,
Kufa college of Medicine, Iraq
Title: Effect of Atorvastatin on Oxidative Stress Parameters and Lipid Profile in
Type 2 Diabetic Patients
Abstract: Background: Evidence has long existed regarding the relationship between oxidative stress & diabetes .Aim of the study:The
present study was conducted to assess the effect of atorvastatin on selected oxidative stress parameters in the form of reduced
glutathione (GSH), lipid peroxidation byproduct malondialdehyde (MDA) levels, glutathione –S- transferase ( GST) activity & catalase
(CAT) activity) & it is effect on lipid profile (total cholesterol (TC), triglyceride (TG), high density lipoprotein (HDL), low density
lipoprotein (LDL) & very low density lipoprotein (VLDL) in dyslipidaemic type 2 diabetic patients Patients and methods: Fifty nine
dyslipidaemic type 2 deabetc patients were included in this study . A full history was taken & general examination was performed .
Those patients were taking glibenclamide ( an oral hypoglycaemic drug ) during the study as a treatment for their disease . The patients
were followed up for 60 days & divided randomly into 2 groups . Group I ( n=31): no drug was given & served as dyslipidaemic diabetic
control . Group II (n=28): received atorvastatin tablets 20mg once daily at night . From those Fifty nine patients included in this
study , forty six patients reached the end of the study while thirteen patients withdrew (eight patients from Group I and five patients
from Group II ). This is due to non compliance of the patients. Blood samples were drawn from the patients at the beginning & after
60 days of follow up between 8:30 &10:30 am after at least 12-14 hours fast . Fasting blood glucose, lipid profile, selected oxidative
stress parameters (GSH, MDA levels, GST & CAT activities ) were measured . Renal & hepatic functions were also assessed .Results:
This study revealed the following Atorvastatin treatment increased serum GSH, reduced MDA levels significantly while did not
significantly affect CAT & GST activity. In atorvastatin treatment, TC, TG, LDL &VLDL decreased significantly while HDL increased
significantly. There were insignificant correlations between atorvastatin induced changes in the oxidation markers & the observed
changes of the lipid profile.
Poster Code F17
Author :
Dr. Maguy El Hajj, BScPharm, Pharm D, Assistant Professor,
Clinical Pharmacy and Practice, College of Pharmacy, Qatar University, Doha, Qatar
Co-Authors:
Dr. Peter J. Jewesson, Ph.D.
College of Pharmacy, Qatar University, Doha, Qatar
Title: Professional satisfaction in a Middle East Country: pharmacist opinions in Qatar
Abstract: Background: Given the changes that the pharmacy profession is going through, understanding professional satisfaction
from the pharmacists’ perspective is essential. There are no published reports regarding the professional satisfaction of pharmacists
in Qatar.
Accordingly, this study was conducted to determine the level of satisfaction of pharmacists and how they perceived it could be
improved.
Methods: An online anonymous survey of pharmacists in Qatar was conducted to solicit their opinions about professional
satisfaction.
Results: Over a 6-week period, we recorded 187 survey responses (23% of registered pharmacists in Qatar). Forty-two percent of
respondents worked in a hospital setting, 36% were employed in community pharmacies, 10% worked in public clinics and the
balance (12%) were employed in other settings.
Seventy-four (40%) respondents rated themselves as professionally satisfied, while 77 (41%) were dissatisfied and 36 (19%) provided
a neutral response. Public clinic pharmacists were the most satisfied (58% of group), while hospital pharmacists were the least satisfied
(30% of group).
Seventy-eight respondents offered suggestions to improve professional satisfaction. Of these, forty-five respondents (58%) cited
professional role and development opportunity needs, 36 respondents (46%) identified human resource issues and the remaining
responses related to medication distribution, regulation and other factors.
Conclusions: This study is the first survey of the pharmacists’ professional satisfaction in Qatar. When compared to the results from
similar surveys from the region and the USA, overall professional satisfaction in Qatar appears to be low. Further investigations to
fully explore this area and efforts to improve professional satisfaction are warranted in Qatar.
118
Poster Code F18
Author :
Prof. Adepu Ramesh, Ph.D., Department of Pharmacy Practice,
JSS College of Pharmacy, Mysore, India
Co-Author:
Siva Kartheek. M
Department of Pharmacy Practice, JSS College of Pharmacy, Mysore, India
Abstract: A study was conducted to assess the influence patient counseling on Lower Urinary Tract Symptoms (LUTS) improvement
and health related quality of life in patients with Benign Prostatic Hyperplasia (BPH) visiting Urology department of a South Indian
tertiary care teaching hospital. A validated Knowledge, Attitude and Practice questionnaire and disease specific ICS-QoL questionnaires
were used to assess the knowledge, attitude and practices and overall health related quality of life in the enrolled patients. Patients
meeting the enrollment criteria were randomized in to test and control groups. Test group patients received education regarding
BPH and its management including life style modifications, and control group patients continued with conventional therapy. KAP
questionnaire was applied at base line and final follow up, where as QoL questionnaire was applied from base line to final follow up
on all the enrolled patients. Result analysis shows a significant (P<0.05) improvement in KAP scores, bothersome symptoms scores
and over all QoL scores were observed in test group patients. The study concludes that counseling has shown a positive impact on the
treatment outcomes and overall health related QoL in BPH patients.
Title: Impact of Patient counseling on Health related Quality of Life in Benign Prostatic
Hyperplasia (BPH) patients – A Study
Poster Code F19
Author :
Dr. Mohammad Harb, College of Pharmacy, University of Sharjah, UAE
Title: Analysis of some heavy metals in some wild-grown Edible mushrooms
Abstract: Different mushroom species were colleted from different zones of Jordan to investigate the heavy metal content . The
metal content in soil substrate and the relation in between metal concentration in mushroom and soil were done. Mushroom species
and soil in which mushroom species were grown were collected from different zones of Jordan. Five different mushroom species and
their underlying soil (0-10 cm layer) samples were analyzed for some heavy metals (Cu,Pb,Fe,Zn,Mn,Ni, rand Co).The analysis was
performed using atomic absorption spectrometer.
The results indicates that in general ,heavy metal contents in all mushroom species were lower than the underlying soil substrates
except for some mushroom species.The results obtained from the analysis of mushroom and underlying soil sample were evaluated
using linear correlation analysis and concentration factors to identify the metal accumulation of mushroom.
Poster Code F20
Author :
Dr. Rana Ibrahim, Pharm. D, College of Pharmacy, University of Sharjah, UAE
Title: Changes in Pharmacy Education Sharpen Counseling Skills
Abstract: Pharmacy education and professional continuing education have undergone significant changes over the past decade in
order to prepare pharmacists to meet the challenges of modern pharmacy practice. Most recently, pharmacy education has begun to
reemphasize courses in patient counseling/communication, behavioral pharmacy, and practice management. Have newer courses
in the clinical and administrative sciences made a difference in the attitudes and practice behaviors of pharmacists. Do pharmacists
feel that these skills are necessary in their daily practice? Have colleges of pharmacy been successful in providing what they have
deemed as necessary skills for pharmacists? The primary purpose of this project is to a least begin answering these questions. We
used surveys all along the projects, and one of those surveys was designed to measure pharmacist’s perception of the role he/she plays
in the provision of medication information. Another survey measured skills in the pharmacy curriculum and their perceived need in
practice. This study will also focus on the curriculum used in the University of Sharjah and how it differs from other curriculums used
in other pharmacy colleges along the UAE.
D U P H A T 2009
www.duphat.ae
119
Poster Code F21
Author :
Dr. Haila Mohamed Alrakaf, Bachelor of Pharmacy, R.Ph., Neonatology Clinical Pharmacist,
Department of Pharmacy, King Fahad Medical City, Riyadh, Saudi Arabia
Co-Authors:
Dr. Hani Lababidi, MD, FCCP, Department of Pulmonary and Critical Care Medicine
King Fahad Medical City, Riyadh, Saudi Arabia
Title: Medications Errors with Drug Prescription and Administration through Feeding
Tubes in the Intensive Care Unit: A Direct Observation Study
Abstract: Background:Enteral feeding is the preferred method of providing nutritional support to ICU patients. There are variations
in the methods of administration of drugs through feeding tubes. Violations of proper drug administration through feeding tube can
result in various types of medication errors(ME).
Objectives:The aim is to determine types of ME that may occur with drug prescription and administration through feeding tubes in
ICU.
Materials and Methods:This is a prospective, direct observational, non-interventional survey conducted in a 16-bed adult medical/
surgical ICU .The data collection form consisted of a check list that identified all steps for drug prescription, dispensing, preparation and
administration via the feeding tube. One ICU pharmacist filled the form while directly observing nurses preparing and administering
drugs through feeding tube. The pharmacist also monitored other aspects that related to medication error. The observations were
carried out during various nurses’ shifts in the ICU. Medication errors were divided into four major groups: Prescribing errors,
Dispensing errors, Preparation errors, Administration errors.
Results:A total of 310 observations were made for 65 patients over a 6 months period. Average number of medications was 4.8 + 3.0
per patient. The total number of errors detected was 514, average = 7.9 + 5.2 per patient. ME occurred during prescription (10%),
dispensing (3%), preparation (32%) and administration (55%).
Conclusions:ME are common during preparation and administration of medications through feeding tubes. Efforts should be made
for proper education on proper preparation and administration of medications through feeding tubes.
Poster Code F22
Author :
Dr. Rabab Kamel, Department of Pharmaceutical Technology,
National Research Center, Cairo, Egypt
Co-Authors:
H. O. Ammar1, M. Ghorab2, S. A. El-Nahhas1
1
Department of Pharmaceutical Technology, National Research Center, Cairo, Egypt.
2
Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Cairo University, Cairo, Egypt
Title: Bioadhesive Monolithic Matrix Films for Transdermal Delivery of
Tramadol Hydrochloride
Abstract: Management of moderate or severe chronic pain conditions is the burden of clinicians dealing with patients trying to
improve their quality of life and diminish their suffering. Although not a new opioid, tramadol has been recently rediscovered and
widely used; this may be due to its favorable chronic safety and dependence profiles together with its high potency. Tramadol is a
centrally acting analgesic with half-life of ~6 h; therefore, it requires frequent dosing. It is freely soluble in water; hence, judicious
selection of retarding formulations is necessary. The current study is focused on the innovation of a novel, simple, monolayer, easy-touse, cost-effective, and aesthetically acceptable bioadhesive transdermal delivery system overcoming the defects of the conventional
“patch” as carrier system for tramadol, ensuring its adequate delivery, along with physicochemical and pharmacodynanic evaluation
of the designed formulations.
Monolithic tramadol matrix films of chitosan, different types of Eudragit®, and binary mixtures of both were prepared. As a singlepolymer film, chitosan film showed best properties except for somewhat high moisture uptake capacity, insufficient strength and
rapid release, and permeation. Polymer blends were monitored in order to optimize both properties and performance. Promising
results were obtained, with chitosan–Eudragit® NE30D (1:1) film showing the most desirable combined, sufficiently rapid as well as
prolonged antinociceptive effect along with satisfactory organoleptic, bioadhesive and physicochemical properties.
120
Poster Code F23
Author :
Prof. Nabeel Eisa Al-Saffar, MS, Ph.D., Assistant Professor, Director of Pharmacy Students Placements,
Department of Pharmacy Practice, Faculty of Pharmacy, Kuwait University, Kuwait
Co-Authors:
Salah Eid, Salah Alqattan, and Heba Metwalli
Faculty of Pharmacy, Kuwait University, Kuwait
Title: Polypharmacy among psychiatric outpatients in Kuwait
Materials and Methods: A prospective study was designed based on selection of the first 20 prescriptions for Kuwaiti patients treated
in the OPD over four weeks period (n=484). Data including age, sex, diagnosis and list of psychiatric medications were recorded and
analyzed.
Results: 40% of patients were treated for an initial diagnosis of mood disorders, 37.5% for schizophrenia, and 10% for neurotic
disorders. The mean number of psychotropic drugs used by the patients was 2.7 (SD± 1.3, range 1-7). 19.7% of the patients were under
monotherapy treatments, while 30.1%, 26.1%, and 24.1% received two, three and four or more drugs, respectively. Polypharmacy was
more prevalent in males, and in patients with schizophrenia, mood disorders and neurotic disorders. Prevalence was significantly
more in the age group 45-65 years and among patients more than 65 years old (p=0.009). Frequency of prescribing was 64.9%
for antipsychotics, 52.1% for antidepressants, and 45.6% for benzodiazepines. 20.7% of schizophrenics used combination of both
atypical and conventional antipsychotics. 7% of mood disorders patients used two antidepressants at the same time.
Abstract: Objective: To investigate the prevalence of polypharmacy with psychotropic medications among Kuwaiti patients attending
outpatient department (OPD) of the Psychological Medicine Hospital (PMH).
Conclusion: Polypharmacy is common among psychiatric OPD. Schizophrenia, mood, and neurotic disorders are associated with
an increase risk of polypharmacy. Conventional antipsychotics and tricyclic antidepressants are also prescribed with an increase
risk of polypharmacy. The introduction of educational programs and guidelines could be effective in decreasing the prevalence of
polypharmacy in psychiatric practice.
Poster Code F24
Author :
Prof. Dr. Annie Shirwaikar, M.Pharm., Ph.D., Department of Pharmacognosy,
Manipal College of Pharmaceutical Sciences, Manipal University, Manipal, Karnataka, India
Title: Effect of Alcoholic Root Extract of Pseudarthria Viscida in Neonatal
Streptozotocin-Induced type Ii Diabetic Rats
Abstract: Pseudarthria viscida (L.) Wight and Arnott (Leguminosae), commonly known as Salaparni in Sanskrit is an essential
component of many famous Ayurvedic formulations like Dashamoola, Mahanarayana taila and Dhantara taila (Deepa et al. 2004). In
addition to several other uses, the roots of this plant have been reported for its use in the treatment of diabetes (Warrier et al. 1995).
Humaira Yousuf Shawl et al. (2004) report the use of Pseudarthria visicda (PV) by the tribals of Madhya Pradesh for the treatment
of diabetes. Hence our study is an attempt to document and scientifically authenticate these traditional claims. The antidiabetic
effect of the alcoholic root extract of Pseudarthria viscida (Leguminosae) was investigated in normal and neonatal streptozotocin
(n2-STZ)-induced non insulin-dependent diabetes mellitus rats and compared with glibenclamide as a reference standard. Graded
doses (250 and 500 mg/kg) of the extract suspended in gum acacia were administered to normal and experimental diabetic rats for
21 days. Fasting blood glucose levels, serum lipid profiles and changes in body weight were evaluated in normal rats while serum
insulin, glycated hemoglobin, urea, creatinine, magnesium, protein, albumin and glycogen levels in kidney and liver were evaluated
additionally in diabetic rats. Treatment with extract at both dose levels was found to be dose dependant, with the higher dose showing
more significant activity. Studies are in progress to elucidate the molecular and cellular mechanism of the extract. Longer duration
studies of Pseudarthria viscida on chronic models may contribute toward the development of a potent antidiabetic drug.
D U P H A T 2009
www.duphat.ae
121
Poster Code F25
Author :
Dr. Heyam Saad Ali, Associate Professor in Pharmaceutics, Dubai Pharmacy College, Dubai, UAE
Co-Author:
Prof. Dr. Yosif Kordofani, Khartoum Teaching Dermatology Skin Hospital, Sudan
Title: New Formulation of Bergamot oil in the treatment of Vitiligo
Abstract: Around 1% of the world’s population has Vitiligo which causes a patchy loss of skin color. The methods currently available
to treat Vitiligo are largely unsatisfactory and vary widely between cultures and within health systems. Potent topical steroids used
along with psoralens ultraviolet or sun exposure are the most effective forms of therapy for localized Vitiligo.
This study was done to evaluate the efficacy of Bergamot oil lotion compared to psoralen lotion using different vehicles along with
sun exposure.
Twenty patients (13 females and 7 males in the age group of 10-55) years, with essentially bilateral and symmetrical lesions were
enrolled in the study. A randomized right/left comparative study of three month ‘duration; all of the subjects had localized Vitiligo,
affecting less than 21% of the body surface area.
For therapy we used topical Bergamot 1% oil and 1% methoxsalen. Both have been formulated in two bases, one base of dilute ethanol
(70-90%) and the other is a lipid free lotion. Seven patients (35%) reported irritation, redness, bullas eruption and itching on alcohol
vehicle base after three weeks, whereas there were no symptoms reported on the lipid free lotion till the end of three study period.
Conclusion: Selection of the vehicle play a great role in improving skin condition .Bergamot oil and methoxsalen in lipid free lotion
was well accepted and no complaint been reported. It has been suggested that ethanol base should be avoided.
Poster Code F26
Author:
Dr. Naglaa G. Shehab, Faculty of Pharmacy, Cairo University, Egypt
Co-Author:
Dr. Essam Abdel-Sattar, Department of Natural Products and Alternative Medicine,
Faculty of Pharmacy, King Abdulaziz University, Jeddah, Saudi Arabia
Title: Antitrypanosomal Activity of Some Pregnane Glycosides Isolated from
Caralluma Species
Abstract: Pregnane glycosides previously isolated from genus Caralluma (C. Penicillata, C. tuberculata and C. russelliana) were tested
for their antitrypanosomal activity. The tested compounds were checked for their purity by TLC and 1H-NMR and by comparison
with data in literarure. Penicilloside E showed the highest antitrypanosomal activity (IC50 1.01 mg/mL) followed by caratuberside
C (IC50 1.85 mg/mL), which exhibited the highest selectivity index (SI 12.04). It was noticed that acylation is required for the
antitrypanosomal activity while glycosylation at C-20 has no significant effect on the activity.
122
Poster Code F27
Author :
MSc Resztak Matylda
Department of Physical Pharmacy and Pharmacokinetics,
K. Marcinkowski University of Medical Sciences, Poznan, Poland
Co-Authors:
Hermann Tadeusz Wladyslaw & Danielak Dorota
Department of Physical Pharmacy & Pharmacokinetics,
K. Marcinkowsi University of Medical Sciences, Poznan, Poland
Abstract: The objective of the current study was to examine and compare pharmacokinetic and pharmacodynamic parameters
of gliclazide immediate (IR) and modified (MR) release tablets administrated orally. The experiment included rats with both
normoglycemia and streptozotocine-induced hyperglycemia. Blood samples were collected at 1, 2, 4, 6 and 8h for the immediaterelease tablets and at 2, 4, 6, 8 and 12h for the modified release tablets. The RP-HPLC method with UV detection was developed
and validated for quantitative determination of gliclazide in plasma. The pharmacokinetic parameters after administration of the
immediate release tablets: Cmax(mg/l), tmax(h), AUC(mg·h/l) were as it follows: 31.49, 0.58, 155.57 and 38.84, 1.14, 243.90 in the
healthy and STZ-diabetic animals, respectively. The IR tablets required less time to reach Cmax for both groups as compared with MR
formulations. Bioavailability of modified release tablets was 6-fold lower in comparison with conventional tablets. However, mean
residence time of MR tablets was approximately 2 hours longer in contrast to the IR formulations.
Title: Pharmacokinetics and pharmacodynamics of gliclazide from immediate and
modified release formulation tablets in rats
Pharmacodynamic activity of the drug was expressed by the difference in increase of glucose concentration at each time between
groups with and without gliclazide administration. Reduction of blood glucose level was higher in immediate release group. The
maximum pharmacodynamic efficacy of gliclazide in the healthy animals group after administration of the IR tablets (47% decrease
of glucose level in comparison with initial value) was observed.
Poster Code F28
Author :
Dr. Ahlam A. Khayrollah, Ph.D.
Head of Pharmaceutical Sciences Department, College of Pharmacy, University of Mosul, Iraq
Co-Author:
1
Moyaser M. Ali & Fatima A. Tawfiq2
Pharmaceutical Sciences Department, College of Pharmacy, University of Mosul, Iraq
2
Pharmaceutics Department, Colleage of Pharmacy, University of Baghdad, Iraq
1
Title: Design and Formulation of Candesartan Cilexetil Tablet
Abstract: Candesartan cilexetil is a potent and long acting angiotensin II (AT1) receptor antagonist. It appears to provide the most
effective and well tolerated alternative up to date among other established antihypertensive agents.
In this study many trials were made to formulate candesartan cilexetil as plain tablets, with properties comparable to those of reference
tablets.
Different formulas have been designed and prepared with several additives using wet granulation method. The characteristics of
the prepared formulas were tested and the results showed that, lactose is the best diluent with which the produced tablets have
good physical properties and an acceptable dissolution time. Among different types and concentration of binders used, PVP 5%
is considered the best and the produced tablets have rapid disintegration and dissolution time. When 2% of starch was used as
disintegrant, the produced tablets posses comparable disintegration & dissolution times with those of the reference tablets. The
most widely used lubricant, magnesium stearate was chosen as a lubricant in the selected formula. From the overall results it can be
concluded that the selected formula of candesartan cilexetil can be considered as a promising formula for mass production of the drug
as tablets, equivalent to the similar reference preparation.
D U P H A T 2009
www.duphat.ae
123
Poster Code F29
Author :
Dr. Nada A. Al-Agil, R.Ph., SSC-PhP,
Drug Information Pharmacist, King Fahad Medical City, Riyadh, Saudi Arabia
Co-Authors:
Tabbara O, R.Ph., BCNSP1, Habib A, R.Ph.1, Lababidi H, MD, FCCP2
Departments of 1 Pharmacy, and 2 Critical Care Medicine, King Fahad Medical City, Riyadh, Saudi Arabia
Multi- disciplinary performance improvement project
Title: Nursing Practices and Perceptions for Drug Administration with Enteral Tube Feeding
Abstract: Background: The correct administration of oral drugs to patients on enteral tube feeding presents a special challenge.
Nursing practices for drug administration with enteral feeding may contribute to treatment failure.
Objectives: The objective of this study is to assess current nursing practices and perceptions on drug administration through tube
feeding.
Methods: A questionnaire was distributed to nurses working at King Fahad Medical City (KFMC). The 25-item survey asked questions
about the type of medications that can be delivered via feeding tube and the procedure to administer these drugs. Nurses were
randomly selected from different units: ICU, CCU, NICU, PICU, pediatrics, stroke unit and general medical floors. Results were analyzed
using SPSS program, a p-value <0.05 was considered as statistically significant.
Results: Out of 245 questionnaires distributed to KFMC nurses, 194 replied with 80% response rate. Around 98% of surveyed nurses
administer drugs through tube feeding; 87% do this more than 3 times per week. About 59% believed that Long Acting (LA) and Slow
Release (SR) preparations can be crushed. Only 60% of nurses stop tube feeding when medication time is due.
There were no significant differences in the practices of nurses working in critical care areas versus regular floors. However, the
following were noted between nurses taking care of adult and pediatric patients: nurses for adult patients have less rate of crushing
LA or SR tablets (32% vs. 61%, p<0.0005), tend to stop feeding more at medication time (70% vs. 39%, p<0.0005), flush tube before
administering drugs (85% vs. 67%, p=0.001), and dilute liquid medications prior to administration (76% vs. 46%, p<0.0005). Pediatric
nurses consult pharmacists more about availability of liquid preparation (40% vs. 24%, p=0.028), give one drug after another in case
of multiple drug administration (87% vs. 41%, p<0.0005), and flush the tube between medications (51% vs. 30%, p=0.007).
Conclusion: The findings of this survey highlight major misconceptions and errors in drug administration through tube feeding among
nursing staff. It supports the need to establish related policies and training programs.
Poster Code F30
Author :
Dr. Yasir A. Ibrahim, BSc, MSc, PharmD, BCPS (AQ Infectious Diseases)
Critical Care Clinical Pharmacy Specialist Tawam Hospital in Affiliation with Johns Hopkins Medicine &
Adjunct Assistant Professor, Faculty of Medicine and Health Sciences, UAE Univsersity, Al-Ain, UAE
Title: Rosiglitazone Medication Utilization Evaluation in Tawam Hospital
Abstract: Introduction: This is an MUE of Rosiglitazone which is an oral hypoglycemic agent of the glitazone family.
Method and results: A 2 week period starting from 25th of June to 6th of July 2005, out patients files were randomly chosen. A total
of 80 files were randomly reviewed. From the 80 files selected only 44 files we were able to extract some useful information that we
used in this MUE.
72% of patients were on triple therapy 16% were on insulin plus rosiglitazone. 85% of the patients started on the recommended
starting dos. The dose of metformin was within the recommended dosing scheme. There was an improvement in the Hb1AC but on
the other hand there is an increase in weight in the majority of the patients. Liver function monitoring test was suboptimal where
80% did not get any type of monitoring in general. However those did a follow up did not show any differences in LFT compared with
baseline. Body weights were available but no heights were recorded and only 2 patients have a height recorded in their files.
Recommendations: A recommendations were made and discussed at the PTC and approved prior the late FDA warning. With a general
recommendation including starting dose, use in combination with other oral hypoglycemic agents or insulin in addition to better
monitoring guidelines to be in place and followed.
124
Poster Code F31
Author :
Dr. Amina Mahdy, Ph.D., Department of Pharmacology & Toxicology,
College of Pharmacy, Cairo University (Assistant Professor of Pharmacology & Therapeutics,
Dubai Pharmacy College, Dubai, UAE)
Co-Authors:
Dr. Hebatallah A. Darwish, Department of Biochemistry, College of Pharmacy, Cairo University
Abstract: Background: Methotrexate (MTX), a folic acid antagonist, is widely used as chemotherapeutic agent for malignancies as
well as in the treatment of various inflammatory diseases. The efficacy of this agent is often limited by severe side effects and toxic
conditions. Regarding the mechanism of these side effects, several hypotheses have been put forward, among which oxidative stress is
noticeable. Aims & Objectives: The present study aimed to determine whether α-lipoic acid (LA) or quercetin (QE), potent free radical
scavengers, could ameliorate MTX-induced oxidative liver injury and modulate immune response. The study also aimed to investigate
the possible role of nitric oxide (NO) and tumor necrosis factor-alpha (TNF-α) in the pathogenesis of MTX-induced hepatoxicity.
Study design/Methods: Rats were randomly divided into four experimental groups beside a normal control group consisting each of 8
animals. Following a single injection of MTX (20 mg/kg; i.p), experimental groups were allowed to receive either LA (50 mg/kg/day;
orally), QE (10 mg/kg/day; i.p in dimethylsulphoxide (DMSO)) or the vehicle DMSO alone. Treatment was carried out for 5 consecutive
days. Blood serum was separated and used for the determination of TNF-α level as well as aspartate aminotransferase (AST) and
alanine aminotransferase (ALT) activities to assess the hepatic function. Liver tissue samples were collected for the estimation of
tissue malondialdehyde (MDA), reduced glutathione (GSH) and NO levels, myeloperoxidase (MPO), superoxide dismutase (SOD)
and catalase (CAT) activities as well as for histological examination. Results obtained were statistically analysed by one way analysis
of variance (ANOVA) followed by Tukey-Kramer multiple comparison test. Significance was considered at p<0.05. Findings: MTX
caused a significant reduction in hepatic GSH level, SOD and CAT activities while MDA and MPO activities were significantly
increased. Hepatic NO as well as serum TNF-α levels were markedly elevated following MTX treatment. Only ALT rather than AST
activity was significantly increased. These changes were significantly reversed by either LA or QE treatment. Similarly, histological
analysis revealed that both treatments were effective in attenuating tissue damage. However, the effect of LA was more pronounced.
Conclusion: The study indicates that oxidative stress, NO as well as TNF-α may play an important role in the pathogenesis of MTXinduced hepatoxicity. LA and QE have protective aspects in this process through their antioxidant and anti-inflammatory effects.
Title: Alpha-lipoic acid and quercetin protect against methotrexate induced-hepatotoxicity
in rats
Key words: methotrexate, α–Lipoic acid, quercetin, nitric oxide, TNF- α, oxidative stress.
D U P H A T 2009
www.duphat.ae
125
Poster Code F32
Author :
Dr. Sumia Sir-Elkhatim Mohamed, B. Pharm, M. Pharm, Ph.D., Associate Professor of Pharmaceutics,
Department of Pharmaceutics, Faculty of Pharmacy, University of Khartoum, Sudan
Title: The University of Khartoum and implementation of patient-centered pharmacy
practice
Abstract: Background: Clinical pharmacy has become part of the mainstream of the pharmacist's contribution to patient care
(pharmaceutical care, PC). There is now widespread recognition of this development not only within the Health Service but also by
professional bodies and by Schools of Pharmacy. Sudan has 12 Faculties of Pharmacy, with 1500 graduates each year, and the number
is rising. The new role of pharmacists, which is different from that of traditional dispensing, is not yet implemented in Sudan.
Objectives: a) to provide data on current situation of pharmacy teaching and practice in Sudan. b) to identify the role of the Faculty of
Pharmacy towards the transition from product-oriented to patient-centered teaching and practice.
Methods: A descriptive study using Face to Face interviews, Records, Steering Committees and experts' views and opinions was
carried out. A full description of the knowledge gained from courses currently taught at undergraduate level and its relation to PC
practice and the efforts exerted toward this is given. The role of regulatory authorities and Leadership was visualized.
Results: the total number of hours in the pharmacy degree curriculum (4 years) is 3960; 1680 hours theory (42.4%) and 2280 hours
practical (57.6%). None of these accommodate the paradigm of PCP. The teaching and practical training are product-focused. The
Faculty of Pharmacy attempted to provide an educational program that will appropriately address contemporary and foreseeable
future changes in the practice by starting academic revision of undergraduate curriculum. It has been envisaged that undergraduate
patient-focused teaching involves the availability of qualified clinical pharmacists for the supervision and follow-up of the clinical
activities as part of the curriculum. The country lacks such human resources. Therefore, we thought of training and qualifying clinical
pharmacy postgraduates first then implement patient-centred curriculum at undergraduate level. Accordingly, Master degree in clinical
pharmacy by courses was establishment (2004) in collaboration with the University of Bath, UK. Four Batches (135 students) were
accepted and now 67 graduates were made available from the first two Batches. Rrefurbishment of the Pharmacy at Soba University
Hospital, to pave the way for implementation of clinical teaching and training and to introduce clinical pharmacy services at hospital
setting and in-service training, was initiated. Master and PhD degrees by research, investigating implementation of PCP, are currently
in progress. The appropriate authorities at the MOH and other professional bodies agreed to initiate changes in pharmacists’ carrier
path to include PCP. Collaboration with the CPD center to increase the awareness, educate and train pharmacists and other health
care providers about PCP was also started.
Conclusion: Clinical Pharmacy is now part of what pharmacists do on a daily basis. The challenge is to develop it in response to need
and gather evidence to show clinical pharmacy improves patient care. This involves many dimensions and collaboration of different
parties. Partnership links are important with other Universities to support and share learning and development. Clinical pharmacy
research is important. Each country is unique; Sudan can learn from Sudanese experience of clinical pharmacy and share it with the
academic community for proper implementation PCP.
Keywords: Clinical Pharmacy, Pharmaceutical care practice, Sudan
126
STUDENT POSTERS
D U P H A T 2009
www.duphat.ae
127
Poster Code S01
Institution:
College of Pharmacy, University of Sharjah
Authors :
1. Eman Abu-Alhanna
2. Aisha Isaak
Supervised by:
Dr. Suleiman Sharif
Student Posters
Title: A Source of Variation in Measurement of Oral Medications
Abstract: Oral medications in the form of solutions or syrups are the most convenient for children and elderly patients or those
can not easily swallow tablets or capsules. Instructions are usually given to administer a teaspoon or a tablespoon measuring 5 and
15 ml respectively. Investigations into the volumes of teaspoons and tablespoons available at home demonstrated wide variations
in the actual volumes of such spoons. Such differences may account for variations in administered doses and may contribute to
mistreatment of disease and the precipitation of adverse effects of orally administered solutions particularly in children and elderly
patients with compromised hepatic and renal functions.
Poster Code S02
Institution:
Authors :
1. Eman M. Ali
2. Mohammed S. Al-Rijjal
3. Nawar Atif
Supervised by:
Dr. Suleiman Sharif
Title: Accuracy and Reliability of Information in Medical Leaflets
Abstract: Information on a drug given in the leaflets insert in drug package must be clear, accurate and complete. These include
mechanism of action, clinical indications, adverse effects, cautions and contraindications. However, it is not uncommon practice to
include vague, misleading or non- evidence-based information in medication leaflets. The latter sometimes intentionally ignore the
mentioning of serious adverse effects. Moreover, claims of the drug being the only available treatment of a certain disease are also
common.
In the present study, we investigated the accuracy of information given in leaflets of some medications marketed in UAE.
Poster Code S03
Institution:
Authors :
1. Nawaf S. Al-Mansoori
2. Omar Sahir
3. Samer Al-Abed
Supervised by:
Dr. Suleiman Sharif
Title: Influence of pictures, Wordings and Colour of Pharmaceutical Advertisements on
Choice of Medication
Abstract: Colourful pictorial pharmaceutical advertisements were collected from various medical journals. At least three advertisements
for each drug or therapeutic class of drugs were used in this investigation. A questionnaire was distributed to pharmacy students
and the advertisements covering each therapeutic class were displayed in their original A4 size. Students were asked to select The
most preferred drug and answer the survey questions pertinent to the advertised drug selected and the picture, colour and wording
included in the advertisement. Results of this study will be presented and discussed in detail.
128
Poster Code S04
Institution:
Authors :
1. Manal Al Sharawi
2. Saleh Edelbi
Supervised by:
Dr. Suleiman Sharif
Title: Unnoticed Daily Exposure to Lead
The present study was undertaken to qualitatively investigate the presence of Pb in children toys, jewellery and other products kept
and used at home. Detailed results will be presented at the meeting and we hope to increase awareness of the public to the hazardous
effects of Pb probably through demonstrating its presence in products to which our society is daily exposed to its Pb contents.
Student Posters
Abstract: Lead (Pb) which has no biological function is a well known cause of detrimental effect on cognition. It is a major cause of
both mental and physical retardation in children. In recent years Pb toxicity became rare in most countries with strict regulations on
inclusion of lead in many products. However, Pb may invade our homes through seemingly innocent children toys, cheap jewellery
stained glass or contaminated food.
Poster Code S05
Institution:
Authors :
1. Firas Ahmed
2. Rami Barakeh
3. Samah Abu Shahla
Supervised by:
Dr. Raafat El-Awady
Title: Pharmacists from drug compounding to pharmacogenomics
Abstract: Since the evolution of pharmacy as a separate health discipline, the role of pharmacists in the healthcare process changed
greatly overtime. During the early evolution of pharmacy, the role of pharmacists was mainly to compound drugs by mixing calculated
amounts of the components of that drugs in the laboratory of their pharmacies. This era was followed by another stage during
which large pharmaceutical companies were established which start supplying pharmacies with ready-made drugs. This achievement
restricted the role of the pharmacist to only selling drugs in his pharmacy. By time healthcare professional realized the presence of a
gap in the healthcare process due to absence of the role of the pharmacist and this gap was manifested as increased mortality rate after
treatment of specific diseases due to either incorrect drug dosing, drug-drug interactions, drug-disease interaction or unexpected
adverse drug reactions and it was realized that pharmacists are those health professionals that are most qualified to understand these
things. Consequently, a new era for the role of the pharmacist in the healthcare process began by establishing the Pharm. D degree
which enables pharmacists today to play a much different role in healthcare than they did just a few decades ago. Today, pharmacists
focus on improving the quality and safety of medication use, and they serve as integral members of the patient care team. With
the development of pharmacogenomics as a pharmacology discipline that aims at individualization of drug therapy, it seems that
pharmacists will play a very important role in the healthcare process in the near future.
D U P H A T 2009
www.duphat.ae
129
Poster Code S06
Institution:
Authors :
1. Dina M.G. El-Khazendar
2. Hiba M. Tohaibsh
Supervised by:
Dr. Suleiman Sharif
Student Posters
Title: Prescribing Trends in Community Pharmacies
Abstract: Analysis of prescriptions was carried out to determine the patterns of drug prescribing in community pharmacies in UAE.
Prescriptions were collected from a pharmacy in Dubai covering a period of 30 days. The total number of drugs prescribed, the mean
number of drugs per encounter and % generic drugs prescribed were determined Information regarding both the prescriber and
patient were also determined. We have also analysed the collected prescriptions for the most commonly prescribed therapeutic classes
and the most frequently prescribed drug of each class. Results of the present study indicate areas of improvement in prescription
writing.
Poster Code S07
Institution:
Authors :
1. Lubna Z. Nofel
2. Daliah Al-Ojjeh
Supervised by:
Dr. Suleiman Sharif
Title: General Aspects of Artificial Sweeteners
Abstract: High sugar in our diet may contribute to obesity, dental problems and other consequent health complications such as
type-2 diabetes, hypertension, hypertriglyceridaemia and vitamin and mineral deficiencies. Two distinct tongue receptors T1R2 and
T1R3 are claimed to respond to sugar and contribute to taste. Non-caloric sweeteners that taste like natural sugar have been produced,
marketed and widely used by the public not only by diabetics but also by healthy individuals on diet, exercising or trying to reduce
or maintain their body weight. However, concerns persist about the safety of sweeteners and the pharmacist can play a major role
in providing vital information to artificial-sweeteners users. This presentation reviews general aspects of the most widely and wildly
used artificial sweeteners.
Poster Code S08
Institution:
Authors :
1. Lama Abdul Moti
2. Sara Mosaad
3. Shaymaa Al Aqad
Supervised by:
Dr. Raafat El-Awady
Title: Consulting a pharmacist: Do you trust him?
Abstract: Due to time shortage, high cost of physicians visits or inability to know which physician they should visit, many people
prefer to go and consult the pharmacist at first. They either ask him to prescribe some OTC drugs or consult him about the medical
specialty that is suitable for their complains. The aim of this study is to investigate whether the public are really trusting the pharmacists
as their first medical consultants and whether pharmacists are really qualified to play this role.
130
Poster Code S09
Institution:
Dubai Pharmacy College
Authors :
1. Eman Khalil,
2. Ashwaq Omar
3. Fatema Alawadi
Supervised by:
Prof. Dr. Karamat A. Javaid
Title: Controlled Drugs and their Dispensing in UAE
The aim of the presentation is to know about these drugs, briefly their actions, chemical and pharmacological groups, prescription
requirements, storage, dispensing and forensic requirements as they are dispensed in the UAE.
Poster Code S10
Institution:
Authors :
1. Ambreen Mallick
2. Sanaa’ Yahia
Supervised by:
Prof. Dr. Karamat A. Javaid
Student Posters
Abstract: Many controlled drugs form a part of the Pharmacy Practice in any society. These drugs because of their great potential for
abuse, misuse and toxicity present a great risk for people. Because of these hazards, the health-regulating authority of a country must
control their procurement, storage, distribution, prescription and dispensing.
Title: Survey and Prevalence of use of a Comination Drug of Ezetimibe and Simuastatin as
Antilipemic Drug
Abstract: Diet and exercise are important parts of lowering cholesterol. In addition to the cholesterol that comes from food we eat,
cholesterol is also produced in our body based on the family history. If it is difficult to lower the cholesterol in spite of dieting and
exercising, it is recommended to use a combination of two drugs; one will reduce the absorption of the dietary cholesterol and the
other will interfere with the production of intrinsic cholesterol.
Ezetimibe reduces blood cholesterol by inhibiting the absorption of cholesterol by the small intestine by acting at the brush border
of the small intestine. Thus it inhibits the absorption of cholesterol, leading to a decrease in the delivery of intestinal cholesterol to
the liver. Simvastatin is an HMG-Co A reductase inhibitor. It works by blocking the enzyme that is necessary for the body to make
cholesterol.
The purpose of the poster presentation is to see the frequency of prescription of the combined drug in comparison to the use of
individual drugs, Ezetimib and Simvastatin. It will also review the clinical effectiveness of the combination for its total cholesterol
reduction effect. The prescription frequency will be reviewed both at hospital pharmacy and at community pharmacy settings.
D U P H A T 2009
www.duphat.ae
131
Poster Code S11
Institution:
Authors :
1. Reem Mazin,
2. Rana Ahmed
3. Zin M.Gassan
Supervised by:
Dr. Heyam Saad Ali
Title: Food Group Allergies and Hypersensitivities based on Blood Types in UAE
Abstract: Purpose: To determine patterns in adverse food reactions based on blood types among people in the UAE.
Student Posters
Design: Blood types A1, A2, B, AB, O and Rh-negative were correlated to four kinds of food allergies and hypersensitivities.
Materials and Methods: Three studies were conducted from 2007-2008.Blood types were correlated to food scores (food hypersensitivity
tests, and T-cell food hypersensitivity tests. An allergy history was recorded. Data were evaluated by statistical analyses.
Results: Results were reported by blood types and food groups as raw scores and classes, and included the following: blood type A1
reacted most strongly to nuts and beans, etc. while type A2 to dairy, eggs and gluten grains. Type B to eggs, nuts and beans, dairy etc.
Type O to dairy, eggs etc. Type AB to nuts and beans etc., and dairy; while A2B also reacted to gluten grains.
Type Rh-negative was most reactive to eggs, dairy etc,. The highest IgE scores were among types B and Rh-negative. The highest IgG
scores were among types O, A2 and Rh-negative. The most lectins reacted with type AB.
Conclusion: The research showed patterns in food group allergies and hypersensitivities based on ABO, A1/A2 and Rh blood types.
Poster Code S12
Institution:
Authors:
1. Mai Jamal,
2. Eman Hany,
3. Aisha Juma
Supervised by:
Dr. Heyam Saad Ali
Title: A Study on the Incidence of Medication Errors in Dubai
Abstract: To err is Human: Building a Safer Health System is mandatory. Medication errors can cost much money, account for deaths
and injuries. The medical path involves many different steps from, diagnosis and prescription through to when it reaches a patient and
there is a risk of error at any point in the process.
Study was conducted in Dubai hospital checking the medical pathway. The files of out-patients and in-patients in Department of
Health, Dubai were reviewed for the incidence of medication errors. Number of in-patient files and number of medication errors
found in those files will be studied. Number of out-patient prescriptions and number of medication errors found in those prescriptions
found in those files will be studied.
Common Causes of Medication Errors: incorrect communication, Look-alike and/or sound-alike drug names, use of abbreviations,
misinterpretation of handwritten prescriptions, verbal misinterpretation, decimal points errors, and other causes. Results of policy
errors found in prescriptions depend on checking the rules in prescriptions as writing the generic name, route, strength, duration,
frequency, dosage form and dose for drugs prescribed in prescription. Common causes, types of medication errors will be evaluated
in percentage. Medicines involved most commonly with Lethal Errors, people at risk of medication errors and high alert medications
will be identified.
132
Poster Code S13
Institution:
Achieved by:
1. Duaa Hussien
2. Bayan Dakhil
3. Elaf Mothafar
Under supervision of: Dr. Amina Mahdy
Abstract: In the blood stream are the red blood cells, which are made of a molecule, haemoglobin. Glucose sticks to the haemoglobin
to make a 'glycosylated haemoglobin' molecule, called haemoglobin A1C or HbA1C. The more glucose in the blood, the more HbA1C
will be present in the blood. Since red blood cells live for 8 -12 weeks before they are replaced, so by measuring the HbA1C a figure
for how high the blood glucose has been on average over the last 8-12 weeks can be obtained. HbA1C is thus used in monitoring
glycaemic control in diabetic patients.
Aim: Many factors including weight, age, lipid profile, …etc., are theoretically proposed to affect the value of HbA1c. Therefore, the aim
of the present research is to study the influence of factors that may affect HbA1c values in order to confirm or neglect the accordance
between such factors and the tight glycemic control. The collection of data will be carried out from several governmental hospitals in
United Arab Emirates.
Student Posters
Title: Glycosylated Hemoglobin In Diabetics Influencing Factors
Poster Code S14
Institution:
Done by:
1. Maryam Hassan AlMashgari
2. Shahad Abdulrhman AlNeaimi
3. Safaa Saleh
Under supervision of:
Dr. Amina Mahdy
Title: Preeminence Of Hope For Vitiligo Patients
Abstract: Introduction: Vitiligo is an acquired depigmentary disorder of the skin that results from the selective destruction of
melanocytes. The etiology of vitiligo is poorly understood. There appears to be a genetic predisposition, but additional factors are
probably involved. Many factors contribute to the incidence of this disease. These include trauma such as radiotherapy, sun exposure ,
psychological factors & endocrine disorders. We hope future research will shed more light on the subject and identify the precipitating
factors, since in the majority of vitiligo cases the contributing factors are as yet poorly identified.
Aim: The Objectives of this study are:
To put hand on the epidemiology of this disease in UAE.
To outline the factors that might play a role in its development.
To elucidate the recent research studies concerning new drugs to treat symptoms of the disease.
Methodology: Collection of information from hospitals and questionnaires from patients to know the percentage of this genetic
disease in the UAE as well as the possible new treatments available.
D U P H A T 2009
www.duphat.ae
133
Poster Code S15
Institution:
Authors :
1. Ann Khalid
Supervised by:
Dr. Doaa & Dr. Heyam
Student Posters
Title: Effect of Anticonvulsant Drugs on Life Span
Abstract: Aging is characterized by widespread degenerative changes in tissue morphology and function and an increase in the
incidence of human diseases such as cancer, stroke, and Alzheimer disease. Findings from recent genetic studies suggest that
molecular mechanisms that influence life span are evolutionarily conserved, and interventions that extend the life span of model
organisms such as worms and flies are likely to have similar effects on vertebrates such as humans. However, little progress has been
made in identifying drugs that delay aging. We identified 3 pharmacologic compounds, ethosuximide, trimethadione, and 3,3-diethyl2-pyrrolidinone, that extend lifespan and delay age-related degenerative changes in the nematode worm Caenorhabditis elegans. All
3 mentioned compounds are anticonvulsants are used to treat absence seizures in humans. We discuss existing evidence that these
drugs might also delay vertebrate aging and suggest experiments that could test this hypothesis. Genetic and cell ablation studies
conducted with model organisms have demonstrated connections between the nervous system and aging.
Results: Our findings suggest that the lifespan extending activity of these compounds is related to the anticonvulsant activity,
implicating neural activity in the regulation of aging.
Conclusion: Our studies provide additional support for the hypothesis that neural activity plays a role in lifespan determination,
since ethosuximide and trimethadione regulated neuromuscular activity in nematodes, that extend lifespan and delay age-related
degenerative changes in the nematode worm Caenorhabditis elegans.
Poster Code S16
Institution:
Authors :
1. Dalia A. Rahim ;
2. Hanan S. Alhabsi;
3. Rima A. Charara
Supervised by:
Dr.Saeed Ahmed Khan & Dr.Naglaa G. Shehab
Title: Antimicrobial and Antioxidant Activitites of the Essential Oil Isolated from Flowers of
Calotropis Procera
Abstract: The essential oil which obtained from hydro-distillation of fresh flowers of Calotropis procera, Family Asclepiadaceae,
collected from Jabal Ali, United Arab Emirates, was analyzed by GC/MS. The sample contained different oxygenated compounds and
hydrocarbons. The isolated oil was tested for its antimicrobial and antioxidant activities. Effect of the oil sample was compared to
those with suitable stander antibiotics as broad spectrum antibiotics. Evaluation of the antimicrobial activity was based on measuring
the diameters of the observed zones of the inhibition in mm. and the relative potency.
Poster Code S17
Institution:
Authors :
1. Durria H. Elremaly
2. Eiman A. Alali
Supervised by:
Dr. Naglaa G. Shehab
Title: Antimicrobial and Antioxidant Activities of Some Plants Cultivated in the UAE
Abstract: The alcohol extracts which obtained from cold maceration of different plant samples (fresh and dry) collected from different
area of the United Arab Emirates (Henna, Ginger, Thyme, Foenugreek and Mentha) were evaporated and tested for their antimicrobial
and antioxidant activities. Evaluation of the antimicrobial activity was based on measuring the diameters of the observed zones of
the inhibition in mm. and the relative potency to stander antibiotics.
134
Poster Code S18
Institution:
Authors :
1. Alaa Omer Hamouda
2. Marwa Al-Araky
3. Sally Sameer
Supervised By:
Dr. Ghazala Khan
Abstract: Nanotechnology is a broad term covering the building of structures and machines on an atomic or molecular scale in
the range from 1-100 nanometers. Cancer nanotherapeutics are rapidly progressing and are being implement to solve several
limitations of conventional drug delivery systems such as nonspecific biodistribution and targeting, lack of water solubility, poor
oral bioavailability and low therapeutic indices. Nanoparticles are particles that deliver chemotherapy drugs directly to cancer cell to
minimize damage to healthy cells. To improve the biodistribution of cancer drugs, nanoparticles have been designed for optimal size
and surface characteristics to increase their circulation time in the bloodstream. They are also able to carry their loaded active drugs to
cancer cells by selectively using the unique pathophysiology of tumors such as their enhanced permeability and retention effect and
the tumor microenvironment.
The aim of this study is to evaluate the use of nanotechnology in patients undergoing cancer therapy in the UAE.
Student Posters
Title: Nanoparticles-- The Bucky Balls
There is no doubt that nanotechnology will open the way for a new generation of cancer treatment that are more effective and less
damaging than those currently available such as the standard radiation and drug therapies(chemotherapy).
Poster Code S19
Institution:
Authors :
1. Mai Safouh Wardeh
2. Day Thaer Jumeal Al Rubayee
3. Marwa Abdullatif Al Naief
Supervised by:
Dr. Gazala Khan
Title: Prevalence of Cancer and AIDS in the UAE
Abstract: Our aim of this study is to evaluate the prevalence of cancer and AIDS in the UAE during the past 5 years.
Cancer is a class of diseases in which a group of cells display uncontrolled growth, invasion & sometime metastasis.
Cancer is the third leading cause of death in the UAE after cardiovascular diseases and accidents . Data from the UAE Ministry of
Health indicate that cancer accounts for approximately 500 deaths per year. It is a disease no one can afford to have. Currently,
millions of Dirhams are being spent to treat advanced cancer cases in the UAE. To our knowledge, the first international scientific
account of cancer in the UAE dates back to year 1981 when Bate and colleagues (1981) described five cases of primary hepatoma
among 209 patients with liver diseases who attended Al-Qassimi Hospital in Sharjah.
A retrospective analysis of patients admitted to Tawam Hospital indicated the presence of 1,357 cases of cancer. These included breast
cancer (9%), head and neck cancer (9%), lung cancer (7%), non-Hodgkins lymphoma (6%), acute leukemia (5%), cancer of the cervix
(5%), stomach cancer (5%), Hodgkins lymphoma (4%), cancers of the colon and rectum (4%), thyroid cancer (4%), and others.
Acquired Immunodefiency Syndrome (AIDS) is caused by Human Immunodeficiency Virus (HIV) and began to spread extensively
in the 80’s. This sexually transmitted virus continues to spread unabated in developing countries. The majority of these HIV infected
people will eventually develop AIDS and will present with different opportunistic diseases and malignancies.
A latest report of the World Health Organization (WHO) showed that the UAE had one of the lowest numbers of reported AIDS cases
in the world over the past few years. Also, the latest statistics by the Ministry of Health (MoH), United Arab Emirates has revealed
645 cases of AIDS at the end of 2006 in the country.
Only a few cases were reported recently. We could say AIDS cases are not increasing significantly. It is admitted that the social stigma
attached to the fatal transmissible disorder was impeding to collect the accurate data of the patients.
D U P H A T 2009
www.duphat.ae
135
Poster Code S20
Institution:
Authors :
1. Jenan Abdelfattah
2. Safa Bkairat
3. Reem FarajAllah
Supervised by:
Dr. Eman Abu-Gharbieh
Title: Let’s open more doors for Clinical Pharmacists
Student Posters
Abstract: Introduction: Clinical pharmacy is a health science discipline in which pharmacists provide patient care that optimizes
medication therapy and promotes health, wellness and disease prevention. In UAE, clinical pharmacy has been recently professionally
applied, as it is required by the international accreditation system for Hospitals.
The objective of our study is to evaluate the knowledge and attitude of medical staff as well as the medical college students regarding
the concept of clinical pharmacy in order to integrate clinical pharmacy in the UAE health care system.
Methods: It is a descriptive cross-sectional study that will be conducted in many different hospitals with doctors, nurses and
pharmacist, in addition to medical college students. Standardized self-filling questionnaires are distributed to evaluate this issue.
Poster Code S21
Institution:
Authors :
1. Heba Al-jabri
2. Iman Al-Hammadi,
3. Noora Al-Belooshi
Supervised by:
Dr. Eman Abu-Gharbieh
Title: Consumption of Aspirin within the UAE Population
Abstract: Background: Aspirin is a highly effective antiplatelet agent that is used by millions of people to reduce cardiovascular
morbidity and mortality. However, ibuprofen can inhibit the antiplatelet effects of aspirin. This effect occurred in people who took
daily ibuprofen before taking aspirin or in those taking ibuprofen regularly. Participants who took a single daily ibuprofen after aspirin
did not exhibit an inhibitory effect. It is therefore possible that ibuprofen, if taken regularly or before daily aspirin, could reduce or
even negate the beneficial effects of aspirin.
Aim: Our aim is to assess national trend and patterns of aspirin use as a prophylactic agent among the UAE population that are at
high risk of atherothrombotic events, in addition, we aim to assess the frequency of concurrent use of aspirin and ibuprofen that this
might be associated with lower cardioprotection than aspirin alone because of a pharmacodynamic interaction.
Methods: The study will be conducted in UAE based on interviewing persons for clinical visits in hospitals and private clinics, 250
patients will be interviewed. The data will be collected with the help of a structured questionnaire and will be analyzed statistically to
bring out the pattern of Aspirin usage among different groups of patients.
136
Poster Code S22
Institution:
Authors :
1. Raghda Al Khani
2. Reem Saeed
3. Maryam Ahmad
Supervised by:
Dr. Bazigha K. Abdul Rasool
Abstract: The Electronic Prescription Service (EPS) allows prescribes working in primary care settings to generate and transmit
electronic prescriptions using their computer system. The electronic prescription is sent to the Electronic Prescription Service, where
it can then be downloaded by the dispensers in community pharmacies who have also upgraded their computer system to use the
EPS. This system is already introduced in the primary care settings across England. It provides the change from a paper-based system
to an electronic one which is more efficient, consistently accurate and able to cope with expected further increases in the number
of prescriptions issued. Furthermore, patients will have the option to choose, or ‘nominate’ a dispensing contractor to receive their
electronic prescription automatically – without the need for any paper.
Since there is a wide expansion in prescriptions that are issued every working day in the UAE and to have more efficient prescription
services; this study suggests the introduction of this system across UAE in form of an electronic net connecting all hospitals
(governmental and private), medical centers and clinics with community pharmacies to bring a range of benefits to patients, physicians
and pharmacists. The present study involves designing of an example EPS based on content-setting interviews and questionnaires
from random samples of physicians, pharmacists and the public.
Student Posters
Title: Integrate of Electronic Prescription Net Across the
UAE: the Convenient Method of Drug Dispensing
Poster Code S23
Institution:
Authors :
1. Sahar Hussain
2. Hana H Akoula
3. Shaikha A Alsuwaidi
Supervised by:
Dr. Bazigha K. Abdul Rasool
Title: Best Practices for Rational Drug Use at Private Hospitals
and Community Pharmacies in the UAE
Abstract: The concept of rational drug use during the past few years has been the theme of various national and international
gatherings. Various studies showed that irrational drug use is a serious global public health problem that causes very significant
patient harm in terms of antimicrobial resistance, unnecessary adverse drug reactions and medication errors, poor patient outcomes
and waste of resources by over dose, under-use or misuse of medicines.
Private hospitals and clinics with community pharmacies have been growing rapidly in the United Arab Emirates (UAE). Various
strategies related to health care application and rational drug use have been formulated by the Ministry of Health (MoH) and
Department of Health and Medical Services (Dubai Health Authority). The majority of these guidelines are applied only to the
primary health care centers and hospitals in the governmental sectors. For this reason the present project is designed to bring to
light the area of strategies implementation for rational drug use and the main reasons behind irrational use of medicines in the
private sectors and community pharmacies in UAE. The study is conducted through content-setting interviews, questionnaires for
physicians, pharmacists and the public. In addition, 100 prescriptions were randomly selected from private hospitals, and community
pharmacies, to be reviewed for the right and safe option of medicines.
D U P H A T 2009
www.duphat.ae
137
Poster Code S24
Institution:
Authors :
1. Huda Ziad
2. Lana Fwaz
Supervised by:
Dr. Ali Algarbi
Title: Study on the Need for Pharmaceutical Care of Contraception in UAE
Student Posters
Abstract: A study was conducted on the methods of contraception, concerning their selection, administration, side effects and
effectiveness. The most popular method is oral contraceptives followed by IUD. The latter was found to be the cause of chronic pain,
bleeding or pelvic infection for certain patients. Oral contraceptives caused hypertension (6%), break-through bleeding, depression,
hirsutism, acne, for users. The majority of the patients who suffer from one or more side effect do not change the pills to more suitable
ones. Regular chick-up is not carried out by the majority of the users,
Variety of methods used to prevent pregnancy. This may be done by preventing implantation, ovulation, or entry of sperm into
uterus. Natural family planning’s objective is to limit coitus around the time of suspected ovulation. The most effective method of
contraception, aside from abstinence, is permanent sterilization. While these methods may be reversible under certain circumstances,
patients should consider them irreversible.
Methods used for contraception include abstinence, CAP, Condoms, Diaphragm, IUD, Contraceptive implant, Contraceptive injections,
Oral contraceptives, Rhythm method, Symptothermal method, and Male & female sterilization.
Risk factors: For pregnancy: any ovulating woman who engages in intercourse with a fertile male, and those who are from a lower
socioeconomic status, or have limited knowledge about reproduction.
General measures for non- drug methods: Latex condom: Instruct on proper use. IUD Should be inserted during menses to be certain
patient is not pregnant, but may be inserted at any time in cycle. Contraindications include pregnancy, history of PID, undiagnosed
genital bleeding, uterine anomalies
Poster Code S25
Institution:
Authors :
1. Lubna E. S. Shat
2. Nasra Khalfan
3. Dunya Hussein
Supervised by:
Dr. Ali Algarbi
Title: Healthy Life Style prevents,controls and can reverse Diabetes II
Abstract: A study was conducted on the incidence, causes, implications and treatment of obesity in the UAE. The total number of
volunteers are 780 consisting of 360 males and 420 females. Out of the 760 volunteers, (7.5%), (34%), (39%) and (11.5%) suffer
from overweight, obesity and over obesity respectively. There is a progressive increase in the incidence of hypertension from 22% to
37%., heart rate from 18% to 60%, diabetes from 12% to 21%, hypercholesterolemia from 12% to 21%, hypertriglycerdemia from
39% to 54%, snoring from 25% to 61% and low back pain 37% to 62% from 39% to 54% by increase in BMI from 30-34.9 to more
than 40. Conclusion: There is an intimate relationship between obesity and hereditary factors. The correlation between medicaments,
childhood obesity, psychological factors, social factors, food phobia and sedentary life was found to occur by 22, 76, 80, 84, 92 and 78
% respectively. Methods tried for the treatment of obesity in a descending order: combined (100%), controlled food (98%), exercise
(60%), medicinal herbs (33.8%) medicaments (28%), surgery (16%) and acupuncture (4%).
138
Poster Code S26
Institution:
Authors :
1. Dima M.Skkal
2. Reham Ali
Supervised by :
Dr. Ali Algarbi
Title: To treat or not to treat: Managing insomnia
How often do your patients seek advice for insomnia? Despite its prevalence, insomnia receives little attention from the health-care
community even though the effects on the quality of life can be severe. In response to this lack of awareness, sleep experts has issued
new insomnia management guidelines.
Objective of this study to:
• Recognize patient risk factors and medications that may contribute to insomnia especially in the elderly
• Discuss non-pharmacologic treatment of insomnia
• Discuss pharmacologic treatment principles of insomnia
• Distinguish between benzodiazepines, zopiclone, zolpidem, and zaleplon in the treatment of insomnia.
• Review appropriate questions to ask and medication counseling for the patients especially elderly insomnia patient
Student Posters
Abstract: Insomnia is a major medical and psychiatric condition in this country. Twenty percent of the young and nearly 39% of UAE
population aged 65 years and older report symptoms of chronic insomnia. It is important to patients affected with insomnia to find
the underlying cause and to seek treatment. Pharmacists can play an important role in counseling patients suffering from insomnia.
Poster Code S27
Institution:
Authors :
1. Anfal Mahmood
2. Hiba Y. Elabdallah
Supervised by:
Prof. Dr. Mervet
Title: Doping Drugs as performance enhancers
Abstract: Objectives: Doping Drugs as performance enhancers, being used by athletes when competing to achieve the winning.
Aims:
• Explaining the term Doping Drugs (DD) and determining its extent use among the athletes and publics and
discussing its mechanism of action and side effects, analyzing the main reasons for its use and the
type of drugs which is being used.
• Providing solutions :
• Reinforcing doping controls.
• Improving detection techniques.
• Providing natural replacements.
• Appling strict punishments for the abusers.
• Support education and awareness.
Methods:
• Questionnaire distribution:
• An anonymous multiple-choice questionnaire was distributed among athletes, doctors, pharmacists,
sport fans and coaches.
• Experiments:
• Injecting some mouse’s with some performance enhancers and monitors its effects on CNS, CVS,
Resp. System and life span.
• Introduction of the natural replacements to other mouse’s and monitor how it does influence their performance.
D U P H A T 2009
www.duphat.ae
139
Poster Code S28
Institution:
Authors :
1. Reem A. Abdulla
2. Nada Elsaqaa
3. Hanan Abdalgani
Supervised by:
Prof. Dr. Mervet
Title: Perception of teratogenic risk by health professionals: a survey in UAE
Student Posters
Abstract: Counselling or prescribing drugs during pregnancy requires health professionals to assess risk/benefit ratio for women and
their baby. A misperception of the risk may lead to inappropriate decisions for pregnancy outcomes. The aim of the present study
was to assess teratogenic and/or foetotoxic risk perception of common medications by general practitioners (GPs) and community
pharmacists (CPs) .
Methods: 103 GPs and 104 CPs were interviewed. For 21 given drugs, a visual-analogue scale was used to evaluate the risk to give
birth to a malformed infant if the mother had taken the drug during first trimester of pregnancy.
Results: 97% and 91% of GPs and CPs respectively thought that isotretinoin and thalidomide are teratogenic and more than 80%
thought that amoxicillin and acetaminophen are safe in early pregnancy. However, 19% of the GPs and 33% of CPs answered there
were no teratogenic risk for valproate. Around 11% of both GPs and CPs said that warfarin was safe during pregnancy. For 22% of GPs
and for 13% and 27% of CPs respectively, ibuprofen and enalapril were safe on late pregnancy. For each drug, mean value of perceived
teratogenic risk by health professionals was higher than values that can be found in scientific references.
Conclusion: These data show that the potential teratogenic and foetotoxic risk of several commonly used drugs is unknown by health
professionals. Conversely, GPs and CPs who think that a risk exists, overestimate it. This misperception can lead to inappropriate
decisions for pregnancy outcomes.
Poster Code S29
Institution:
Authors :
1. Lamia Bassam
2. Najah Mostafa
3. Huda Mohammad
Supervised by:
Dr. Khan
Title: Key role of community pharmacist in maximize elderly health
Abstract: “Were medicines safe, pharmacy as a profession would have never existed”
That said, it remains without doubt that community pharmacies play an essential role in maintaining the general population’s
health – elderly in particular. This is a consequence of geriatrics requiring more medications, having a higher rate of interaction
with pharmacists and trusting them as the most approachable and accessible health-care member. This study was carried out to
understand the importance of pharmacist care and intervention within the elderly category as well as estimate their awareness of
their medications.
Our study was conducted on the basis of 200 questionnaires handed out to random patients (age range 45 – 65 yrs) .In addition; 100
pharmacists were also assessed on their role.
The results proved that pharmacists are best suited to ensure that patients consume medications in the safest manner possible.
Available data also suggested pharmacists possess the potential to exert a substantial effect in reducing polypharmacy, increasing
adherence and preventing ADRs thereby improving patients’ quality of life.
Furthermore, a pharmacy alert system plus ‘physician – pharmacist’ collaboration can reduce inappropriate drug prescribing among
the elderly.
On the other hand, as clinicians, pharmacists can offer fundamental advice with regard to the identification and possible elimination
or substitution of unnecessary agents in a patient drug regimen. If applicable, they may also be able to suggest possible non –
pharmacological therapy.
As pharmacists, our golden role in advancing geriatric’s health should serve as an encouragement to seize the many humane
opportunities in our profession - from complex medication regimens and monitoring adherence to simply exhibiting empathy and
taking our elderly by the hand to help them walk through their memory lane,because if we don’t, who will?
Key-words : geriatrics, elderly health-care , polypharmacy , elderly drug-monitoring
140
Poster Code S30
Institution:
Authors :
1. Safa
2. Nour Mohamed
3. Mariam Abdullah
Supervised by:
Dr. Fazilatun Nessa
Abstract: Calcium oxalate stone is an important part of kidney stone. Several factors are involved for the formation of calcium
oxalate stones. Research advances to better understanding of the factors that promote stone formation and inhibitors that prevent
stone formation. Hypercalciuria, hyperuricosuria, hyperoxaluria, hypocitraturia, cell injury, lipid peroxidation products, free radicals,
xanthine oxidase, hydrogen peroxide and superoxide radicals facilitated the formation of calcium oxalate crystal and, on the other hand
antioxidants, free radical scavengers, xanthine oxidase inhibitors, superoxide scavengers and calcium oxalate crystallization inhibitors
can prevent stone formation. All these observations implicated the radical-mediated membrane changes, predisposing a favorable
environment for subsequent crystal disposition and retention. Antioxidants intervene in this process, protect the membrane from
injury and prevent adherence or retention of the crystals by free radical scavenging mechanism.
Student Posters
Title: Antioxidants in the Prevention of Kidney Stone Disease
Poster Code S31
Institution:
Year 3 students, Department of Health Sciences, Dubai Women’s College,
Higher Colleges of Technology
Authors :
1. Maryam Al-Ali
2. Hanan Mohammad
3. Anood Mohammad
Title: Ezetimibe/ simvastatin and risk of cancer
Abstract: Vytorin (simvastatin and ezetimibe) was recommended to use to control cholesterol levels in hyperlipidemic patients.
Post marking surveillance was conducted to ensure the safety of this medication. The three trials conducted of this subject include
SEAS (Simvastatin and Ezetimibe in Aortic Stenosis) trial, SHARP (Study of Heart and Renal Protection) trial and IMPROVE-IT
(Improved Reduction of Outcomes: Vytorin Efficacy International Trial) trial. SEAS trial suggests that most of the patients who take
Vytorin® may develop cancer but there has not been enough clinical evidence collected to prove this. The SHARP trial is expected to
be completed in 2010 and the IMPROVE-IT trial is scheduled for completion around 2012. These three trials suggest that the most
common types of cancers developed in the sampled patients are skin, prostate and stomach cancers.
Poster Code S32
Institution:
Authors :
1. Ayesha Mohammad
2. Aisha Saeed
3. Iman Mohammad
Title: Antibiotics during pregnancy: Are they safe?
Abstract: Antibiotics are commonly used drugs which can save lives and prevent life threatening infections. On the other hand,
antibiotics may cause dangerous undesirable effects if they are not used in appropriate way. This paper focuses on the effects of
antibiotics on pregnancy. Many studies indicated that consumption of antibiotics during pregnancy affects the childhood outcomes.
The results of one of the trials, which were done on pregnant women with preterm rupture of the membranes, showed that after taking
antibiotics there was an improvement in respiratory function with erythromycin and an increased bowel disorders with co-amoxiclav.
On the other hand, a second trial with pregnant women with spontaneous preterm labour shows that the erythromycin can cause an
increased functional impairment in these children who was exposed to the drugs. The undesirable effects of antibiotics depend not only
on the action of the drug, but also on other factors such as the quantity of medication, duration, and the trimester stage.
D U P H A T 2009
www.duphat.ae
141
Poster Code S33
Institution:
Authors :
1. Duha Ali
2. Hessa Ali
3. Noora Mohamed
Student Posters
Title: Correlation between Paracetamol and asthma in pediatric patients
Abstract: Paracetamol is one of the non-prescription drugs used worldwide as an analgesic and antipyretic agent in pediatric
practice. It is well-evidenced that the prevalence of asthma is increasing in developed countries, especially among the pediatric patient
populations. Research findings suggest that the frequent consumption of paracetamol in pregnant women and in the first 12 mounths
of child’s life are the main reasons for this phenomena. The correlation between the use of paracetamol and asthma in childhood has
been proved by many studies. One study of the Phase Three of the International Study of Asthma and Allergies in Childhood (ISAAC)
programme was done on children aged 6–7 years from 31 countries in September 2008. The odd ratio (OR) of asthma symptoms
was calculated., parents of children aged between 6–7 years also completed questionnaires about asthma symptoms their children
experienced. Another study in three Mexican cities used the same method of the first study. In a study of March 2007, skin pricks
testing was used to prove the relationship between the use of paracetmol and asthma. Until now, there is no 100 % convincing
evidence that would confirm the close link between the use of paracetamol and asthma in childhood.
Poster Code S34
Institution:
Authors :
1. Alaa Hasab Elrasol Bakhit
2. Doaa Khamis Younis
3. Dalia Shaker Makarem
Supervised by:
Dr. Iman Saad
Title: In vitro dissolution studies of metformin commercial tablets
Abstract: Metformin is the most popular oral anti-diabetic drug used for the treatment of type 2 diabetes. Metformin is one of
the most prescribed drug in UAE and the whole world. Lots of generic drug products containing metformin have been registered
in UAE by several pharmaceutical groups and are present in the UAE market. Due to the wide medical prescription of products
containing metformin, it seemed interesting, from a technological and biopharmaceutical point of view, to perform a comparative
in vitro dissolution evaluation of a trade marked and generic tablet formulations containing metformin available in the UAE market.
Material and Methods: The trial was carried out on six preparations, including Glucophage (500 mg) as reference product and five
generics named Formet, Glymet, Omformin, Neomet and Metfor.
The in vitro technological parameters (dissolution, potency, uniformity of content, uniformity of weight) are determined using the
methods described in the United States Pharmacopeia 30 (USP 30). Results from generics are compared to the reference product and
statistical significance is calculated.
Poster Code S35
Institution:
Authors :
1. Fatima Ali Abdelgadir
2. Maryem Abdelnaser Morkos
3. Meaad Abdelrahman Mohamed
Supervised by:
Dr. Iman Saad
Title: In vitro dissolution studies of omeprazole commercial capsules
Abstract: Generic drug products are marketed throughout the world and are generally regarded as being equivalent to the name
of the brand product. Omeprazole is a broadly used proton pump inhibitor for the treatment of dyspepsia, peptic ulcer disease and
gastroesophageal reflux disease. Omeprazole is one of the most widely prescribed drugs and is available over the counter in UAE.
142
Several generic drug products containing omeprozole have been registered in UAE by several pharmaceutical groups and are present
in the UAE market. Differences in formulations produced by different manufacturers can be assessed by measuring dissolution rate
and potency. The objective of this study is to perform a comparative dissolution evaluation of five marketed omeprazole capsules each
containing 20 mg active drug. The potency of the drug in the different products is also evaluated. Materials and Methods: the study
was carried out on six omeprazole preparations, including Losec as reference product and the five generics named Omecare, Omeprex,
Omiz, Omeral, and Omezyn. An enteric coated omeprazole tablet (Omedar) was also included in the study for comparison. The in
vitro technological parameters (dissolution, potency, uniformity of content, uniformity of weight) are determined using the methods
described in the United States Pharmacopeia 30 (USP 30). Results from generics are compared to the reference product and statistical
significance is calculated.
Institution:
Authors :
1. Maya El Khanas
2. Lima Wadie
3. Rima Ali
Supervised by:
Dr. Osama Mohamed
Student Posters
Poster Code S36
Title: Acceptance of UAE physicians to the clinical role of Pharmacist
Abstract: Physicians’ acceptance to the clinical role of pharmacist is one of the most important factors for the success of implementing
pharmaceutical care process. To apply a decent pharmaceutical care, you need the cooperation of the whole health care team specially
the physicians. The objective of the current study is to assess the acceptance of physicians to the clinical role of pharmacist. Also, to
understand what are the areas of expertise that they need the pharmacist’s collaboration and help.
Method: A survey will be designed and disseminated to physicians in different hospitals and private clinics to ask the physician about
their opinion about the clinical role of pharmacist, what are the most accepted clinical roles for the pharmacist from the physician’s
point of view, what are the qualification that are required to get the physician acceptance to the clinical pharmacist, and what are the
specialty of physicians that accept the clinical role of pharmacists.
Demographic data about the participants will be also collected. The data will be analyzed statistically and results will be presented
during DUPHAT 2009.
Poster Code S37
Institution:
Authors :
1. Lara N. Abdalla
2. Ahmed Sultan
3. Mohamad Abo-foul
Supervised by :
Dr. Osama Mohamed
Title: Assessment of Community Pharmacists Role in patient care
Abstract: Community pharmacist is considered the most accessible member of the medical team. Patient can seek help or medical
information through the community pharmacists almost at any time without a significant cost.
The study objective is to assess the current role of community pharmacists in patient care in order to determine the required steps to
achieve a satisfactory level of patient care.
Method: A survey will be done by personal interview in pharmacies from different locations. The survey will be designed to find
information about the time spent to discuss medical information with the patient, incidence of detecting drug-drug interactions,
acceptability of patients for pharmacist’s scientific opinions and self satisfaction of pharmacists about their role in patient care.
The results of the survey will be analyzed statistically and will be presented during DUPHAT conference 2009.
D U P H A T 2009
www.duphat.ae
143
Poster Code S38
Institution:
Author:
1. Hadil Hajjar
Supervised by :
Dr. Osama Mohamed
Student Posters
Title: How can pharmacists empower the knowledge and self-care activities of type
2 diabetic patients?
Abstract: Diabetes Mellitus is a challenging disease to be managed successfully. Being diagnosed with diabetes, a person enters a
realm where everyday aspects of life are altered. Although the diabetes care regimen is complex, patients with good diabetes self-care
behaviors can attain excellent glycemic control. If patients adhered to their treatment recommendations, they could do well and avoid
diabetes-related complications. The fact that so many patients can not adhere to their treatments is very frustrating. The aims of this
project are to assess the knowledge & self-care activities of type II diabetic patients, assess population awareness about diabetes, and
demonstrate the pharmacist role in educating diabetic patients. Two questionnaires were developed, one for diabetic patients and one
for general population; in addition, to some leaflets that aid patient-education process. It is hoped that the outcome of this study will
help us as healthcare providers to understand the factors associated with the poor control of diabetes, and to document the impact of
pharmacist role in educating diabetic patients.
Poster Code S39
Institution:
Authors :
1. Reem El Fares
2. Nermeen Elgasim
3. Laila Abbasi
Supervised by:
Dr. Mohamad Harb
Title: The role of pharmacovigilance in risk management
Abstract: Risk assessment during product development should be conducted in a thorough and rigorous manner; however, it is
impossible to identify all safety concerns during clinical trials. Once a product is marketed, there is generally a large increase in the
number of patients exposed and more drug related problems are detected. Therefore, post-marketing observations, including safety
data collection and risk assessment, are critical for evaluating and characterizing a products risk profile, and for making informed
decisions on risk minimization. In fact, this is the main purpose for arising pharmacovigilance.
The term pharmacovigilance is the science and activities related to the detection, evaluation, understanding and prevention of adverse
drug reactions or any other drug related problems.
There is a global awareness regarding this issue for the rationale of avoiding hospital admissions, morbidity and mortality rates due to
adverse effects; and we hope to discuss “the role of pharmacovigilance in risk management” effectively in our poster.
Poster Code S40
Institution:
Authors :
1. Inas Razouk
2. Nawal Abdalla
Supervised by:
Dr. Wasfiy Obeidat
Title: Formulation and processing factors for imoproving the properties of tablets made of a
novel combination of anionic and cationic polymethacrylate polymers
Abstract: The aims of this study were a) to prepare a novel controlled-release tablet formulation for neutral drugs (paracetamol)
using a binary mixture of polymethacrylate polymers Eudragit E-100 (EE) and Eudragit L-100 (EL) in their salt forms and study the
drug release behavior and mechanism and b) to investigate formulation and processing factors optimization tablets made of Eudragit
E-100 (EE) and Eudragit L-100 (EL) in their salt forms to be used in the large scale production.
In this work, Eudragit E (EE) was dissolved in 0.33 N citric acid solution, and Eudragit L (EL) was dissolved in 1 N NaOH and then
144
polymer solutions were spray dried separately using BÜCHI 190 Mini spray dryer. The operations conditions were adjusted as follow
to yield the maximum efficiency. The resulted spary dried powders were shaped into matrix tablets by the direct compression method.
In addition tablets containing salt forms of Eudragit polymer were prepared by the wet granulation method. Moreover, matrix tablets
prepared using an aqueous dispersion of IPEC were prepared by the wet granulation method. The release of the drug was investigated
at 3 different stages; the first stage lasted for one hour at pH 1.2 and the volume of the dissolution medium was 500 ml. The second
stage was conducted at pH 5 for 2 hours. The final stage was conducted for 5 to 24 hours and the pH was adjusted to 6.8.
Student Posters
The use of mixture of EE-Citrate/EL-Na in their salt form provided better sustained-release profiles than those prepared using IPEC
(impure) in all dissolution media especially when they were prepared at lower polymer content (5-12% w/w) with lower variability and
better physical properties of tablets. The effect of changing the pH of the dissolution medium from pH 1.2 to 5 and then 6.8 seemed
to have little influence on the release of paracetamol from matrices containing mixture of Eudragit polymers.
Results proved
that the combination of Eudragit E and Eudragit L in their salt form is suitable for formulating matrix tablets basically for neutral,
unionized drugs such as paracetamol. In addition, tablets from an aqueous dispersion of IPEC prepared by wet granulation and tablets
prepared by directly compressing spray dried polymers salts resulted in producing tablets of better controlled and sustained release
properties.
Poster Code S41
Institution:
Authors :
1. Rafat Awad
2. Nada Haider
Supervised by:
Dr. Rana Ibrahim
Title: International Network Database
Abstract: Imagine a world without financial restrictions where technology is life, and life will continuously bring newer technology.
The main idea starts from Sharjah where the need and demand are high. The network will connect all the pharmacies, hospitals,
insurance companies, and government. It will be a non-profit service for users in need. The database will provide information about
the prescription and registers the patient’s medical history, and his/her filled drugs from the pharmacy. The system will provide
information about new drug discoveries that have big financial impact on patients/healthcare. Through the internet, the system will
provide a medium for virtual societies and forums where patients can share medical information about their cases. One of the aims
of this development is to reduce the amount of human errors caused by medical professionals. In a nutshell the goal of this project is
to eliminate financial restrictions on patients.
Poster Code S42
Institution:
Authors :
1. Latifa Khalifa
2. Ebtesam Saeed
3. Ahmad Saeed
Supervised by:
Dr. Rana Ibrahim
Title: Osteoartritis quality of life assessment in the UAE
Abstract: Osteoarthritis (OA) is a degenerative disease that is the most common among many different types of arthritis affecting
more than 20 million people in the United States alone. In the United Arab Emirates, the percentage of people diagnosed with OA
has been tremendously increasing due to the hot climate and extreme humidity most of the year making the use of Air Conditioning
a necessity in every place. Cold temperature and humidity does affect joint range of motion, or the flow of the synovial fluid that
lubricates the joint worsening arthritis pain. Based on applying the prevalence rate from the U.S to the population of other countries, it
is only estimated that 158,581 persons are diagnosed with osteoarthritis in the UAE with the estimated population used is 2,523,915.
OA affects greater than 50 % of patients over 55 years of age and almost all patients over 75. OA affects the weight-bearing joints of
the axial and peripheral skeleton, causing pain, limitation of motion, deformity, and decreased quality of life.
Pharmacists play a pivotal role in assisting patients with managing their OA through non-pharmacological and pharmacological
methods. Our study aims to get more accurate statistics about OA by targeting patients above 55 years of age who are at higher risk
of the disease. Our main goal is to categorize severity of the disease in various patients and recommend appropriate counseling/
treatment in order to minimize disease deterioration, decease health costs due to OA, and improve patients overall quality of life.
D U P H A T 2009
www.duphat.ae
145
Poster Code S43
Institution:
Authors :
1. Mariam Bahnasawe
2. Rebhea Ismail
3. Rafat Awad
Supervised by:
Dr. Rana Ibrahim
Student Posters
Title: Continuous Outpatient Warfarin counseling and its effects on adherence
Abstract: Clinical Trials since the 1990’s showed that oral anticoagulation such as Warfarin was almost twice as effective as Aspirin
as preventing strokes in patients with Atrial Fibrillation and other cardiac abnormalities. Warfarin patients and their adherence
patterns will impact the health system financially by ways of anticoagulation – related ED visits and complication management. The
shortage of anticoagulation clinics in the U.A.E, increases complications and cost due to warfarin therapy, and adherence will still
be an issue. Warfarin is involved in many adverse drug events that include dosing, drug interactions, vitamin K containing dietary
intake, and patient compliance which can dramatically affect its levels. This study is aimed at observing the improvement, if any, of
adherence in warfarin patients who are continuously being counseled either by phone, mail, or periodic home visits by either a nurse
or pharmacist.
Poster Code S44
Institution:
Authors :
1. Dana Helal
2. Nada Alzubaidi
3. Maria Swaid
Supervised by:
Dr. Rana Ibrahim
Title: Drug Mix-ups due to SALA (Sound alike Look alike drugs) threatening patient safety
Abstract: The incidence of medication errors due to drug mix-ups as a result of Sound alike look alike medications has been increasing
tremendously worldwide and especially in the UAE. Stricter measures should be taken to minimize this patient safety threatening
incidence through community/hospital pharmacists, physicians, and patients/consumers education. The aim of our study is to
increase awareness of errors due to SALA drugs and develop tools to minimize these errors. We developed different questionnaires/
surveys that were shared with community/hospital pharmacies, physicians, and patients throughout Dubai, Sharjah, Abu-Dhabi, and
Al-Ain emirates. The surveys distributed to pharmacists included questions such as percentages of errors due to SALA drugs. As far
as the physicians questionnaire; it included questions looking at their views and measures taken to minimize drug errors due to SALA,
and method of delivery of their prescription orders. As far as the patient/consumer questionnaire, it included questions targeting
their knowledge about the medications they are taking. Finally, a list of common SALA medications was distributed to physicians,
pharmacists, and patients. At the end, Communication strategies for SALA error preventions was designed and distributed to
physicians, consumer measures for SALA error prevention was distributed to patients, and health professional strategies for SALA
error prevention was distributed to pharmacists. In conclusion, we have to put all our efforts as Health care professionals to ensure
patient safety and minimize health care cost due to medication errors caused by SALA drugs.
146
Poster Code S45
Institution:
Authors :
1. Noha Siddiq
2. Sarah Saleh
3. Lubna Ziad
Supervised by:
Dr. Sana Enayah
Abstract: A lot has been published in the literature about pharmacist competency and what skills and behaviors pharmacists are
supposed to master and exercise in their care of patients. Five essential competencies were called for to be part of the training of all
professionals entering to their professions by the Health Professions Education Summit convened by the Institute of Medicine in
Washington DC in 2003 and they are: deliver patient-centered care, work in interdisciplinary teams, employ evidence-based practice,
apply quality improvement approaches and utilize informatics. Looking at several documents including; the Pharmaceutical Society
of Australia’s competency Standards document, the AACP CAPE Educational Outcomes 1998 document, the ACPE Accreditation
Standards and Guidelines for the Professional Program in Pharmacy leading to The Doctor of Pharmacy Degree, a list of competencies
for UAE pharmacists is developed. Subsequently and based on this list, a survey of pharmacist self perception of their own competency
is piloted on a sample of pharmacists from different practice types. The results of the survey will be assessed and compared to data
from other countries.
Student Posters
Title: What makes a pharmacist competent: Self-perception of
competency among UAE pharmacists
Poster Code S46
Institution:
Authors :
1. Rahaf Cheikhali
2. Sara Kalo
3. Ola Nabil
Supervised by:
Dr. Sana Enayah
Title: Emphasizing the role of the pharmacist in detecting and management of
adverse drug reactions in the Emergency room
Abstract: Adverse drug reactions (ADRs) are a major cause of patient morbidity and mortality. Adverse effects from drugs are thought
to affect between 10 and 20 per cent of hospital admissions.
Prompt reporting of ADRs remains the fundamental key of pharmacovigilance and is necessary to ensure patient safety. Unfortunately
in many countries, UAE being one, pharmacists do not usually report ADRs, presumably due to lack of tradition or proper training,
work-overload, or insufficient pharmacist-physician contact. A need to assess ADR-related emergency-room visits and hospital
admissions and the pharmacist’s role in detecting, reporting, preventing, and reducing such incidences is addressed. It is proposed
that if there is a close cooperation between pharmacists and physician by making a pharmacist available in the emergency room,
pharmacists could have a crucial role detecting and managing adverse drug events. We plan on serving in the emergency room of
hospitals in the UAE and involve in assessing possible ADR’s and plan interventions to manage reactions and finally to try to prevent
further episodes by patient education and counseling.
D U P H A T 2009
www.duphat.ae
147
Poster Code S47
Institution:
Author :
1. Ruba Esreb
Supervised by:
Dr. Sanah Enayah
Student Posters
Title: The Pharmacist role in public health: An awareness campaign to reduce cardiovascular
risk in the UAE
Abstract: Cardiovascular disease is the leading cause of death among all ages of UAE population. Major presentations of this disease
include ischemic heart disease (IHD), acute myocardial infarction (AMI) and hypertension (HTN). Awareness of symptoms of the
disease and aggressive prevention and management of risk factors are more cost effective than sometimes invasive diagnostic tests.
Prevalence of risk factors for the disease in a UAE sample population was explored and it was noted that many modifiable risk
factors are contributing to the increased risk of cardiovascular disease. A campaign is organized to increase the awareness of the UAE
population regarding risks and prevention of cardiovascular disease, the campaign will cover a diverse sample of the population and
will involve high schools, universities and areas of public use. The campaign will consist of a combination of seminars, lectures, written
educational information in the form of a brochure. Approval of Ministry of Health to the written information material will support
the campaign and give credibility to the intervention. The pharmacist role in public health awareness programs is again emphasized
and role modeled by students.
Poster Code S48
Institution:
Authors :
1. Ola Ahil
2. Kawkab Badbess
3. Dalia Al-Ojeh
Supervised by:
Dr. Sanah Enayah
Title: Self-care cards: How about in the Arabic language
Abstract: Patient information leaflets are an important adjunct to verbal exchange between health professionals and patient. They also
serve as a reference material that the patient can refer to at their convenience. The value of such leaflets is dependent upon whether
they contain useful information from the viewpoint of the patient and are easily understood. Unfortunately, patient information
material in the Middle East is available in the English language and its availability in the Arabic language is limited to drug package
inserts that come as literal translation of the English content making it hard to understand for the patient. We will work in a team of
pharmacy students and another from the linguistics department. Students will be split in to groups that will cover different health
topics, and will search for any translated patient education material already available. All results will be consolidated and reviewed by
faculty members for appropriateness for material and presentation. We plan to have a model of Arabic educational material after the
Self Care Cards available for public use in Australia. Ministry of Health approval will be sought to allow for widespread use by health
professionals.
Poster Code S49
Institution:
Authors :
1. Maythaa Bin Bader
2. Salma Al Fadeel
3. Klaithem Salem
Supervised by:
Dr. Marwa Donia
Title: Back to nature: Conception in pediatric treatment in UAE
Abstract: Nowadays, there is an increased appreciation of things “organic” and “natural”. The potential herbal contributions to
pediatric medicine are receiving much attention worldwide but it is important to find the right balance between the appropriate use
of drugs and herbs. There are times when anti-biotics or surgery can be life saving. Similarly there are times when using the powerful
tools of modern medicine is excessive and the desired results can be achieved herbally especially that most herbs are nontoxic, with
148
few, if any, harmful side effects and well tolerated by children.
This study aims at exploring the percentage of UAE population that believe in and use herbal medicines for treating their children
in cases of digestive, respiratory and minor skin disorders. A questionnaire will be designed and addressed to mothers, pharmacists,
nutrition specialists in different locations describing the age of children, the gender, the disease as well as the herb used indicating
its efficacy and its safety. Statistical analysis of the data will be used to describe the degree of use of herbal medicines in pediatrics
in UAE.
Institution:
Authors :
1. Fatima Mahmood
2. Fatima Hussain
3. Khuloud Ahmed
Supervised by:
Dr. Marwa Donia
Title: Can “Natural or herbal medicines” be considered substitutes to drugs in UAE?
Student Posters
Poster Code S50
Abstract: From a historical perspective, the production and the pharmacologic treatment of diseases began with the use of herbs.
When we consider that the history of classical herbal medicine spans more than 2500 years from antiquity to modern times, it is
reasonable to assume that many of the medicinal herbs used during that period not only have specific actions but are also free of
hazardous side effects. Otherwise they would not have been passed down so faithfully through so many epochs and cultures.
In this survey, the attitude of UAE public toward natural remedies will be explored through questioning the herbal dealers and the
nutrition specialists in different locations. Descriptive statistical analysis of the questionnaire aims to describe the percentage of UAE
population that consumes herbal medicine as alternative to drugs. We will also investigate the mostly used herbs, their uses as well
as their efficacy and safety.
Poster Code S51
Institution:
Authors :
1. Hawra Ali Al Sayed
2. Nadin Numan
3. Sara Majdi
Co-Author:
Saba Islam
Supervised by:
Director – Pharmaceutical Services Department, Dubai Health Authority
Title: Rational use of NSAIDs with Gastroprotective drugs
Abstract: To investigate to what extent recommendations for co-prescribing gastro-protective agents in prevention of NSAIDinduced gastrointestinal complications are followed in clinical practice, since there is an occurrence of neglect. The aim of our study
is to evaluate the prevalence of concomitant use of gastroprotectives with NSAIDs in patients, because chronic NSAID use has been
implicated in the development of severe and potentially life-threatening gastointestinal complications, emphasis were made on age
over 65 years, prolonged use and other drugs like COX-2 selective NSAIDS. If people have at least one of these risk factors, and have
to take an NSAID then some form of gastroprotection is recommended!!
D U P H A T 2009
www.duphat.ae
149
Poster Code S52
Institution:
Ajman University of Science and Technology Network Faculty of Pharmacy and Health Science
Authors :
1. Sara Sabri
2. Amira Gamaleldin
3. Buthaina Mostafa
Supervised by:
Dr. Yasser El-Shabrawy
Student Posters
Title: Osteoporosis
Abstract: Osteoporosis is a condition characterized by low bone mass and increased bone fragility, putting patients at risk of
fractures, which are major causes of morbidity substantially in older people. Osteoporosis is currently attributed to various endocrine,
metabolic and mechanical factors. An activated immune profile has been hypothesized as important risk factor. Chronic inflammation
and the immune system remodelling characteristic of ageing, as well as of other pathological conditions commonly associated with
osteoporosis, may be determinant path-genetic factors. The present poster will review the current perspectives on the interaction
between bone and immune system in the elderly, providing an interpretation of osteoporosis in the light of inflame-ageing.
Poster Code S53
Institution:
Authors :
1. Hind Al-Khalifa
2. Marwa Al-nayer
3. Sara Mustafa
Supervised by:
Dr. Ibrahim Abulfotooh
Title: Marijuana
Abstract: Cannabis sativa (of the family Canabinaceae) is the Latin name for Marijuana and Hemp. The primary reason for the
cultivation of this plant was for making ropes and clothes from the fibers of the stem. The leaves and flowers of this plant produce
resins, which is smoked to attain an alerted state of consciousness or generally known as “High”.
In that state of mind, the individual experiences mild euphoria, stress reduction, increased appreciation for humor, music, art, and
colors. It also includes paranoia, anxiety, increased heart rate, dry mouth, decreased concentration and much more.
Harvesting fibers differs from harvesting the leaves or the resins of this plant because they require different timings for their collection.
The psychoactive constituent responsible for the pharmacological effects is delta 9-tetrahydrocannabinol (delta 9-THC). When the
herbal cannabis is inhaled in the mainstream smoke, nearly all of it is absorbed through the lungs, rapidly entering the blood stream
and reaching the brain within minutes. This will in turn, affect multiple organ systems and the peripheral nervous system inducing
atrophy, seizers and addiction or personality disturbances in the long term use. This plant is considered more of a health hazard and a
major cause of psychotic illnesses and thus has been banned from the United States and many other countries.
150
Poster Code S54
Institution:
Author :
1. Ahmed Sadeq
Supervised by:
Dr. Yasser Al-Shabrawi
Abstract: In search for potent and selective histamine H3 receptor antaginists, ketone derivatives as well as oxime derivatives
(Imoproxifan) have been developed [2]. These compounds proved to inhibit the negative feedback loops of H3 receptors, thus leading
to an increase of histamine level in the CNS. Most of the title compounds possess high antagonistic potency, especially Imoproxifan,
which displayed high potency in vitro ([3H]histamine release model on rat synaptosomes; Ki = 0.26 nM) and also in vivo (increase of
Ni-Methylhistamine level in the cerebral cortex of Swiss mice after oral application; ED50 = 0.034 mg/kg).
Furthermore, Imoproxifan was selected for determining of receptor profile, including various functional serotoninergic, adrenergic,
histaminergic, and muscarinic receptor models. The observed extraordinary potency and high selectivity of Imoproxifan suggests
that this histamine H3 receptor antagonist might thus be a potential candidate for further investigation and development for the
treatment of many different diseases influencing cognitive and memory functions, e.g., attention-deficit hyperactivity disorder,
Alzheimer’s disease, or epilepsy.
Student Posters
Title: Histamine H3-Receptor Antagonists for Therapeutic Management Of
Alzheimer Disease
Poster Code S55
Institution:
Authors :
1. Yuosef Shamsaldeen
2. Hazem Shukfa
Supervised by:
Dr. Yasser El-Shabraway
Title: Rational uses of Saccharin and its hazardous
Abstract: We use it in our iced tea, put it in our cereal and eat it in many reduced-calories or sugar-free foods and beverages everyday…
saccharin. It has been a part of our daily lives for more than 100 years and is used by millions of people to stay in better overall health
and control weight. Saccharin also has been the subject of controversy almost since it was discovered, but now it is one of the most
thoroughly tested food ingredients. In fact, saccharin’s safety is supported by 30 human studies, a century of use, the approval of the
World Health Organization and 100 countries around the world, as well as leading health groups. Saccharin is not adequate to human
health, since it’s carcinogenic especially for urinary bladder, also it’s not safe to be used publicly since it has hazardous teratogenic
effect. However there are other substitutes and many procedures can be taken to avoid its carcinogenicity if it’s ingested
D U P H A T 2009
www.duphat.ae
151
Floor Plan
152
List of Exhibitor
Company name
Stand No.
ABBOTT LABORATORIES S.A
102, 103, 104, 125, 126 & 127
ABBOTT NUTRITION INTERNATIONAL
96
ABUDHABI INT'L MEDICAL SERVICE
89
ACCUTEST RESEARCH LAB (I) PVT LTD
67
ACTAVIS GROUP
154, 155, 156, 177, 178 & 179
ADAM FABRIWERK PVT. LTD.
14
AJMAN UNIVERSITY OF SCIENCE & TECHNOLOGY NETWORK 36
AL HESN SCHOOL
218
AL HAYAT PHARMACEUTICALS
154, 155, 156, 177, 178 & 179
AL HIKMA FZ CO
66
AL ITTIHAD DRUG STORE
55
AL ITTIHAD PRIVATE SCHOOL
19
AL MUTANABBI BOOKSHOP
167
AL RAZI PHARMACY COMPANY
186
AL SHOROUQ SCHOOLS
16
ALCON
15
AMGEN
107, 108, 121 & 122
APTEKA MOSCOW 2009
163
ARABIAN HEALTH CARE SUPPLY COMPANY
174
ARNO KNOF PHARMA GMBH
162
ASTELLAS EUROPE B. V.
40
ASTRAZENECA FZ LLC
209, 210, 227 & 228
BAXA LTD
192
BAXTER
160
BAYER
58
BEIJING CANLUSO TECH CO., LTD
114
BIN SINA PHARMACY
5
BIOPHARMA LABORATORIES LTD
111
BIOTECH PHARMA / MEDAC GMBH
159
BIOTEST
180 & 181
BOEHRINGER INGELHEIM
229,230 & 231
BORMIOLI ROCCO & FIGLIO S.P.A
118
BRISTOL MYERS SQUIBB
128, 129, 151, 152 & 153
CAVA PHARMA INC
84
CEREBRAL LIFESCIENCES
193
CITY PHARMACY CO / SEBAMED PH5.5
56
DAWNRAYS
85
DEREAK FOR MEDICAL & PHARMACEUTICAL CONSULTATIONS 194
DR. WILD & CO. LTD
154, 155, 156, 177, 178 & 179
DUBAI HEALTH AUTHORITY
50, 51, 52, 73, 74 & 75
DUBAI INTERNATIONALSCHOOL
22
DUBAI NATIONAL SCHOOL
21
DUBAI PHARMACY COLLEGE
37
EBEWE PHARMA GES.M. B. H NFG. KG
173
ELI LILLY
53, 54, 71 & 72
ELIS PHARMACEUTICALS
34 & 35
EXPOPHARM 2009
170 & 171
FATER S.P.A
188
FERRING PHARMACEUTICALS
38
FOREST LABORATORIES UK LTD
154, 155, 156, 177, 178 & 179
FRESENIUS KABI
205
GAKO INTERNATIONAL GMBH
197
GANZONI &CIE AG
154, 155, 156, 177, 178 & 179
GENZYME
204
GLOBALPHARMA
1&2
G-PHARM MACHINERY CO., LTD
166
GRUNENTHAL
196
GSK
79, 80, 97, 98
GULF INJECT
61
HAMDAN BIN MOHAMMED E-UNIVERSITY
59
HOFFMANN LA ROCHE
41 & 42
HUALIAN PHARMAEUTICAL MACHINE
113
Company name
Stand No.
INDIA MART
93
INTERNATIONAL PHARMACEUTICAL STUDENTS FEDERATION (IPSF) 219
ISOCAB (A THYSSENKRUPP COMPANY)
92
JANSSEN-CILAG
81 & 82
JIANGSU HONGHUI PHARMACEUTICAL
139
JIANGSU JIANGSHAN PHARMACEUTICAL
144
JIANGSU VICTOR MACHINERY CO., LTD.
145
JULPHAR - GULF PHARMACEUTICAL INDUSTRIES
44,45 & 46
JUM JUM WORLD
62 & 63
KELUN PHARMACEUTICAL
165
LCA PHARMACEUTICAL
88
LEO PHARMACEUTICAL PRODUCTS
43
LES LABORATOIRES SERVIER
11, 12 & 13
LUNDBECK
64
MEDPHARMA, UNITED ARAB EMIRATES
3&4
MEPHA LTD. SWITZERLAND
8&9
MERCK SERONO
69 & 70
MERCK SHARP & DOHME
133, 134, 147 & 148
MODERN PHARMACEUTICAL COMPANY
99, 100 & 101
NCPC INTERNATIONAL CORP
141
NEOPHARMA
47
NEW ACADEMIC SCHOOL
17
NEW MEDICAL CENTRE FOR TRADING
48
NEW WORLD PRIVATE SCHOOL
20
NORGINE PHARMACEUTICALS LIMITED - UK
182
NOVARTIS PHARMA SERVICES INC.
105, 106, 123 & 124
NOVO NORDISK
222, 223, 214 & 215
NUTRICIA
208
NYCOMED GMBH
76, 77, 78
ORION PHARMA
154, 155, 156, 177, 178 & 179
PFIZER
131, 132,149 & 150
PHARMATRADE LLC / MADAUS GMBH
185
PIERRE FABRE MEDICAMENT
39
PHARMACEUTICAL SOLUTIONS INDUSTRY (PSI)
203
RAK MEDICAL & SCIENCE UNIVERSITY
220
RIONLON BOHUA INDUSTRY INT. TRADE
140
RIYADH PHARMA
206 & 207
RPS PUBLISHING
87
SAJA PHARMACEUTICALS GULF
10
SANOFI AVENTIS
211, 212, 225 & 226
SAUDI PHARMACEUTICAL SOCEITY
217
SCHERING PLOUGH
199 & 200
SERUM INDO GULF LLC
191
SHANDONG MINGYUAN IMP. & EXP. CO., LTD.
137
SHENZHEN GOSUN PHARMA CO., LTD
136
SHENZHEN SCIPROGEN BIO-PHARMACEUTICAL CO., LTD
139
SHIJIAZHUANG NO. 4 PHARMACEUTICAL CO., LTD
168
SICHUAN KELUN BIO-TECH PHARMACEUTICAL CO., LTD
142
SINOCHEM JIANGSU CORPORTION
115
SOLVAY PHARMACEUTICALS
157, 158, 175 & 176
SPIMACO
119
STARWAY PHARM CO., LIMITED
189
TABUK
49
TEKNI-PLEX INDIA
110
THE PRIVATE RELIGIOUS INSTITUTE
18
UCB/SCHWARZ PHARMA
6&7
VALEANT PHARMACEUTICALS
95
VITAVISION MEDICAL SUPPLIES
130
WYETH
183, 184, 201 & 202
ZHEJIANG MEDICINE & HEALTH PRODUCTS CO.LTD
90
ZHEJING CHEMICALS I&E CORP.
116
D U P H A T 2009
www.duphat.ae
1
Exhibitors Profile
Abu Dhabi International Medical Services
Abbott Laboratories S. A.
Abbott Laboratories is a global, broad-based health care company
devoted to discovering new medicines, new technologies and new
ways to manage health. Our products span the continuum of care,
from nutritional products and laboratory diagnostics through
medical devices and pharmaceutical therapies.
Mission Statement: A Promise for Life.
The promise of our company is in the promise that our work holds
for health and life
Exhibitors Profile
Values: Pioneering, Achieving, Caring, Enduring
History: Founded in 1888 by Dr. Wallace Calvin Abbott, a Chicago
physician. Headquartered in north suburban Chicago.
The first office in the Middle East region was started about 35 years
ago. We now have offices in all countries throughout the Middle
East to be closer to our customers and to cater more effectively to all
markets in the region.
In the Middle East Abbott is the first pharma company to be ‘Class
A’ certified.
ABBOTT'S COMMITMENT TO IMMUNOLOGY
Abbott is focused on the discovery and development of innovative
treatments for immunologic diseases. The Abbott Bioresearch
Center, founded in 1989 in Worcester, Massachusetts, United States,
is a world-class discovery and basic research facility committed to
finding new treatments for autoimmune diseases.
About Humira:
Humira (adalimumab) is a fully human monoclonal antibody therapy
that targets a protein called tumour necrosis factor alpha, which is
known to play a role in the body’s inflammation response.
Established at the term of the millennium, Abu Dhabi International
Medical Services (ADI) has taken huge strides in a very short
time today stand as respected and influential healthcare solutions
provider in this highly competitive healthcare market.
Strategically headquarter in the Capital Abu Dhabi; we also have a
significant presence through branches in futuristic City of Dubai
and the rapidly developing Al Ain. This network helps us reach, and
support customers across the UAE.
Our growth is reflected in an impressive and ever growing client
list that includes various Health Ministries not only in the UAE but
across the MEA.
Actavis Group
Stand No. 154, 155, 156, 177, 178 & 179
The Actavis Group is one of the world’s leading players in the
development, manufacture and sale of high-quality generic
pharmaceuticals in the international market. Actavis recent
acquisitions have positioned the Group among the world’s five
largest companies in the industry. Founded in 1956, the Group is
operating in over 30 countries around the globe. Its headquarters
are in Iceland.
Adam Fabriwerk Pvt. Ltd
Stan No. 14
Humira is a prefilled syringe that is available under a prescription
of a physician and is taken subcutaneously every other week for the
approved rheumatology indications of Rheumatoid Arthritis (RA),
Ankylosing Spondylitis (AS), Psoriatic Arthritis (PsA).
Adam Fabriwerk has been delivering quality mixing and processing
machinery products to Biopharmaceutical, Pharmaceutical, Cosmetic
and Allied Industries, since the past 26 years.
It is also indicated in the treatment of Crohn’s Disease (CD) and
Psoriasis (Ps) with worldwide more than 300,000 patients being
currently treated with the therapy on all indications.
Our corporate offices are based in Mumbai, India and our 2
manufacturing facilities and R&D lab is located at Nashik,
approximately 200 kms away from Mumbai.
Abbott Nutrition International
Stand No. 96
Abbott Nutrition International is a global, broad-based health care
company devoted to discovering new nutritional supplements and
ways to manage health. Our comprehensive line of products encircles
life itself – addressing important health needs from infancy to the
golden years.
Throughout our 100+ year history, Abbott people have been driven
by a constant goal: to advance medical science to help people live
healthier lives. It’s part of our heritage. And, it continues to drive
our work. Today, 65,000 Abbott employees around the world share
the passion for “Turning Science into Caring.” It’s a commitment to
focusing on what matters most: life and the potential it holds when
we are feeling our best.
2
Stand No. 89
We offer clients the opportunity to view first hand our machines
and the extensive design and manufacturing facilities employed.
We offer facilities to carry out confidential formulation or recipe
development, as well as scale up work and operator training. Our
display and training facility has helped scores of potential users get
a first hand look at the end products and finalizing on their own
project/process critical requirements.
We operate a comprehensive QA system with documentation
compliant with FDA requirements and offer tailor made solutions
for Customers; adaptable control concepts for different levels of
automation and constant innovation make us a key player in the
processing machinery industry.
Machinery is always designed and fabricated from an End User’s
perspective and has resulted in close relationships with our
customers. This Customer Focus is a tradition at Adam Fabriwerk
and a result of the Founder’s long experience of operating pharma
machinery over a substantial time period.
1.
Fully Automated Cleaning In Place (CIP) Module for Wockhardt
– Research Centre, Aurangabad for Vaccines.
2.
Blending Vessel with Magnetic Mixer for Wockhardt Aurangabad for Vaccines.
3.
Built in Raking System for Fluid Bed Dryer for Vikram Sarabai
Space Centre- Allepy for drying of Solid Rocket Fuel.
EXECUTED PROJECTS:
1.
Fully Automated SCADA based State of the Art processing plant
for Johnson and Johnson at Baddi.
2.
State of the Art Blending vessels with CIP/SIP Modules for
Serum Institute of India for Vaccines and Biological Products.
3.
Blending Vessels for Reliance Lifesciences for Plasma
Fractionation Project.
4.
Processing Vessels with CIP and SIP modules for Dabur Pharma
- Oncology Project at Baddi.
EXPORT FOCUS:
Adam Fabriwerk also actively operates in International markets and
has supplied equipment to the European Union, the UK and UAE.
All bioprocessing equipment is designed in accordance with ASME
BPE and EHEDG norms, with World Class bought outs supporting
the processing machinery.
We operate in regulated markets with CE Marking and are represented
in the U.K. and Ireland.
Our clients include Astra Zeneca, Biological E, Cipla, Glaxo
SmithKline, Johnson & Johnson, Sanofi Aventis, Pfizer, Ranbaxy,
Serum Institute of India, Shantha Biotechnics and Wockhardt to
name a few.
Adam Fabriwerk was founded by Mr. Waman Wagh and Mr.Devidas
Shirude, industry stalwarts with experience spanning 15 years
of active process engineering and finance in the Pharmaceutical
sector with Laboratories Grimault, Warner Hindustan and the allied
machinery sector.
Our diverse product portfolio includes
Blending vessels with magnetic mixers, Digestion vessels, Buffer/
Storage vessels, cleaning in Place (CIP) modules for vessels, CIP
modules for lyophilizers and Sterilization in Place (SIP) modules for
the Biopharmaceutical industry.
Exhibitors Profile
INDUSTRY FIRSTS
Our range of Pharmaceutical machinery includes Ointment
Processing Systems, Liquid Oral Processing Systems, and Processing
Vessels for Sterile Applications, Cleaning in Place (CIP) modules and
Sterilization In Place (SIP) modules.
We also manufacture Creams/Gel/Cold Creams/Lotions/Shampoo/
Toothpaste Processing Systems and Cleaning In Place (CIP) modules
for the Cosmetics industry.
Stand No. 67
D U P H A T 2009
www.duphat.ae
3
Ajman University of Science & Technology Network
Stand No. 36
Nowadays, more than ever, nations need universities with a
Comprehensive vision, which reflects their ambitions for progress
and modernity and preserves their culture, traditions and identity.
In effect, globalization and information technologies are imposing
today the uniform model of a new information society where cultural
diversity and humanity heritage, is disappearing.
Ajman University of Science and Technology Network, is an
institution promoting a new active role of education in the society.
Exhibitors Profile
It is eclectic (i.e selective) in the adoption of positive aspects of
modernity. It considers the teaching, research, training, expertise
and practice are activities which must continuously evolve and
which require an adequate environment for innovation. In fact, this
comprehensive environment which leads to creativity and favors
emergence of poles of excellence supposes also an ideal infrastructure
with adequate communication and interaction.
Al Hesn Private School
Stand No. 218
Al Hayat Pharmaceuticals
Stand No. 154, 155, 156, 177, 178 & 179
Established in 1982 as a pharmaceutical and medical company,
today, Al Hayat Pharmaceuticals is a leading organization in the
UAE with branches in Dubai, Abu Dhabi, Sharjah & Ras Al Khaimah,
representing leading international firms in medical, dental,
laboratory equipments and supplies. Also, execution of hospital
turn key projects. Al Hayat Pharmaceuticals is dedicated to quality
and services.
Al Hikma FZ Co.
Stand No. 66
Al Hikma FZCO specialized in the field of importing, exporting,
distributing and promoting pharmaceuticals, and medical health
care devices, hospital supplies and whatever related to medical fields
in the Middle East Countries by a highly qualified professional staff
of more than 52 employees which consists of either pharmacists or
doctors with a marketing and business management background.
Holding a trade license from Jebel Ali Free Zone in 2005 and based
in the heart of Dubai enabling it to launch the business relatively
with all over parts of the world.
We have an excellent history record in dealing (supplying and
consulting) with both private and government sectors supplying:
4
•
Finished pharmaceutical products
•
Dietary Supplement from the primier companies in Canada and
USA.
•
Medical supplies including disposable lines like syringe, cloves,
canula and so
•
Raw material used in pharmaceutical products manufacturing
•
Laboratory Equipments including a highly sophisticated
laboratories.
•
Pharmaceutical, disposables and I.V Fluid Factories according to
International GMP standards.
•
Hospital including CCU and ICU units
•
Chemical Reagent for an international dependable sources
•
Biochemical Kits used in bioclinical tests
•
Health Food (such as palm oil and anti-hypertension salt)
Al Hikma markets its products in world through the following list
of distributor: UAE (Al Shafar Group), Iraq (Al Yakeen Company),
Kuwait (All Medical Company), Yemen (Magnico for Trading &
Agencies), Iran (Persia Aras Co.), Syria (Sante Naturelle Drugstore),
Canada (Satiscon Marketing Inc.), London (T.K. Impex Limited),
Libya (Albonyan Company), Sudan (Girshab Group of Pharmacies)
and we are aiming to target the rest of the market of other GCC
Countries, Egypt, Tunisia,Germany and all over parts of the world.
The companies and brands Al Hikma represents:
1) Adrien Gagnon
- Canada
2) Pharma Science
- Canada
3) Interactive Nutrition
- Canada
4) Vacumed
- Canada
5)
Vacumed
- USA
6
21st Century
- USA
7)
Labsco
- Germany
8)
Optika
- Italy
9)
Amdipharm
- UK
10) Biotech
- Korea
11) Jee Sung Corp. for Disposable
& I.V. Fluid Factory Supply
- Korea
12) Ibin Sinna
- Syria
13) Unichema
- Syria
14) Dam Pharm
- Syria
15) Medpharma
- UAE
16) Canu Soft
- Canada
17) SK + F
- Bangladesh
18) Keepharma
- India
Al Ittihad Drug Store
Stand No. 55
IDS (Al Ittihad Drug Store) is a leading supplier & distributor in the
UAE representing a range of premium high quality and international
health care products in:
1. Pharmaceuticals; reps for GSK (Beecham), Sanofi-Aventis,
Bayer Healthcare & UPM
2. Industrial Hygiene; reps for Henkel / Ecolab, Kitchen Master
& Hypros
3. Consumer Healthcare:
• Infant milk powder - Neolac
• Oral Hygiene - Pierrot
Al Ittihad Private School
Alcon Pharmaceuticals
Stand No. 19
Stand No. 15
Stand No. 186
Aims to provide innovative and excellent quality product for your
eye care need. Alcon Pharmaceuticals is passionate about advancing
the preservation, restoration and enhancement of sight around the
world.
Al Razi Pharmacy Company
Alcon Pharmaceuticals strive for excellence in developing and
manufacturing differentiated products to improve vision and eye
health.
Stand No. 16
Under the name of AL- Shorouq Private Nursery, this school was
opened in 1986 - 1976 for Kg 1+2.
After achieving success with the nursery level and with parents’
support, the decision was taken to add basic primary levels in
1991 - 1992. Since then it came to be known as “Al shorouq Private
School”.
The people in charge had their determination for better education
under new philosophy and development which reflected the positive
vision towards brilliant future for the students, by adding the two
levels: preparatory and secondary in 1998.
“School Curriculum”
After intensive study, a decision was taken to adopt the curriculum of
the ministry of education as the most effective and comprehensive
one. The school has efficient supervision upon the students’ abilities
and their feed back productivity.
“Administrative and Teaching Staff”
The school mission works according to the new developed educational
methods. This field is supervised by a group of qualified supervisors
who are dedicated and sincerely committed to the profession of
teaching.
“School premises”
The school started as a rented villa. Due to the increasing numbers
of the students and the new levels, it was decided to build a new
modern building.
The new building consists of:
1
2
3
4
Administrative section for the principal and the
administrative staff.
Kinder garden section, and its teaching staff.
Girls section which contains:
a- Low Primary stage.
b- Advanced primary, preparatory and secondary Levels.
Boys section contains the grades from (5 to 12)
“Facilities”
The school has laboratories and computer sections, supplied with the
modern apparatuses to enable students to be familiar with science
and knowledge.
The school library meets the student’s needs.
The school auditorium Provides activities by the talented students.
Sport activities as football , basketball and volleyball are available.
Transportation : a large fleet of air conditioned coaches provides
transportation for the students and some teachers.
Alcon Pharmaceuticals operates with integrity respect and
commitment making us the first choice of eye care products and the
most trusted eye care in the world.
Exhibitors Profile
Al Shorouq School
Amgen
Stand No: 107,108, 121 & 122
Amgen is a leading human therapeutics company in the biotechnology
industry. For more than 25 years, the company has tapped the
power of scientific discovery and innovation to advance the practice
of medicine.
Amgen pioneered the development of novel products based on
advances in recombinant DNA and molecular biology and launched
the biotechnology industry’s first blockbuster medicines. Today, as a
Fortune 500 company serving millions of patients, Amgen continues
to be an entrepreneurial, science-driven enterprise dedicated to
helping people fight serious illness
Apteka Moscow 2009
Stand No. 163
Apteka Moscow is Russia’s leading international trade fair for
pharmaceuticals and related products as well as for all products
and services offered to and by pharmacies, laboratories and medical
practices. Started in 1993 it has grown into the most important event
for the exchange and marketing of new technology, developments,
and trends within an industry which is boosted by an annual growth
of over 15% in the past years. Together with a highly informative
Assembly on new medical technologies, Apteka is a must for anyone
interested in this market.
Arabian Health Care Supply Co.
Stand No. 174
Arabian Health Care Supply Company (AHCSC), founded in Riyadh
in 1979, occupies a leading position in the Saudi medical business
market as a distributor of a wide array of medical and pharmaceutical
products. These include robotic systems, pharmacy automation
systems, renal equipment, capital equipment, implantable
prostheses, medical disposables and critical care products used in
CCUs and operating rooms.
AHCSC handles products from many of the biggest names in the
industry, including Baxter, Edwards Lifesciences, Kimberly-Clark,
Cardinal Health (Pyxis), Orthofix, Mediflex, Script Pro, JVM, Health
Robotics and Orion Health. The company has offices in major cities
throughout the Kingdom of Saudi Arabia, offering full geographical
D U P H A T 2009
www.duphat.ae
5
coverage.
Stand No. 40
To ensure that patients receive the best possible service, AHCSC
provides educational and training programs for both doctors and
nurses. With a team of 90 skilled and dedicated professionals
supplementing its strategic alliances, AHCSC is committed to setting
the highest standard for customer service, value and product quality
for the people of Saudi Arabia.
Arno-Knof Pharma GmbH
Stand No. 162
Ginger candies combine fresh ginger with a little sweetness to
provide an extremely exotic but also exhilarating taste experience.
Exhibitors Profile
But it’s not just ginger’s characteristically light tangy taste which
explains its triumphant progress in the world. Its prominent role in
Asian medicine too makes it not just a healthy food but, at the same
time, a natural and effective remedy against headaches, stomach
pains or travel sickness for example.
The ginger candies are composed of pure ginger, sugar cane and
natural starch, which contain no gluten. The complete absence of
additives makes the candies especially highly-prized and healthy
sweets.
At the moment there are five types of Original Ginger Candies:
Classic and with Peanut-, Peppermint-, Orange- or Mango-taste. The
Candies are offered in 60g boxes each containing 14 pieces. 12 boxes
per inner display carton, 20 inner cartons per export carton.
We are looking for distribution partners / importers in Middle East
Astellas Europe B. V
Launched in April 2005, Astellas was formed by the historical
merger of Japan’s third and fifth largest pharmaceutical companies
– Yamanouchi, founded in 1923, and Fujisawa, founded in 1894.
Both companies possessed similarities where it matters mostphilosophy and vision. But the companies also differed where it
matters most-areas of therapeutic concentration and expertise.
Yamanouchi brought a record of developing blockbuster drugs, a
pipeline full of promising new compounds like Fujisawa, a sales and
marketing culture of deeply grounded, data-driven expertise.
Fujisawa brought dominance in transplantation, a soaring reputation
for in-depth understanding of the disease stales and treatments
within its market nichs and a track record for developing high-profile,
market-leading products that become new standards of care.
Baxa Ltd
Stand No.192
Baxa is a customer-focused medical device company that provides
innovative, solution-based technology for fluid handling and
delivery products that promote patient safety. For more than 30
years, Baxa has developed pharmacy and nursing products for safe
and efficient medication preparation, packaging and administration.
Its Exacta-Mix™ and MicroMacro™ Automated Compounders safely
mix parenteral nutrition solutions for home and hospital use.
Automated Filling Systems such as the Repeater™ Pump and RapidFill™ ASF provide accurate fluid transfer and syringe filling. Other
key products include the Exacta-Med® Oral Dispensers, ZR® Prefilled
Saline Flush Syringes and CyTwo-FerTM Needle. Baxa Corporation
is based in Denver, CO.
Stand No: 167
6
Stand No. 209, 210, 227 & 228
D U P H A T 2009
www.duphat.ae
7
process of getting registration in Philippines, Yemen, Bhutan,
Tanzania, Nigeria, Ivory Coast, Ghana, Liberia, Senegal and Benin
Baxter
Stand No. 160
Bayer Healthcare
Stand No. 58
Biopharma has taken an extension plan to set up TG, UKMGRA
and FDA approved facilities, API (Active Pharmaceutical Ingredient)
Industry and also going to introduce Natural Products with
Innovative Formulation.
Biotech Pharma / Medac GmbH
Beijing Canluso Tech. Co., Ltd
Stand No. 159
Stand No. 114
Exhibitors Profile
Beijing Canluso (Expo) Connetcs Chinese Manufacturers with
the world leading professional exhibitions.We are an agent of
international exhibitions,conferences, congresses, seminars,
meetings,etc.
We organize Chinese companies to participate overseas exhibitions
and to tap the potential markets. Our vision is to be recognized and
respected as one of the premier international exhibition organizer
in China.Our mission is to bring our customers adding value and
unlimited growth space with our one-stop services in delivering and
organizing international exhibitions.
We are a reliable and efficient partner of many international
exhibitions.We expect to introduce more professional and influential
exhibitions to our clients.
Bin Sina Pharmacy
Stand No. 5
•
BinSina Pharmacy Chain, is one of the largest group of
Pharmacies in U.A.E.
•
BinSina’s passionate pursuit of value-added services we intent
to develop a Pharmacy Management System and Labeling
System for pharmacy medicines and online insurance billings.
•
The pharmacies are modern, well-equipped outlets.
•
Resident pharmacists speak Arabic, English, and are readily
available to offer medical support to customers.
•
We are available in a number of U.A.E locations; some of our
branches operate 24 hours.
Biopharma Laboratories Limited
Stand No. 111
BIOPHARMA was established in the year of 1973 as limited
company. It sailed its new journey in 1999 with the involvement of a
group of physicians with innovative mission and global conception.
Biopharma is now manufacturing more than 150 products including
life saving drugs at affordable price and committed to serving the
need of ailing community with products of excellent quality, safety
and efficacy complying the guideline of WHO cGMP and Quality
Management System.
Biopharma has gained a leading edge in many important therapeutic
groups including Antibiotics, Antiulcerants, and Laxative,
Bronchodilator, NSAIDs, Vitamins & minerals, Cardiovascular and
Dermatological products.
Biopharma is now exporting its products to Kenya, Sri Lanka,
Myanmar, Vietnam and Afghanistan. Biopharma is also in the
8
Biotech Pharma Services
Biotech Pharma Services is a pharmaceutical and medical equipment
company, established 2007 in UAE, with the intention to provide
support and services to the health care divisions in UAE and the Gulf
region, our main focus is the advanced and modern technologies and
sciences in the field of pharmacy in the world, like Biotechnology,
Nanotechnology and Heath Robotic pharmacy workflow systems,
and we are committed to the provision of the highest quality of
health and medical services for our customers in UAE and the Gulf
region
we are the agent of the following companies:
Medac GmbH: one of the leading manufacturers of Oncology &
Hematology Products in Germany & in International Markets.
Medac offers new & well proven therapeutic options in the field of
Urology, Autoimmune disease & Fibrinolysis.
Health Robotics: the global leading supplier in the automation of
life-critical intra-venous patient-specific medication preparation,
compounding, and dispensing, providing health care facilities
around the world with robotics and software automation solutions
CytoCare™ and IV Station™.
Biotest
Stand No. 180 & 181
Biotest manufactures preparations derived from human blood
plasma using state-of-the-art biotechnological processes. The
preparations are used as immunotherapeutic agents in cases of
antibody deficiency or in autoimmune diseases, in severe bacterial
infections, in transplantation medicine and in the treatment of
coagulation disorders.
Plasma is obtained, processed and virus-inactivated in accordance with
international standards. These guarantee the excellent quality and
safety of our preparations. Biotest manufactures preparations derived
from human blood plasma using state-of-the-art biotechnological
processes. The preparations are used as immunotherapeutic agents
in cases of antibody deficiency or in autoimmune diseases, in
severe bacterial infections, in transplantation medicine and in the
treatment of coagulation disorders.
Plasma is obtained, processed and virus-inactivated in accordance
with international standards. These guarantee the excellent quality
and safety of our preparations.
Immunoglobulins: Intratect, Intraglobin F, Pentaglobin, Cytotect
CP, Varitect CP, Hepatect.
Coagluation Factors: Factor VIII SDH
Protein Solutions: Biseko, Human Albumin
City Pharmacy Co. / Sebamed pH 5.5
Stand No. 229, 230 & 231
Stand No. 56
Boehringer Ingelheim was founded in 1885 in Ingelheim near Mainz,
Germany. Our business consists largely of Prescription Medicine,
Consumer Health Care, Biopharmaceuticals and Animal Health.
We focus on the production of innovative drugs and treatment that
represent major therapeutic advances. Our products have long been
highly successful in the treatment of respiratory, cardiovascular,
central nervous system, urological and virological disorders. We have
research facilities in nine countries and production plants in more
than 20. Our pharmaceuticals research and development spending
corresponds to about 18% of net sales in Prescription Medicines.
Excellence in innovation and technology guides our action in all
areas.
CITY PHARMACY CO is always setting the standards and as such it
was the First Medical & Pharmaceutical Company got registered with
the UAE Ministry of Health (1967), first in its field to get the ISO
9001 accreditation (1998) and currently having the Environmental
Standard accreditation (ISO 14001:1996) in year 2004. The sky is
the limit and the company is still aiming for what is best for the UAE
medical field.
Bormioli Rocco Figlio – Italy
Stand No. 118
Bormioli Rocco from ITALY, tradition of quality since 1825, shows
its glass proposals for the world of health, it is one of the few realities
capable of offering type I glass, chemically more stable, as well as
glass type II and III, made according to specifications imposed by
the international pharmacopoeia. The range: vials and containers for
antibiotics, drops, tablets, syrups, infusions and aerosols.
The facilities and products are accredited according to BS EN ISO
9001: 2000 standards and approved by F.D.A. (U.S. Federal Drug
Administration – D.M.F. no. 14003), T.P.P. and Chinese S.D.A.
Cava Pharma Inc.
Stand No. 84
Çava Pharma Inc. is a wholly owned Canadian company based
in Kirkland, Quebec specializing in neutraceuticals, weight loss
and sports nutrition products. We produce and export a variety
of natural health food supplements for adults and children at our
Health Canada approved cGMP facilities. Our flagship products are
the 12 hour Time Released Glucosamine, Children Gummy Bear
multivitamins, Hoodia, Shark Cartilage and Prenatal multivitamins.
We are currently seeking agents and distributors throughout Middle
East and Asia.
Cerebral Lifesciences
Stand No. 193
Cerebral Lifesciences (CLS) is a global medico-marketing service
provider headquartered at Manipal Center, Bangalore - the silicon
valley of India. Managed by a team of distinguished medical
professionals having versatile domain expertise and collective
experience of over half a century, CLS provides comprehensive
Medico-marketing, Scientific content and Training services to
Pharmaceutical and Biopharma industry. With unsurpassed
expertise in 2D and 3D medical animations, virtual perception and
medical infotainment, CLS offers an assortment of Electronic and
Print deliverables customized to scientific and marketing requisition.
CLS envisages being trend setter in medico-marketing, establishing
eminent and innovative benchmarks around the globe.
Following a simple philosophy of strictly adhering to the highest
ethical standards CITY PHARMACY Co., working hands-in-hand
with its Principal Companies for the benefit of the UAE community.
Exhibitors Profile
Boehringer Ingelheim
Being a 100% local establishment and sole distributors for leading
Principal Companies [in the Pharmaceutical, Medical, Laboratory,
Medical Disposables, Dental and Consumer], we took it as our
mission to upgrade these fields and to provide services according to
the latest International Standards.
Our Network covering all UAE, having Head Office in Abu Dhabi
and Branches in Dubai, Sharjah and Al Ain. Our state-of-art Central
Stores in Abu Dhabi, Dubai and Al Ain are equipped to fulfill the
minute-to-minute requirements of Private & Institutional sectors.
Our Showrooms are on prime locations in different emirates of the
UAE market.
Dawnrays
Stand No. 85
As the leading manufacturer of pharmaceutical intermediates, API
and formulations in China, Dawnrays is manufacturing Ceftriaxone
Sodium, Cefotaxime Sodium, Cefoperazone Sodium, Sulbactam
Sodium, Cefepime Hydrochloride, Amlodipine Besylate, Cetirizine
Hydrochloride, etc.
Dereak for Medical & Pharmaceutical Consultations
Stand No. 194
Dereak is a world-class professional and specialized medical and
pharmaceutical consultation in Saudi Arabia and Bahrain which
offers a full range of healthcare services.
We provide distinguished solutions based on our scientific
experiences, in-depth understanding of research technology,
consultation, data collection and healthcare information technology
for a wide range of medical and pharmaceutical problems which
might encounter clients who tend to be decision makers.
Dr. Wild & Co. Ltd
Stand No. 154, 155, 156, 177, 178 & 179
Dr. Wild & Co. Ltd. was founded in 1932 by Dr. Samuel Wild and
Werner Wild as an independent and self-supporting company in
Switzerland.
The first products to appear on the market were the EMOFORM
® medicated toothpaste, which are famous today in more than 50
countries worldwide.
D U P H A T 2009
www.duphat.ae
9
Stand No. 128, 129, 151, 152 & 153
Exhibitors Profile
Bristol-Myers Squibb is a global biopharmaceutical
company whose mission is to extend and enhance
human life. Bristol-Myers Squibb's 41,000 employees
are dedicated to discovering, developing and providing
innovative medicines that address significant unmet
medical needs of patients worldwide. By living our
mission and building our company for well over a
century, we are also making a difference in the lives of
our shareholders, employees and neighbors.
10
Recently Dr. Wild’s dental research department succeeded in
stablising the efficacious and clinically well-documented stannous –
II-fluoride for treating sensitive toothnecks, irritated gums and as
prophylaxis of enamel and dentine caries.
Dubai International School is fully accredited by the Ministry
of Education in the U.A.E. under permit No. 218. It is a privately
owned and self-supporting institute that is administrated by a Board
of Directors.
Languages
Stand No. 50-52 & 73-75
The Dubai Health Authority (DHA) was created in June 2007, by Law
issued by His Highness Sheikh Mohammad Bin Rashid Al Maktoum,
UAE Prime Minister and Vice President, and Ruler of Dubai.
The DHA is empowered to set policy and strategy for health, and
to assure the application of that health policy and strategy. His
Excellency Qadhi Saeed Al Murooshid is the Director General of the
Dubai Health Authority (DHA).
The DHA leads an integrated approach across the spectrum of
health, anticipating our future needs and being responsive to the
people using health services.
The new Dubai Health Authority (DHA) structure will ensure that
health services are better positioned to meet the demand for better
healthcare services in the future. The DHA implementation will be
undertaken in phases and will take around four years to complete
ending in 2012.
The DHA will stimulate growth and innovation in the health
market and ensure the quality of health services through effective
regulation.
The DHA will work to:
Provide a Health Strategy for Dubai that will meet the needs of the
predicted growth and change in population.
Ensure Public Health is protected and quality of life improved.
Ensure partnership between public and private health service
providers, bringing together the best international experience to
ensure we deliver the best health system possible.
Achieve international accreditation of healthcare services delivered
across the Emirate by ensuring world-class quality and standards of
healthcare.
Ensure effective regulation and licensing across the Dubai Health
Sector guaranteeing the quality of health services provided.
Increase the transparency and accountability of the healthcare
system.
Drive efficiency so that funding is spent on the most effective
healthcare for those who need it.
Improve accessibility to the healthcare system and sustainability for
the future.
Deliver the best training and education opportunities for Dubai
healthcare practitioners.
D.I.S. is a bilingual school, where English is the medium of instruction
in all classes for all subjects except for those prescribed by the
Ministry of Education- i.e. Arabic Language, Islamic Studies, and
Social Studies are taught in Arabic. An emphasis is also placed on the
teaching of the French Language which starts at the Kindergarten
stage.
School Stages
The school divides its programs into three main stages:
Exhibitors Profile
Dubai Health Authority
Kindergarten: a two-year program (KG I and KG II).
Elementary: a six-year program (Grade 1 through Grade 6).
Intermediate: a three-year program (Grade 7 through Grade 9).
Secondary: a three-year program (Grade 10 through Grade 12).
Programs:
The school’s programs are designed to meet the philosophy and
objectives of the school, and they are continuously modified
accordingly. Highly-qualified and experienced Heads of departments
follow the implementation of each program in each department.
The following subjects are offered in the stages mentioned earlier:
Grades 1-3:
Arabic Language, Islamic Education, English Language, French
Language, Mathematics, General Sciences, and Computer Science.
Grades 4-9:
Arabic Language, Islamic Education, English Language, Mathematics,
General Sciences, and Social Sciences. Students at this level will
choose either to take French or Computer Science.
Grades 10-12:
At this level students are to choose depending on their future plans
and interests between the Scientific or the Commercial Stream.
In the Scientific stream students study: Arabic Language, Islamic
Education, English Language, Mathematics, Physics, Chemistry, and
Biology.
In the Commercial stream students study: Arabic Language, Islamic
Education, English Language, Mathematics, Business Studies,
Economics, and Computer Science.
In addition, students are prepared for and are ready to take the
American Examinations, SAT and TOEFL, by the end of grade
11. In grade 12 they will have the chance to sit for the SAT II
examinations.I
Dubai National School
Stand No 21
Dubai International school
Stand No. 22
Dubai International School was founded in 1985. The school
is located in the heart of Dubai and situated in Al Garhood area.
Together with its branch in Bur-Dubai (Nud Al-Shiba area) the
school is suitable to serve the most populated areas in Dubai and the
Northern Emirates.
Academic excellence, as well as the physical, moral and spiritual
development of every student are our main concern.
Provide suitable learning environment and facilities to help students
discover and develop their capabilities.
Provide appropriate and updated educational programs to prepare
students for their further education.
Provide proper educational materials and programs to enable
D U P H A T 2009
www.duphat.ae
11
Muslim students maintain their Islamic values and practices such
as patriotism, faithfulness, honesty, forgiveness, respect for all,
tolerance and the love to assist the needy.
Encourage students to care for their social, mental and physical
health.
As our products save and improve lives, they also save overall health
care costs: they are often less expensive than other forms of health
care, such as surgery and hospitalization.
Elis Pharmaceuticals Ltd
Help students appreciate and preserve their country’s natural
resources and environment.
Provide all staff members with opportunities such as seminars,
workshops and lectures to enrich and develop their capabilities in
technology, education and other aspects.
Exhibitors Profile
Stand No. 37
Allied health professionals of outstanding quality are vital for holistic
healthcare . With this in view Dubai Pharmacy College was established
in 1992 by the astute vision of Founder and Chairman , Haji Saeed
Al Lootah to produce successful, competent pharmacists.
The first Pharmacy College in the Gulf region exclusively dedicated
to educate aspiring Muslim girls in the field of pharmacy sciences, is
accredited by Ministry of Higher Education and Scientific Research to
award Degree in Bachelor of Pharmacy. It offers a four year BPharm
program. Today, DPC graduates play an important role as a vital link
between physicians and patients, and as scientists influencing the
development of pharmaceuticals.
Stand No 173
Ebewe is a leading Austrian pharmaceutical comany, internationally
active, Specialized in technologies and applications in the fields of
oncology, immunology and contract manufacturing. We offer one
of the widest product lines in the Oncology. To maintain the high
EBEWE standard, our offer is complemented by:
•
innovative solutions (such as our Onko-Safe) for dealing safely
with cytotoxics.
•
numerous services such as international symposia, patient
information or psycho-oncology.
Ebewe is a globally recognized and specialized contract manufacturer
of parenteral cytotoxics, narcotics and vaccinations, as well as
biological and conventional preparations.
More than 20 major international pharmaceutical companies trust
in our expertise.
Eli Lilly (Suisse) S.A.
Stand No. 53, 54, 71 & 72
Eli Lilly and Company, is a leading innovation-driven pharmaceutical
corporation. We are developing a growing portfolio of best-in-class--often first-in-class pharmaceutical products by applying the latest
research from our own worldwide laboratories, by collaborating with
eminent scientific organizations, by making use of the most up-todate technological tools, and by providing exceptional service to our
customer.
Through these internal programs and external initiatives, we’re
seeking answers for some of the world’s most urgent medical needs.
Operates as a generic pharmaceutical company worldwide. It develops,
manufactures, markets generic, and human pharmaceuticals, active
pharmaceutical ingredients, diagnostics test kits, medical disposable
products, laboratory equipments & glassware, surgical instruments,
hospital supplies, pharmaceutical test apparatus and equipments,
ointments & creams manufacturing process equipments.
The company offers generic pharmaceutical products in various
dosage forms, including tablets, capsules, ointments, creams,
liquids, and injectable. The company manufactures and distributes
more than 300 pharmaceutical products globally.
The company serves drug wholesalers; generic distributors; hospitals
and affiliated organizations worldwide; managed care institutions;
and others, governmental institutions.
Expopharm 2009
Stand 170 & 171
EXPOPHARM – International Pharmaceutical Trade Fair
The most important and largest pharmaceutical trade fair in
Europe.
Ebewe Pharma Ges.m.b.H Nfg.KG
12
Stand No 34 & 35
With exhibitors and visitors from around the world.
Main topics:
Medicines/pharmaceutical products; services; laboratory, practise;
Bandages & dressings, medical aids; personal hygiene products,
Cosmetics; nutrition, hygiene; fixtures & fittings/furnishings &
Equipment for pharmacies; software/hardware; comprehensive,
Free of charge seminar programme (in German language).
Service Facilities:
International Meeting-Point; Internet-Lounges; Free kindergarten.
Facts and figures:
EXPOPHARM 2008 in Munich
Exhibitor’s total:
507
From Germany:
433
Foreign:
64 from 24 Countries
Total Area:
24.057 m²
Visitor’s total:
24.961
From Germany:
22.448
Foreign:
2.513
From pharmacies: 16.746
Pharmacists
50 %
Fater S.p.A
Stand No. 188
Fater is an italian company with headquarter and plant to Pescara
that this year complete 50 years of business.
The company is a joint venture between P&G an the pharma company
Angelini and the turnover is 750 million of euro producing diapers
for children, pads, liners, tampons and diapers for adult.
Our interest towards the market is face to commercialization of the
products for incontinence.
Ganzoni & Cie Ag
Stand No. 154, 155, 156, 177, 178 & 179
The incontince is a social disease that it hits, according to data
OCSE 3% of the world wide population and is therefore a disease
with upgrades them social impact if not supported with suitable
products.
Ganzoni is Swiss Company Established in 1896, Ganzoni is
considered as a world wide market leader for the treatment of varicose
veins. Ganzoni owns its brand name sigvaris compression stockings
with different medical compression degree. It is characterized by
durability comfortable & skin breath.
Our company searches for the Middle East a distributor who can
support in the commercialization and lauch to us of ns the range of
products for incontinence.
Genzyme
Stand No. 204
Stand No. 38
Ferring produces pharmaceuticals in specific areas that enable
doctors to treat patients on the body’s own terms.
We are speciality, research-driven biopharmaceutical company that
identifies, develops and markets innovative products in the fields of
urology,Gynaecoloy, gastroenterology and endocrinology.
Ferring Pharmaceuticals was one of the first in the world to produce
synthetic peptides on a commercial scale. Today, our expertise and
technologies in these compounds make us a key player in the field of
peptide and protein chemistry.
Ferring began in Europe but today, we operate globally. We employ
about 20,000 people in some 40 countries. Ferring invests heavily
in research and development to ensure a future flow of new and
innovative products. We are currently working on some major R&D
projects, which will complement Ferring’s existing portfolio, and
add a new generation of products to some of our most medically
successful and profitable speciality brands.
We will consolidate Ferring Pharmaceuticals’ position and strengthen
our international image by further exploiting our acquired skills
and technologies. If necessary, we will pursue these objectives in
partnership with other companies.
Forest Laboratories UK LTD.
Stand No. 154, 155, 156, 177, 178 & 179
One of the world’s foremost biotechnology companies, Genzyme is
dedicated to making a major positive impact on the lives of people
with serious diseases. Founded in Boston in 1981, Genzyme has
grown from a small start-up to a diversified enterprise with annual
revenues exceeding $3 billion and 10,000 employees in locations
spanning the globe.
With many established products and services helping patients in
nearly 90 countries, Genzyme is a leader in the effort to develop
and apply the most advanced technologies in the life sciences. The
company’s products and services are focused on rare inherited
disorders, kidney disease, orthopaedics, transplant, cancer, and
diagnostic testing. Genzyme’s commitment to innovation continues
today with a substantial research and development program focused
on these fields, as well as immune disease, infectious disease, and
other areas of unmet medical need.
Globalpharma
Stand No. 1 & 2
Globalpharma is a joint venture and an important subsidiary of
Dubai Investments PJSC, the largest investment company listed on
the UAE stock exchange employing 42,000 staff in its 43 entities.
Globalpharma is the first Dubai based pharmaceutical company
with stat of the art world class 2 separate manufacturing plants
respectively dedicated for production of penicillin and general
pharma products is under stringent cGMP and Quality assurance
controls as per international guidelines by FDA-USA and MHRAUK.
Forest Laboratories UK Ltd (Pharmax Ltd.) has been established
since 1938 as an ethical and research pharmaceutical manufacturer
in the UK known for its research product sustained release GTN such
as Sustac Enema range such as steroid enema prefoam/ predenema
child health care products such as infacol & vasogen and the well
known antacid mucogel.
Currently Global pharma is manufacturing over 50 products in
diverse range including Antibiotics, Anti-ulcerants, Analgesics,
NSAIDs, Food supplements, Vitamins, Anti-diabetics, Respiratory
and Cardiovascular products in Tablet, capsules, dry powder susp
and syrup dosage forms
Fresenius Kabi
Globalpharma is currently marketing its products in more than 20
countries including GCC, Middle East, Asian and African markets
through its net work of exclusive agents and dedicated sales force in
most of the countries.
Stand No. 205
Exhibitors Profile
Ferring Pharmaceuticals
Fresenius Kabi Germany is one of the leading companies in the field
of infusion therapy, clinical nutrition and Transfusion Technology
D U P H A T 2009
www.duphat.ae
13
Exhibitors Profile
G-Pharm Machinery Co., Ltd.
Grunenthal
Stand No. 166
Stand No. 196
G-PHARM Machinery Co., Ltd has a professional, experienced and
responsible staff team qualified in manufacturing of pharmaceutical
machinery as well as international trading affairs in China. With
rich experiences gained over the last 30 years, the company has
established mutual beneficial business relationship with customers
of over 50 countries and regions in the world. In order to develop
our international markets, the company participates, every year, in
Canton Fair and around 15 international well-known exhibitions.
Our project and product covers air clean & condition system-clean
room, solid dosage production, extruder, granulator & coater, rotary
tablet press, capsule filling, ampoule linked production line, syrup
production line, eye drop liquid filling, oral liquid filling, biotic
powder, liquid, granulator packing machines
Grünenthal GmbH is an independent, research-based and global
pharmaceutical company, specializing in the field of pain therapy,
contraception and innovative formulations for established active
substances.
Glaxosmithkline
Gulf Inject has been promoted by AGCC nationals to provide world
class I.V. Fluids manufactured locally in technical collaboration with
Fresenius AG, Germany.
Stand No. 79, 80, 97, 98
GSK’s mission is to improve the quality of human life by enabling
people to do more, feel better and live longer.
GSK produces medicines that treat six major disease areas:
-
Asthma
-
Virus control
-
Infections
-
Mental health
-
Diabetes
-
Digestive conditions.
In addition, we are a leader in the important area of vaccines and are
developing new treatments for cancer
GSK supplies one quarter of the world’s vaccines and by the end of
2005 we had 25 vaccines in clinical development
GSK is a research-based pharmaceutical company every hour GSK
spends more than £300,000 (US$562,000) to find new medicines;
with over 15,000 people work in research teams to discover new
medicines, they screen about 65 million compounds every year in
search for new medicines
GSK is the only pharmaceutical company to tackle the World Health
Organization’s three ‘priority’ diseases – HIV/AIDS, tuberculosis
and malaria.
Headquartered in the UK and with operations based in the US, GSK
is one of the industry leaders, with an estimated seven per cent of
the world’s pharmaceutical market.
GSK’s business employs over 100,000 people in 116 countries, makes
almost four billion packs of medicines and healthcare products every
year
14
The development and marketing of innovative formulations for
established active substances are aspects on which we particularly
focus. The company, founded in 1946, markets its products in
approx. 100 countries; in addition Grünenthal is internationally
active with seven production sites and companies in 29 countries.
Gulf Inject
Stand No. 61
Gulf Inject manufactures I.V. Fluids using the "Form-Fill-Seal"
Technology - which is accepted world wide as the safest and most
aseptic technology to manufacture I.V. Fluids.
The manufacturing facilities of Gulf Inject conform to the US Federal
Standards 209 E.
Hamdan Bin Mohammed e-University
Stand No. 59
Hamdan Bin Mohammed e-University the first e-University in the
UAE, was officially inaugurated in February 2009. It is the natural
inheritor and successor of the e-TQM College which was initially
inaugurated on September 30th 2002 by the visionary leader Sheikh
Mohammed Bin Rashid Al Maktoum, Vice President, Prime Minister
of the UAE and Ruler of Dubai, to be a unique and pioneering
e-learning institution in the Arab World and beyond.
H.H. Sheikh Hamdan Bin Mohammed Patron of Hamdan Bin
Mohammed e-University aims for the first e-University to excel
in e-learning through offering high quality programs, supporting
lifelong learning, and addressing critical economic development
activities in the Arab world, as well as providing learners with unique
experiences, developing and disseminating knowledge through
excellence in research.
Hamdan Bin Mohammed e-University comprises four main
colleges, e- School of Business and Quality management , school
of e-education, e-school of Health and Environmental studies and
e-school of Continuing Education.
In addition to being accredited by national bodies and academic
Hualian Pharmaeutical Machine
Stand No. 113
first years of operation, several breakthrough drugs were developed
in areas such as anesthesia, pain management, psychiatry,
gastroenterology, mycology and numerous other therapeutic areas.
Cilag (an acronym of Chemical Industry Laboratory AG) was founded
in Switzerland (Schaffhausen) in 1936.
In 1959, Cilag joined the Johnson & Johnson family of companies.
In 1961, Janssen Pharmaceutica became part of the Johnson &
Johnson group. This initiated an international expansion that has
resulted in the establishment of Janssen Pharmaceutica companies
in virtually all countries of the world.
Zhejiang Hualian Pharmaceutical Machinery Co.,Ltd. is specialized
in researching, developing and producing pharmaceutical
machinery and foodstuff machinery as well as interrelated service
for 19years.
In 1994, Janssen Pharmaceutica integrated its sales and marketing
organizations worldwide with that of Cilag and became JanssenCilag. Later the two research organizations merged into Johnson &
Johnson Pharmaceutical Research & Development (J&JPRD)
Main products:
Janssen-Cilag companies operate in virtually all countries of the
world and are active in a number of therapeutic areas such as pain,
psychiatry, neurology, gastrointestinal and fungal diseases.
Flat-plate automatic blister packing machine, High-speed roller-plate
automatic blister packing machine, Automatic cartoning machine,
Blister packing & cartoning production line, Aluminum-aluminum
packing machine, Capsule filling machine, High-efficiency coating
machine, Extracting & concentrating whole set machine.
Exhibitors Profile
institutions, particularly the Ministry of Higher Education
and Scientific Research in the UAE. Hamdan bin Mohammed
e-University enjoys international accreditation from major
educational institutions and universities, such as University of
Bradford, University of Wisconsin, University of Huddersfield and
the University of California, Berkeley
Janssen-Cilag develops a wide range of innovative products, each
serving to improve people's health all over the world. Janssen-Cilag's
products serve a broad range of therapeutic areas.
Main Products:
International Pharmaceutical Students
Federation (IPSF)
•
Concerta® (methylphenidate HCL): For ADHS, the only oncedaily methylphenidate that last through 12 hours.
•
Durogesic® (fentanyl patch): For moderate to severe chronic
pain that requires the use of strong opioids.
The International Pharmaceutical Students’ Federation (IPSF) was
founded in 1949 by eight pharmacy student associations in London.
The Federation now represents approximately 350,000 pharmacy
students and recent graduates in 70 countries worldwide. IPSF is the
leading international advocacy organisation for pharmacy students
promoting improved public health through provision of information,
education, networking, and a range of publications and professional
activities.
•
Eprex® (epoetin alfa): For anemia in chronic renal failure
patients, Cancer patients with a hemoglobin level less than
10.5g/dl, in which chemotherapy treatment is planned and
Pre-operatively for prevention of Allo-transfusion / Autologous
Blood transfusion
•
Livostin® (levocabastine): Topical antihistamine for the
treatment of allergic conjunctivitis and allergic rhinitis.
•
Motilium® (domperidone): Gastro-kinetic and anti-emetic.
IPSF initiatives focus mainly on the areas of public health and
pharmacy education and professional development. Initiatives
include public health campaigns, research on issues in pharmacy
education and workforce development, the Student Exchange
Programme, organising international and regional congresses and
symposia, and publication of the IPSF News Bulletin, Newsletter
and educational supplement Phuture.
•
Pariet* (rabeprazole): Proton pump inhibitor.
•
Reminyl® (galantamine hydrobromide): For mild to moderate
Alzheimer’s disease.
•
Risperdal® (risperidone): Atypical antipsychotic for treatment
of psychotic disorders.
•
Risperdal CONSTA® (risperidone): The first long-acting atypical
antipsychotic.
•
Sporanox® (itraconazole): Broad-spectrum oral antifungal.
•
Topamax® (topiramate): Broad-spectrum anti-epileptic drug.
•
Tylenol® (paracetamol): Analgesic & anti-pyretic
•
Velcade® (bortezomib): Chemotherapy for multiple myeloma.
Stand no. 219
IPSF holds Official Relations with the World Health Organization
(WHO), Operational Relations with the United Nations Educational,
Scientific, and Cultural Organization (UNESCO), and Roster
Consultative Status with the Economic Social Council of the United
Nations (UN ECOSOC). IPSF works in close collaboration with the
International Pharmaceutical Federation (FIP). The IPSF Secretariat
is supported and hosted by the FIP in The Hague, The Netherlands.
Janssen-Cilag
Jiangsu Honghui Pharmaceutical
Stand No. 139
Stand No.: 81 & 82
Janssen-Cilag, one of the worlds leading research-based
pharmaceutical companies. Janssen-Cilag is a product of the merger
of two companies, Janssen Pharmaceutica and Cilag
During 10 years, Jiangsu Honghui Pharmaceutical Co., Ltd.,
founded in February 1998, we has developed into a enterprise of
introduction, development, agents, production and marketing
intergrating science, industry and trading.
Dr. Paul Janssen, who has been described as “arguably the most
successful drug discoverer of all time”, established Janssen
Pharmaceutica in 1953 in Belgium. Already during the company's
The institute being affiliated with Jiangsu Honghui Pharmaceutical
Co., Lltd. researches and developments high technology and good
market prospects products cooperating in scientific research
D U P H A T 2009
www.duphat.ae
15
community. Jiangsu Shenlong Pharmaceutical Co., Ltd. being
affiliated with Jinagsu Honghui Pharmaceutical Co., Ltd. has more
than 100 kinds of dosage form, including large capacity injection,
water injection, Chinese medicine extraction, tablets, capsules,
granules , API and so on. And Jiangsu Shenlong also passed the
GMP certification.
Jiangsu Jiangshan Pharmaceutical
scale in the world. Kelun also supplies sterile powder for injection,
small volume injection, tablets, capsules and healthcare products
with best quality. Our products range covers water and electrolyte
supplements, nutrition supplements, plasma volume expanders,
anti-infectives, cardiovascular, and others. Those products made by
Kelun have been exported to Middle Asia and Southeast Asia. More
than 10 countries are in the process of registration. US market is
also under developing.
LCA Pharmaceutical
Stand No. 144
Exhibitors Profile
Founded in 1990, Jiangsu Jiangshan Pharmaceutical Co., Ltd. (JSPC)
develops, manufactures and markets a comprehensive range of
vitamin C series products, nutritional & health supplements. Today
the company has been certified with GMP, ISO, HACCP, HALAL
and KOSHER as well. We are committed to supply you value-added
products and excelsior service.
Stand No. 88
LCA Pharmaceutical is a French laboratory developing and
manufacturing high quality medical devices in ophthalmology,
rheumatology and dermatology with long experience and high know
how in injectable viscoelastic devices. All products are CE marked.
LCA Pharmaceutical is present in many countries in Europe, Middle
East, Asia, Africa and South America.
Jiangsu Victor Machinery CO., LTD.
Stand No. 145
VICTOR MACHINERY,the leading manufacture of plastic
extruder,injection blow molding machine and moulds,devote us
into high quality packing material industrial.we are the key unit of
China Plastic Machinery Association,and High-tech Corporation in
Jiangsu Province.
LCA Pharmaceutical is involved in three medical fields:
-
Ophthalmology with intraocular lenses, viscoelastic devices,
sterile instrumentation for surgery and eye drops
-
Rheumatology with joint injection for osteoarthritis (ARTHRUM
H, COXARTHRUM, RHIZARTHRUM)
-
Dermatology: HYALUDERM wrinkle filler / HYALUDERM
Revitalize for bio revitalization by injection
With the mind of “Credit,Innovation and Service”,all the whole
plant equipment we make for oversea and domestic market got good
reputation.we had ISO9001:2000 and CE certificated,our products
well sold in Asia,Europe,South America,Middle East and Africa
countries.
Choose VICTOR,you can find the best solution and partner.
Julphar - Gulf Pharmaceutical Industries
Les Laboratoires Servier
Stand No. 11, 12 & 13
•
•
•
•
•
Stand No. 44, 45, 46
JULPHAR is a share holding company that owns manufacturing
plants, scientific and commercial offices spread all over the world.
Julphar manufactures and sells more than 417 products including
Julmentin-cp-amoxiclav,
Azomycin-Azithromycin,
ProfinalIbuprofen, Rantag-Ranitidine, Juplphamox- Amoxicillin, ButalinSulbutamol, Cefuzime-Cefuroxime, Mebo-Herb, Risek-Omeprazole,
Sigmasporin-Cyclosporine and Epotin-Erythropoietin.
Finally, Julphar has recently reinforced its position as a generic
company with innovative formulations with the launching of Jusline
(Human Insulin) in three different forms: Jusline N, Jusline R and
Jusline 70/30. Jusline has already been tested in all MOH hospitals
all over the UAE.
Stand No. 165
KELUN PHARMACEUTICAL is a modern pharmaceutical group
particularly focusing on manufacture and R&D of IV solutions. 2008
sees a big leap to 2 billion units in production which is the largest
•
•
•
•
Leo Pharmaceutical
Stand No. 43
Kelun Pharmaceutical
16
•
Leading French independent pharmaceutical company
Second French pharmaceutical company worldwide
SERVIER is established in 140 countries
85% of SERVIER’s sales are achieved internationally
Consolidated turnover for the 2007/2008 financial year : £3.7
billion
More than 25% of SERVIER’s turnover is invested in Research
and Development
Worldwide workforce of over 20 000, including nearly 3 000 in
Research and Development
769 million boxes of drugs were made available for patients by
our productin sites in 2007
SERVIER contributes 29% of the trade surplus of France’s
pharmaceutical industry
The main lines of SERVIER research are:- Neurosciences,
Oncology, Cardiovascular disease, Metabolic Disease and
Rheumatology basic research.
LEO Pharma is a research based pharmaceutical company in
Dermatology and Critical care portfolios. LEO Pharma provides safe
and efficacious drugs. Drugs that treat and alleviate diseases. Drugs
that help people to better quality of life including Psoriasis, Renal
osteodystrophy, prevention and treatment of VTE.
Exhibitors Profile
Lundbeck
Stand No. 64
Through extensive and ongoing research, Mepha has been pioneering
in the pharmaceutical field, by developing innovative dosage forms
that enhance the patient compliance and optimise the efficacy of the
active ingredients.
Mepha quality complies world wide with all pharmaceutical standards
of Good Manufacturing Practice, ISO 9001 and US FDA.
Medpharma, United Arab Emirates
Stand No. 3 & 4
MEDPHARMA Pharmaceutical & Chemical Industries LLC,
Our Mission – Serving humanity and the well being of people by
producing products with the highest international standards that
contribute to the health and people’ quality of life
Our Vision - We want to be amongst the leading companies in our
areas of expertise, which may not be necessary always be in size but
definitely in Quality which enrich healthier life.
MEDPHARMA,
MEDPHARMA that is founded in 1998 as Sharjah’s premier
Pharmaceutical and Chemicals Company.
MEDPHARMA is proud to be associated with the Government of
Sharjah, Economic Development Department, which has undertaken
this noble task of putting the industries and companies based in the
Emirate of Sharjah on the global economic map.
Mepha is globally active and our top quality products reflect the
latest developments in the pharmaceutical technology.
Patented dosage forms such as Gastrocaps™, Depocaps™, Multi
tabs™ etc., are the result of the outstanding formulation techniques
developed by Mepha. Mepha combines tradition and innovation
under one roof. As an innovative Swiss company we set highest
standards of quality for our products and services. Thanks to
pioneering research and advanced technology we are in a position to
continuously improve our product range. We invest in improving the
effectiveness of proven active substances and create added value for
the benefit of the patients.
In addition to galenics, we are specialized in malaria research. To
control this infectious disease we have launched medicines for
both prophylaxis and therapy. One of our newest developments
is a preparation that can be easily administered (Plasmotrim™
Rectocaps™) by laymen in areas of malaria and is also affordable for
people in developing countries. Mepha medicines stand for quality
at fair prices.
Olfen™, Gasec™, Bactiflox™, Neurorubine Forte™, Pectoral™ Syrup
are the major Mepha brands available in the GCC countries.
Mepha Ltd. Switzerland
Stand No 8 & 9
Mepha – the innovative Swiss pharmaceutical company.
D U P H A T 2009
www.duphat.ae
17
Merck Serono
Stand No 69 & 70
Exhibitors Profile
“Merck Serono Middle East is a company of the Merck Group.
With a representation extends to 7 countries in the region and a
presence in the Middle East region from the early seventies.
Merck Serono has leading brands serving patients with cancer
(Erbitux®), multiple sclerosis (Rebif®), infertility (Gonal-f®),
metabolic and cardiometabolic disorders (Glucophage®, Concor®,
Saizen®, Serostim®), as well as psoriasis (Raptiva®). we are
committed to growing our business in specialist-focused therapeutic
areas such as Neurology and Oncology, as well as new therapeutic
areas potentially arising out of our research and development in
autoimmune and inflammatory diseases.”
Modern Pharmaceutical Company
Stand No. 99, 100 & 101
For four decades, MPC has been an active partner in the advancement
of healthcare in the UAE. It has remained in the forefront by having
a single objective: excellence in the products and the services it
provides to satisfy the needs of customers and principals.
Developing products in quick succession is our core competence.
Robust product development, Hi-tech manufacturing, quality
embedded operations and skilled regulatory support all work in
synergy for one common goal – world-class pharmaceuticals.
Neopharma markets its products in the UAE and in GCC countries.
World-class recognition through EUGMP, GCC-DR and the
prestigious Mohammed Bin Rashid Al Maktoum award are stellar
examples of our world-class manufacturing.
Today, Neopharma has made a mark in the minds of the doctors and
consumers alike for its irrefutable quality.
New Academy School
Stand No. 17
The New Academy School was established in Dubai in 1990. The
School followed the British curriculum until 1995 when it switched
to the American Curriculum in tune with most schools in the
United Arab Emirates. The School includes all academic stages from
kindergarten to grade 12.
MPC, as an Exclusive Agent and Distributor, is engaged in the Import,
Distribution as well as Marketing (optional) of Pharmaceuticals,
Medical Equipment, Laboratory Reagents, Skin & Beauty Care
Products, Home Monitoring Devices, and Dietary Supplements.
The school has, since its founding, assumed the responsibility
of giving the students a solid academic grounding with the major
goal of preparing them for a successful career in the various fields
expected to emerge in the future. The school aims at developing
the student’s cultural, scientific, and practical skills required for
building a distinguished generation able to keep abreast of scientific
progress.
With four dedicated divisions i.e. Pharmaceutical, Medical
Equipment (consumables, dental, laboratory and diagnostic
products), Consumer Products (Personal Health and Beauty Care)
and Retail Pharmacies, MPC serves many varied customers with a
most comprehensive range of products and equipment.
The school comprises a modern campus especially designed
to enable the students to do the various school activities in a
hospitable environment. The school contains large classrooms,
science laboratories, and a big library which has encyclopedias and
invaluable books and a theatre for school functions.
New Medical Centre For Trading
NCPC International Corp.
Stand No. 141
Stand No. 48
North China Pharmaceutical Group Corporation (NCPC) is one
of the largest pharmaceutical manufactures in China. From the
date its foundation stone was laid in June 1953, NCPC created a
history of mass production of pharmaceuticals in China and now we
have more than 500 pharmaceutical products being active in over
60 countries. During her 52 years’ development. NCPC has been
continually growing and taking the lead in China pharmaceutical
industry, ranking among the Top 500 Enterprises in China. In Feb
2004, NCPC was chosen as one of China Top 5 industrial Brands by
Forbes. In 2008, NCPC achieved sales revenue of USD850 million,
oversea sales of USD 296 million.
NMC Trading, the trading arm of the NMC Group, is one of
the U.A.E’s leading marketing and distribution companies, for
prestigious brands in Pharmaceuticals, Medical Equipment, FMCG,
Foodstuff, Veterinary products, Analytical Lab Equipment, Medical
Consumables & Disposables, and Educational resources.
Within a short span of time the company has emerged as one of the
leading players in the trading business - backed by efficient planning,
a dedicated team of sales & marketing professionals, strategically
located warehousing facilities, a robust sales & distribution network
and a fully computerized inventory management system. The major
players include Pfizer, SanofiPastuer, Boehringer, Dr. Reddy’s,
Biocon etc..
NEOPHARMA
New World Private School
Stand No. 47
Stand No. 20
Abu Dhabi’s first state-of-the-art pharmaceutical plant – Neopharma
With an aspiration to backward integrate the healthcare chain, NMC
has made a planned foray into pharmaceutical manufacturing and
thus was born Neopharma.
18
Stand No. 41 & 42
Roche is a leading healthcare company with a uniquely broad spectrum of innovative solutions. For more than 100 years, Roche have
been active in the discovery, development, manufacture and marketing of novel healthcare solutions. Roche products and services address
prevention, diagnosis and treatment of diseases, thus enhancing well-being and quality of life.
Providing products and services to treat and monitor diseases is at the core of Roche's activities in all major therapeutic areas. Roche is
concentrating efforts especially on those areas, where there are important medical needs and where patients can benefit from an adequate
treatment regimen. Roche broad product base makes it possible to offer real improvements to doctors, hospitals and patients.
•
•
•
•
•
•
Anaemia
Central nervous system
Infectious diseases
Metabolic disorders
Cancer
Transplantation
•
•
•
•
•
•
Exhibitors Profile
Focusing on prescription drugs, Roche is currently engaged in the following areas (amongst others):
Cardiovascular diseases
Dermatology
Inflammatory and autoimmune diseases
Osteoporosis
Respiratory diseases
Virology
Roche in Rheumatoid Arthritis (RA)
Rheumatoid arthritis is a progressive, systemic autoimmune disease characterized by inflammation of the membrane lining in joints. This
inflammation causes a loss of joint shape and function, resulting in pain, stiffness and swelling, ultimately leading to irreversible joint
destruction and disability. MabThera® (rituximab) selectively targets a subset of B cells that express CD20, leaving stem, pro-B and plasma
cells unaffected. The B cells play a key role in the autoimmune process of RA and MabThera aims to interrupt this process by inhibiting
a series of reactions inflaming the synovia and leading to cartilage loss and bone erosion that is characteristic of the disease . More than
1000 patients with RA have been treated with MabThera in clinical trials to date. MabThera is well established in the treatment of a form of
lymphatic cancer called non-Hodgkin’s lymphoma (NHL) where over 730,000 patients have been treated with MabThera over a seven year
period without major safety concerns.
Roche in Osteoporosis
Bonviva® (ibandronic acid) a potent and highly effective bisphosphonate1 is the first ever oral treatment administered as one tablet once a
month for any disease. This means patients will only have to take 12 Bonviva tablets a year versus 52 or 365 required with current weekly
or daily bisphosphonate treatments. Bonviva, a potent bisphosphonate, has been studied to date in clinical trials involving over 12,000
patients.
Bonviva (known in the US as Boniva), was approved by the US Food and Drug Administration in March 2005. In the US, Boniva 150mg is
indicated for the treatment of osteoporosis in postmenopausal women.
Roche in Hepatitis
Roche is committed to the viral hepatitis disease area, having introduced Roferon-A for hepatitis B and C, followed by Pegasys in hepatitis C
and B. Roche have its own brand of ribavirin, Copegus, which is used in conjunction with Roferon A or Pegasys for HCV.
Pegasys® [peginterferon alfa-2a (40 KD)] the market leader worldwide in hepatitis C therapy, provides significant benefit over conventional
combination interferon therapy in HCV patients of all genotypes. The benefits of Pegasys are derived from its large 40 kilodalton (KD)
branched-chain polyethylene glycol (PEG) construction, which allows for sustained drug levels over the course of a full week. Pegasys also
distributes more readily to the liver (the primary site of infection) than conventional interferon. Pegasys is available as a ready-to-administer
solution. Each weekly subcutaneous injection contains 180mcg of pegylated interferon alfa-2a (40KD), which is the approved dose for all
patients, regardless of body weight.
Roche examines the unmet medical needs of hepatitis C patients. Roche’s commitment to viral hepatitis also extends to its pursuit of
strategic alliances and partnerships to develop new compounds for the future
Its core businesses are pharmaceuticals and diagnostics. Roche is number one in the global diagnostics market and is the leading supplier of
pharmaceuticals for cancer and a leader in virology and transplantation. As a supplier of products and services for the prevention, diagnosis
and treatment of disease, the Group contributes on a broad range of fronts to improving people’s health and quality of life.
Hoffmann La Roche
D U P H A T 2009
www.duphat.ae
19
Exhibitors Profile
Stand No. 93
20
Stand No. 92
Exhibitors Profile
Thinking the future
of steel !
Isocab® - Retan Cleanroom Constructions
Retan Cleanroom Constructions, a division of Isocab, has been
working over the past years on international markets in most
different sectors and handles complete structural cleanroom
projects from the design stage to a fully installed system.
Isocab
A ThyssenKrupp Steel company
visit us: www.isocab.be
Norgine Pharmaceutical Ltd, UK
Stand No. 182
Founded in 1906, ¬¬ is a specialty pharmaceutical company with an
extensive pan-European presence. Throughout our long history, we
have sought to develop and market high quality, innovative products
for the benefit of both patients and physicians. We are committed to
developing products not only to treat life-threatening conditions but,
importantly, to improve the quality of life for patients with a range
of acute and chronic illnesses. We have a long standing tradition of
building relationships, based on the highest standards, with patients,
physicians, employees, partners and other key stakeholders.
In the last fifteen years, we have focused on expanding our panEuropean infrastructure, and have moved to strengthen the Research
& Development base of the company.
As a result, we are now positioned with:
•
A strong portfolio of internal development projects, principally
in the areas of gastroenterology, hepatology and incontinence
•
An extensive sales and marketing organisation
•
An established manufacturing base
•
A solid geographical base with affiliates in all major
European countries functioning together as a single coherent
organization
In addition to developing, manufacturing and marketing our own
pharmaceutical products, Norgine is an ideal partner for companies
seeking assistance in the development and launch of innovative
pharmaceutical products across Europe. We value our development
partnerships as, together with our own in-house product
development, they support our growth ambitions and will help to
facilitate our continued business expansion.
By consolidating our successes, we can ensure we meet the
challenges of an exciting future.
We have the resources to bring products to market on a panEuropean or single country basis, combining sales and marketing
expertise together with all development, clinical research, product
registration or manufacturing resources that our partners require.
In the years ahead Norgine will continue to implement this successful
strategy, building on our established infrastructure, strengthening
our pan-European presence and collaborating with like-minded
companies and organisations. By consolidating our successes, we
can ensure we meet the challenges of an exciting future.
Novartis Pharma Services
Stand No. 105, 106, 123, 124
The Novartis Pharmaceuticals Division is a world leader in the
discovery, development, manufacture, and marketing of prescription
medicine. Our goal is to provide a broad portfolio of innovative,
effective and safe products and services to patients through
healthcare professionals around the world. Our current product
portfolio includes more than 40 key marketed products, many of
which are leaders in their respective therapeutic areas.
D U P H A T 2009
www.duphat.ae
21
Stand No. 185
PHARMATRADE – Established in 1977, Pharmatrade is a leading
distribution company in the UAE supplying Medical, Laboratory
and Pharmaceutical products from over 30 Multinational companies
in the Healthcare industry. The company has in its Portfolio over
5000 products from medical supplies to hospital equipments, to
pharmaceutical and consumer health products.
Pharmatrade has three dedicated operating division- Medical,Lab
and Pharmaceutical, which handle the UAE
Pierre Fabre Medicament
Stand No. 39
Pierre Fabre is France’s second largest independent pharmaceutical
group with a foothold in more than 120 countries. Pierre Fabre focus
the investment program on research where 20% of the turnover is
invested in CNSOncology- Cardiovascular and immunology
Pharmaceutical Solutions Industry (PSI)
Stand No. 203
Life saving solutions.
RAK Medical & Health Sciences University
located at Burairat, Ras Al Khaimah offers all the required facilities
to cater to all programs including Library, Anatomy Dissection hall,
Skills Laboratories, Computer Labs, Lecture halls and Demonstration
rooms. Clinical training and Internship is provided at Government
Hospitals at Ras Al Khaimah. Separate hostel facilities are provided
for male and female students. Student visa is also provided.
More details on RAK MHS University can be seen at www.rakmhsu.
com.
Rionlon Bohua Industry Int. Trade
Rionlon Bohua (Tianjin) Pharmaceutical & Chemical Co., Ltd. /
Rionlon(Tianjin) Industry Co., Ltd.are the outstanding high-tech
enterprises combined with R&D, industry and trade. Relying on
the strong R&D ability and wholesome international marketing
system, they have established their own system of strong R&D,
manufacturing, quality control and marketing and service. With
their unique technology of R&D and application in special chemicals,
refined chemicals and biochemical products, they have mastered the
advanced level in production and quality control.
Rionlon (Tianjin) International Trade Co., Ltd. mainly deals with the
products from the plants of Rionlon. Meanwhile it also deals with the
foreign business of pharmaceutical raw materials and intermediates,
refined chemicals and natural abstracts from domestic market. A
good fame has been gained both from domestic and foreign clients.
Riyadh Pharma
Stand No. 220
RAK Medical and Health Sciences University ,Ras-Al-Khaimah,
United Arab Emirates(UAE), has been established by the Ras Al
Khaimah Human Development Foundation (RAK – HDF) under
the visionary leadership of His Highness Sheikh Saud Bin Saqr
Al Qasimi, Crown Prince & Deputy Ruler of Ras Al Khaimah and
Chancellor of the University.
The University is a joint venture of Government of Ras Al Khaimah ,
Al Ghurair Investments & ETA Ascon Group, Dubai.
RAK Medical and Health Sciences University has been granted
Initial Licensure and Initial Accreditation for the Bachelor of
Medicine and Bachelor of Surgery-MBBS program by the Ministry
of Higher Education and Scientific Research, UAE in July 2006. The
Medical College of the University started its operations in October
2006, with its first batch of MBBS students. The Medical College of
the University will be enlisted in WHO upon graduation of the first
batch of students.
Stand No. 140
Stand No. 206 & 207
Riyadh Pharma ultra modern manufacturing facilities are capable
of producing more than 300 licensed and generic products to the
highest global standards required for local and international markets.
The company manufacturers and markets human use medicines,
antiseptics and non Pharma products such as disinfectants and
personal care preparations. Absolute quality, safety and efficacy of the
finished products is of paramount importance to the management
and staff of Riyadh Pharma.
All production operations are conducted to the strict criteria of
the internationally recognized standard of GMP and to Saudi
Moh standards. Riyadh Pharma – a commitment to excellence,
commitment to quality healthcare – a commitment to our
customers.
RPS Publishing
The second academic session for MBBS commenced on 18th
September 07.
The Bachelor of Dental Surgery (BDS) program, BSc. Nursing program
and Bachelor of Pharmacy (B Pharm) programs have also obtained
Initial Accreditation from the Ministry of Higher Education and
Scientific Research,UAE and these programs commenced on 21st
Oct 2007.
RPS Publishing produces high quality books, journals, digital
products and online subscription services (MedicinesComplete),
providing essential drug information for integration within decision
support systems for pharmacists and other healthcare professionals.
Our publications are internationally recognised as leaders in their
field and include Martindale and other titles published under the
Pharmaceutical Press imprint. RPS Publishing is also responsible for
such highly respected publications as the British National Formulary
(with the BMJ Group) and The Pharmaceutical Journal.
The University will shortly commence the construction of its future
campus adjacent to Saqr Hospital, Ras Al Khaimah. The University
building will be completed by Sept 2008 with state-of-the-art
facilities meeting international standards. The present campus
Exhibitors Profile
Pharmatrade LLC / Madaus GmbH
Stand No. 87
D U P H A T 2009
www.duphat.ae
23
SAJA Pharmaceuticals Gulf
Stand No. 10
Exhibitors Profile
Saudi Arabian Japanese Pharmaceuticals Manufacturing Company
(SAJA) - a joint-venture begun five years ago between Tamer
Industries and a consortium of Japanese partners to produce the
latest medicines for the Saudi Arabia and Middle East market. The
consortium includes two of the leading Japanese pharmaceutical
companies, Sankyo and Astellas. Both companies are the major
players in the Japanese health care sector, each wit an impressive
portfolio of an ethical medicine. SAJA’s state-of-the-art production
facility in the Kingdom was designed by senior technicians from
both Japanese companies and built to exacting Japanese standards
and specifications. The design of the facility is characterized by an
obsession with quality, safety and efficiency in every aspect of the
manufacturing process.
Our mission:
SAJA pharmaceuticals is a health care company whose primary
purpose is to locally manufacture the highest quality modern
medicines produced by the international research and development
facilities of the largest Japanese companies over the world.
SAJA is focused on research products obtained primarily from
Japan, as well as the US and Europe. The Future success of the local
pharmaceuticals industry will depend on agreements that allow
the local entity to obtain the latest technology and latest research
products. SAJA’s Japanese partners currently have a plenty of
new ethical Medicines in the R&D pipelines with activities focus
on Urology, Rheumatology and Cardiovascular sectors. SAJA
pharmaceuticals have the pleasure to introduce in the GCC market
highly innovative products which is designed and matched with
Japanese High Quality control standards like:
Cardiovasculars
Dermatologicals
Central nervous system and other disorders
Schering-Plough also has a global animal health business and
leading consumer brands of foot care, over-the-counter and sun care
products.
For more than 50 years, our success in the worldwide pharmaceutical
marketplace has been driven by our company's commitment
to innovative research, effective marketing and solid financial
management. In fact, growth through research is central to our
business strategy—our innovation has earned us market leadership
positions in many of our key therapy areas.
Schering-Plough has facilities in more than 50 countries worldwide,
with headquarters located in Kenilworth, New Jersey.
Shandong Mingyuan Imp. & Exp. CO., LTD.
Stand No. 137
MINGYUAN GROUP NOW OWNS FOUR SUBSIDIARY
COMPANIES: SHANDONG MINGYUAN IMP. & EXP. CO., LTD.
(YANZHOU, SHANDONG); SHANGHAI TERUN IMP. & EXP. CO.,
LTD. (PUDONG, SHANGHAI); MINGYUAN INTERNATIONAL CO.,
LTD. (HONGKONG); JINING MINGYUAN FRUITS & VEGETABLES
CO., LTD. (JINXIANG, SHANDONG).WE ALSO HAVE TWELVE
JOINT VENTURES. WE HAVE BECOME A PROFESSIONAL
IMPORTERS AND/OR EXPORTER OF PHARMACEUTICALS,
FINISHED MEDICINES, MEDICAL & HEALTH PRODUCTS,
DAILY TEXTILES (Robes,Blankets,Towels etc), BEVERAGES AND
CANNED FOODS IN CHINA SINCE 2002. WE WELCOME YOUR
FURTHER VISIT TO OUR WEBSITE www.mingyuangroup.com.cn
FOR SEARCHING THE ITEMS YOU ARE INTERESTED IN.
•
OMNIC: used for functional treatment of BPH symptoms, this
is holding No.1 position in its class.
•
ROXONIN: Star product in the field Rheumatology, which has
distinctive superior characters rather than others.
Shenzhen Gosun Pharma Co., Ltd
•
OLMETEC: Unique profile among the ARBs for the treatment
of Hypertension
In addition to high quality 2nd brands which is manufactured in
strict accordance with Japanese standards like Floxacin, Omeprex,
Simvaten and Azomax. Through qualified staff, SAJA is committed
to supply the health care professions with highest quality, state of
the art medicine available in the world today.
Stand No. 136
Gosun pharma is one of the earliest and leading pharmaceutical
companies engaged in developing, manufacturing and marketing
cephalosporin in China since 1992. For API, the key product is
cefotaxime sodium Sterile with advanced quality, high assay, few
impurities, low water, which can meet EP, USP, and BP standards.
Shenzhen Sciprogen Bio-pharmaceutical Co., Ltd
Saudi Pharmaceutical Soceity
Stand No. 217
Schering Plough
Stand No. 199 & 200
A worldwide, research-based pharmaceutical company, engaged in
the discovery, development, manufacturing and marketing of new
therapies and treatment programs that can improve people's health
and extend their lives.
24
•
•
•
Stand No. 139
SHENZHEN SCIPROGEN BIO-PHARMACEUTICAL CO.,LTD is the
TOP 1 manufacturer and exporter of bulk and final formulation of
rh EPO (Recombinant Human Erythropoietin) in China,with the
annual production capacity as 200g pure EPO protein(equals to
12Million final formulation).Available with 2000IU,3000IU,4000IU,
5000IU,10000IUvial and Pre-filled Syringe.
DMF document available.
Low molecular weight heparin Calcium was launched in 2006.
The primary business involves prescription products in core product
categories, including:
Products under development: PEG-EPO, oral EPO.and Insulin
inhalant.
•
•
Countries export: South America, ASEAN countries, Middle
East,India.
Allergy and respiratory
Anti-infective and anticancer
Shijiazhuang No. 4 Pharmaceutical Co., Ltd
Stand No. 168
We, Shijiazhuang No.4 Pharmaceutical Co., Ltd are specializing in
the manufacturer & export of various Large Volume Intravenous
infusion with more than 60 years experience in China, over the past
years, we have sold our products to more than 30 countries and
regions all around the world. The main products in our company
include 5%, 10% Glucose infusion, 0.9% sodium chloride infusion,
Ringers’ lactated insuion, Ciprofloxacin infusion, Metronidazole
infusion, Etc.
Exhibitors Profile
We can provide excellent pharmaceutical products with competitive
price!
We are the parter of present & future market leaders!
Sichuan Kelun Bio-tech Pharmaceutical Co., Ltd
Stand No. 142
Sichuan Kelun Bio-tech Pharmaceutical Co., Ltd. is committed to
supplying to global community with safe, highly efficient and pricecompetitive biological medicines and best service. With a professional
team of pharmaceutical import and export trading, CMO and OMO
service in medical industry, Sichuan Kelun Bio-tech Pharmaceutical
is proficient in international medicine registration for exportation,
providing specialized service timely and high efficiently as per
individual requirements of customers from domestic and overseas.
We focus on exporting blood products, gene-tech (Recombinant
DNA Technology) products, Bio-chemicals, Vaccines, Peptides and
Plant Extracts.
Sinochem Jiangsu Corportion
Stand No. 115
Sinochem Jiangsu Corporation (Sinochem Jiangsu) is one of the
key subsidiaries of Sinochem Corporation (Sinochem), which is one
of the largest companies in the "Fortune 500". It is mainly engaged
in export business of chemicals, pharmaceuticals and other items.
It's commodities are being exported to more than 80 countries
and regions in the world which covers: Pharmaceuticals (raw
material and finished products),Fine chemicals,Agrochemicals and
Petrochemicals.
Solvay Pharmaceuticals
Stand No. 157, 158, 175 & 176
Solvay Pharmaceuticals is a global research-based pharmaceutical
company dedicated to improving quality of life of patients and to
support their healthcare professionals in the therapeutics areas of
cardio metabolic, neuroscience, gastroenterology, women & men
heath as well as Immunology and Vaccination. The new Cardio
metabolic products Teveten: All the blocker that acts also on the
SNS- Physiotens; Antihypertensive that acts safely on the SNS
overactivity - Omaxor; unique highly concentrated omega -3 for
26
2ry prevention PMI, Hyperetriglyceridemia- Lipanthyl; for mixed
Dyslipidemia in addition to the time honoured products; Duspatalin,
Duphalac, Duphaston, Betaserc, Faverin & Influvac have always
provided innovative solutions to human health.
Spimaco
Stand No. 119
SPIMACO was established in 1986; one of the main objectives
was to set up an advanced pharmaceutical industry in the Middle
Eastern region. SPIMACO is committed to provide high quality
pharmaceutical products, complying with international good
manufacturing standards, thereby earning the loyalty of its
customers.
SPIMACO operates in several markets of the Middle East & the
North Africa & enjoys reputable relations both with the regulatory
bodies & the medical profession at large. Its heavy investment in
manufacturing & regulatory coupled with a professional marketing
& sales function justified various multinational pharmaceutical
companies to form alliances with SPIMACO, at different levels.
In SPIMACO, we emphasize on catering the needs of the Medical
community not just by offering high quality products but also by
furnishing their academic needs through comprehensive information
upon the latest developments in the Medical field.
Starway Pharm Co. Limited
Stand No. 189
Starway Pharma, an experienced, professional and reliable
distributor and producer of Antibiotics, APIs, Vitamins, Veterinary,
Feed Premix and Feed Additives. DMF/GMP documentary supports
for registration is available. New Products in 2009 including:
API: Meropenem, Imipenem, Vancomycin, Cefixime, Azithromycin
Granular, Iohexol, Conjugated Esterogen, Drospirenone, Orlistate,
Mycophenolate, Atracurium, Insulin, Enoxaprin,
Vitamins: beta-Carotene, Q10, Taurine, Vitamin A to Z.
Tabuk
Stand No. 49
“Tabuk Pharmaceutical Manufacturing Company- www.tpmc.com.
sa, is a fully owned subsidiary of Astra Industrial Group – AIG (one
of the biggest industrial groups in the Middle East region) www.
aig-co.com.sa, founded in 1994, headquartered in Riyadh, Saudi
Arabia with Export Representative Office in Cairo, Egypt, with GMP
facilities in Tabuk City, the company has strong presence across the
MENA region, Central Eastern Europe and a promising outlook in
Western Europe, Common Wealth of Independent States and the
USA. Tabuk has also established strong relations with companies
from all over the World mainly in the field of in – licensing of unique
originator and generic products. Tabuk enjoyed the European GMP
certified facilities, and is currently ready for the FDA inspection
soon.”
Tekni-Plex India Pvt. Ltd
Valeant Pharmaceuticals
Stand No. 110
Stand No. 95
Tekni-Plex is a global, diversified manufacturer of packaging,
products and materials for the healthcare, consumer and food
packaging industries. The company has built a leadership position
its core markets and focuses on vertically integrated production of
highly specialized products.
Valeant Pharmaceuticals International is a multinational specialty
pharmaceutical company that develops and markets prescription and
nonprescription pharmaceutical products that make a meaningful
difference in patients' lives. Valeant’s expertise is focused in the
therapeutic areas of neurology and dermatology.
Tekni-Plex’s operations are aligned under two business groups:
Our diverse portfolio includes products such as Eldoquin and
Eldopaque for skin bleaching, Dermatix for scar management,
Fefol, Mestinon, Disflatyl, Solcoseryl products, and Kinerase – our
premium face care brand.
Consumer Packaging and Products
•
Industrial Packaging, Products and Materials
The Private Religious Institute
Vitavision Medical Supplies
Stand No. 18
The Institute was established under the authority of H.H. Sheikh
Hamdan Bin Rashid Al Maktoom. Deputy Ruler of Dubai & Minister
of Finance.
Under the name of the Private Religious Institute, this school was
opened in 2002-2003 starting from grade 6.
The decision was taken to add basic pre- levels and secondary level.
Now the institute has grades 6 to 12.
The positive vision towards brilliant future for the students is the
main goal behind establishing the institute
School Curriculum:
After intensive study, the decision was taken to adopt the curriculum
of the ministry of education in addition to specific curriculum for
the Arabic and religious subject.
Administrative and teaching staff:
The school mission works according to new developed educational
method. This field is supervised by a group of qualified supervisors
who are dedicated and sincerely committed to the profession of
teaching.
School premises:
The institute started as a rented villa in the area of Al Wasel. Due to
the increasing numbers of the students and the new levels, it was
decided to build a new modern building.
Stand No. 130
Vitavision are the authorized distributors for Nature’s Bounty and
Natural Wealth in U.A.E.
Nature's Bounty & Natural Wealth are the trusted name in nutritional
supplements for more than 30 years. They provide premium quality
vitamins, minerals and herbal supplements. From start to finish, the
supplements are overseen by hundreds of professionals dedicated
to maintain the highest standards of quality. The products meet all
U.S. FDA- Good Manufacturing Practices (GMP). Nature's Bounty
& Natural Wealth undergo regular inspections by federal, state and
county agencies to ensure regulatory compliance.
The most frequently prescribed products are Flex-a-min, Haemo-Fer,
Q-Sorb, Theravim-M, Pregnaplus, Calcium 600 and many
Wyeth Pharmaceuticals
Stand No. 183, 184, 201 & 202
Wyeth is a global leader in pharmaceuticals, consumer health care
products, and animal health care products.
Outstanding Global Brands, Exciting New Products and a Rich
Research Pipeline
80 % level in grade 7
Wyeth improves the lives of millions of people around the world
with its outstanding products. And new, innovative medicines
are on the way. With research and development (R&D) programs
focused on small molecules, vaccines and biotechnology, Wyeth is
exploring more than 60 new therapies for medical conditions such as
diabetes, breast cancer, multiple sclerosis, HIV, Alzheimer’s disease
and schizophrenia.
Facilities
Wyeth Pharmaceuticals
The institute has laboratories and computer section supplied with
modern devices to enable students to be familiar with science and
knowledge.
Wyeth has a long history of pioneering developments in
pharmaceuticals and biotechnology, with leading products in
the areas of women’s health care, neuroscience, musculoskeletal
disorders, cardiovascular therapy, vaccines and infectious disease,
hemophilia, immunology and oncology. Wyeth also is a leader in the
development of nutritionals.
Admission:
The student must be UAE citizen
70 % percent level in grade 6
The school library meets the students' needs.
The school auditorium provides activities to the talented students.
Sport activities as football, basketball, hand ball, & volleyball ….etc
are available.
Transportation
A large fleet of air conditioned coaches provide transportation for
the students and some teachers.
Exhibitors Profile
•
Neuroscience
Wyeth’s global neuroscience efforts have produced a novel therapy
for depression and for the treatment of generalized anxiety disorder.
Working with three discovery platforms — small molecules,
vaccines and biotechnology — Wyeth researchers continue to
D U P H A T 2009
www.duphat.ae
27
develop treatments targeted for a wide range of central nervous
system disabilities, such as multiple sclerosis, Alzheimer’s disease,
depression, anxiety and schizophrenia.
cardiovascular and gastrointestinal products. Wyeth’s internal
medicine researchers are exploring novel approaches to treat
diabetes, heart conditions and vascular disorders.
Vaccines and Infectious Disease
Hemophilia Treatment
Wyeth’s vaccines and infectious disease franchises share a common
mission: to reduce the number of serious illnesses and deaths from
bacterial and viral infections and to address the growing problem of
bacterial resistance to existing treatments. In recent years, Wyeth
has developed some of the most innovative vaccines in the health
care arena. Our R&D focuses on producing vaccines for infants and
children around the world. We are proud of the impact Wyeth has had
on children’s lives, and we are dedicated to continually developing
vaccines so children can have a healthier future.
Since the 1980s, Wyeth has been a global leader in the search for safer
and more effective treatments for hemophilia A and B. As a result of
this commitment and a significant investment in recombinant DNA
technology, our efforts have led to important medical advances in
the treatment of these potentially debilitating diseases.
Exhibitors Profile
Musculoskeletal Disorders
Wyeth’s musculoskeletal disorders franchise develops important
new therapies for patients with joint and bone disease. Our products
include treatments for rheumatoid arthritis that help patients lead
more active lives. In addition, Wyeth has a strong presence in the
osteoarthritis treatment market. In research, Wyeth scientists are
investigating novel treatments for bone and tissue repair.
Immunology and Oncology
Wyeth’s work in immunology focuses on producing novel
immunosuppressants for organ transplantation. Our efforts in
oncology include chemotherapy agents for acute myeloid leukemia
and a platelet growth promoter to help patients after chemotherapy.
Wyeth currently has several promising oncology therapies in clinical
trials, including treatments for renal cell carcinoma, breast cancer
and mantle cell lymphoma.
Internal Medicine
Our broad and expanding internal medicine franchise includes
Stand No. 222, 223, 214 & 215
28
Zhejiang Medicine & Health Products CO.LTD
Stand No. 90
Exhibitors Profile
Zhejiang Medicines & Health Products Import & Export Co.,
Ltd.,(ZMC) was established in June,1999,on the basis of former
Zhejiang Medicines & Health Products Import & Export Corporation
that was set up in 1984. In Oct., 2001, it became one of the
subordinated companies of Zhejiang Grand Glory (Holding) Co.,Ltd.
ZMC is located in Hangzhou. Zhejiang Province, on China’s east
coast which is China’s most economically developed area. Hangzhou
is famous for its long history, beautiful scenery, bountiful talented
people and litterateure, and its highly-developed economy. It is one
of the seven ancient capitals of China and a city of tourist attractions
well-known all over the world.
Zhejing Chemicals I&E Corp.
Stand No. 116
Zhejiang Chemicals I&E Corp. is located in the famous tourist
city Hangzhou and established in 1980. We mainly engaged in the
manufacturing and international business of API, Veterinary and
Finished formulations. In the past 20 years, we have established
business relationship with more than 80 countries with “Top Quality,
Best Service and Reasonable Price” taking high reputation in the world
market and the annual sales has surpassed $100,000,000. Insisting
on our management motto “People Foremost” and carrying out our
business culture “Integrity, Earnest, Cooperative and Creative", we
sincerely welcome all friends abroad to negotiate business with us.
D U P H A T 2009
www.duphat.ae
29